

CITATION REPORT

List of articles citing

Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study

DOI: 10.1056/nejm198712243172603

New England Journal of Medicine, 1987, 317, 1625-9.

Source: <https://exaly.com/paper-pdf/18814958/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2249	Perusing the literature. 1988 , 9, 152-62		
2248	Update on the aminosalicylates: a promise fulfilled. 1988 , 95, 1677-80		5
2247	5-ASA for ulcerative colitis. <i>New England Journal of Medicine</i> , 1988 , 318, 1620-1	59.2	
2246	Rapid Colorimetric Assay of 5-Aminosalicylate. 1989 , 22, 1703-1708		3
2245	Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. 1989 , 298, 82-6		806
2244	5-aminosalicylic acid in a cream base improves psoriasis. A double-blind study. 1989 , 1, 5-7		5
2243	Advances in the assessment of disease activity in inflammatory bowel disease. 1989 , 64, 800-7		30
2242	Newer 5-aminosalicylic acid based drugs in chronic inflammatory bowel disease. 1989 , 37, 73-86		36
2241	Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease. 1989 , 38, 500-23		58
2240	New metabolites of the drug 5-aminosalicylic acid. I: N-beta-D-glucopyranosyl-5-aminosalicylic acid. 1989 , 19, 891-9		21
2239	Chapter 18. Recent Advances in the Treatment of Inflammatory Bowel Disease. 1989 , 24, 167-175		1
2238	Newer pharmacologic agents for the therapy of inflammatory bowel disease. 1990 , 74, 133-53		8
2237	The release profile of a controlled release preparation of 5-aminosalicylic acid (Rowasa I) in humans. 1990 , 33, 21-5		10
2236	Acute pancreatitis during oral 5-aminosalicylic acid therapy. 1990 , 35, 1180-2		53
2235	Sulfasalazine inhibits the binding of TNF alpha to its receptor. 1990 , 20, 217-24		57
2234	Advances in drug therapy for inflammatory bowel disease. 1990 , 112, 50-60		75
2233	A Double-Blind, Placebo Controlled, Multicentre Study of the Efficacy And Safety of 5-Aminosalicylic Acid Tablets in the Treatment of Ulcerative Colitis. 1990 , 4, 463-467		35

2232	Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. 1990 , 31, 1271-6	144
2231	Inflammatory Bowel Diseases 1990. 1990 ,	1
2230	Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II). 1990 , 19, 94-125	32
2229	Insulin and C-peptide levels following oral administration of insulin in intestinal-enzyme protected capsules. 1991 , 22, 243-6	31
2228	Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease. 1991 , 6, 192-219	61
2227	Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. 1991 , 115, 350-5	162
2226	Mesalamine in ulcerative colitis. 1991 , 25, 140-5	1
2225	Inflammatory bowel disease (2). <i>New England Journal of Medicine</i> , 1991 , 325, 1008-16	59.2 276
2224	Histopathological evaluation of colonic mucosal biopsy specimens in chronic inflammatory bowel disease: diagnostic implications. 1991 , 32, 1514-20	157
2223	Tests of renal function in patients with quiescent colitis: effects of drug treatment. 1992 , 33, 1348-52	34
2222	Lung disease associated with orally administered mesalamine for ulcerative colitis. 1992 , 101, 1469-71	35
2221	Effect of drugs on colonic eicosanoid accumulation in active ulcerative colitis. 1992 , 27, 968-72	26
2220	Prandial and diurnal effects on the absorption of orally administered enteric coated 5-aminosalicylic acid (5-ASA). 1992 , 33, 179-82	17
2219	New therapeutic agents in the treatment of inflammatory bowel disease. 1992 , 93, 199-208	25
2218	Drug therapy for inflammatory bowel disease: Part I. 1992 , 164, 85-9	9
2217	Aminosalizylsäurepräparate bei chronisch entzündlichen Darmerkrankungen. 1992 , 8, 19-22	
2216	Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease. 1992 , 37, 29-32	66
2215	5-aminosalicylic acid preparations in the treatment of inflammatory bowel disease. 1993 , 2, 247-262	

2214	A critical evaluation of the therapeutic benefits and side-effects of aminosalicylate analogues in the treatment of inflammatory bowel disease. 1993 , 2, 263-276	0
2213	Delivery, safety and efficacy of 5-aminosalicylate preparations. 1993 , 2, 277-287	6
2212	Current management of inflammatory bowel disease. 1993 , 8, 70-83	10
2211	Assessment of disease severity and activity in inflammatory bowel disease. 1993 , 28, 1-9	51
2210	Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin. 1993 , 34, 242-6	51
2209	Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. 1993 , 118, 540-9	191
2208	Mezlocillin-induced thrombocytopenia. 1993 , 119, 862	4
2207	Anaphylactoid-anaphylactic reactions associated with ondansetron. 1993 , 119, 862	14
2206	Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. 1993 , 104, 1293-301	304
2205	Colitis granulomatosa und Colitis ulcerosa aus der Sicht des Internisten: Epidemiologie & Pathologie Diagnostik. 1993 , 9, 5-24	0
2204	Using grids to document laboratory results. 1993 , 119, 863	
2203	Do ACE inhibitors affect diabetic morbidity and mortality?. 1993 , 119, 860-1	
2202	Racial disparities in coronary artery disease prevalence. 1993 , 119, 861	1
2201	Treatment of ulcerative colitis with 5-aminosalicylic acid. 1993 , 119, 858-9	
2200	Prazosin, Diuretics, and Glucose Intolerance. 1993 , 119, 859	
2199	The cost of treating common variable immunodeficiency. 1993 , 119, 862	
2198	Salicylates for inflammatory bowel disease. 1994 , 8, 203-31	6
2197	Intermittent therapy with high-dose 5-aminosalicylic acid enemas maintains remission in ulcerative proctitis and proctosigmoiditis. 1994 , 37, 58-62	51

2196	Pouchitis after ileal pouch-anal anastomosis: a Pouchitis Disease Activity Index. 1994 , 69, 409-15	590
2195	A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. 1994 , 106, 1429-35	103
2194	Medical therapy of inflammatory bowel disease. 1994 , 78, 1413-26	18
2193	Medical Therapy of Ulcerative Proctitis and Proctosigmoiditis, Including Refractory Disease. 1995 , 1, 207-219	3
2192	Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group. 1995 , 40, 296-304	110
2191	Oral colon-specific drug delivery: a review. 1995 , 2, 81-93	51
2190	DNA flow cytometric evaluation of cell cycle distribution in ulcerative colitis: a proposed method for assessing severity of disease. 1995 , 36, 50-4	6
2189	Newer treatments for inflammatory bowel disease. 1996 , 23, 577-608	10
2188	Randomized Controlled Trials in Inflammatory Bowel Diseases: The Case for the Positive Control. 1996 , 2, 260-264	
2187	Polymers for colon specific drug delivery. 1996 , 39, 327-338	79
2186	Randomized controlled trials in inflammatory bowel diseases: The case for the positive control. 1996 , 2, 260-264	
2185	Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. 1996 , 39, 63-8	77
2184	An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. The Mesalamine Study Group. 1996 , 124, 204-11	120
2183	Dexpanthenol enemas in ulcerative colitis: a pilot study. 1997 , 72, 616-20	10
2182	Standards for Trials of Therapy in Inflammatory Bowel Disease. 1997 , 3, 277-283	1
2181	A dose-ranging study of azathioprine pharmacokinetics after single-dose administration of a delayed-release oral formulation. 1997 , 37, 38-46	17
2180	Alternatives to Sulfasalazine: A Meta-analysis of 5-ASA in the Treatment of Ulcerative Colitis. 1997 , 3, 65-78	59
2179	Dexpanthenol Enemas in Ulcerative Colitis: A Pilot Study. 1997 , 72, 616-620	8

2178	Leukotrienes in ulcerative colitis: results of a multicenter trial of a leukotriene biosynthesis inhibitor, MK-591. 1997 , 112, 725-32	79
2177	Colonic Drug Delivery. 1997 , 23, 893-913	141
2176	Intestinal fate of 5-aminosalicylic acid: regional and systemic kinetic studies in relation to inflammatory bowel disease. 1997 , 81 Suppl 2, 1-28	20
2175	Hypersensitivity to 5-ASA suppositories. 1997 , 42, 1076-8	10
2174	Controlled trial of 4-ASA in ulcerative colitis. 1997 , 42, 354-8	17
2173	Differences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis: a case control study. 1997 , 40, 451-6	116
2172	Nicotine tartrate liquid enemas for mildly to moderately active left-sided ulcerative colitis unresponsive to first-line therapy: a pilot study. 1997 , 11, 663-71	57
2171	A dose-ranging pharmacokinetic study of nicotine tartrate following single-dose delayed-release oral and intravenous administration. 1997 , 11, 865-74	25
2170	Alternatives to sulfasalazine: A meta-analysis of 5-ASA in the treatment of ulcerative colitis. 1997 , 3, 65-78	56
2169	Standards for Trials of Therapy in Inflammatory Bowel Disease. 1997 , 3, 277-283	3
2168	Scintigraphic evaluation of a new capsule-type colon specific drug delivery system in healthy volunteers. 1998 , 87, 531-5	26
2167	Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis. 1998 , 41, 93-7	97
2166	Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. 1998 , 12, 707-15	40
2165	Mesalazine release from a pH dependent formulation: effects of omeprazole and lactulose co-administration. 1998 , 46, 173-5	8
2164	Ciprofloxacin as a treatment for ulcerative colitis-not yet. 1998 , 115, 1289-91	24
2163	Intestinal adaptation: molecular analyses of a complex process. 1998 , 115, 1291-4	10
2162	Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease. 1998 , 7, 135-6	10
2161	Tobacco industry promotion of cigarettes and adolescent smoking. 1998 , 279, 511-5	391

2160 A 66-year-old woman with ulcerative colitis. **1998**, 279, 949-53

2159 Relationship of Dietary Folate and Vitamin B6 With Coronary Heart Disease in Women. **1998**, 280, 417

5

2158 Error in Table. **1998**, 280, 422

1

2157 Chronic interstitial nephritis due to 5-aminosalicylic acid. **1999**, 19, 373-6

21

2156 Lupus-like syndrome caused by 5-aminosalicylic acid in patients with inflammatory bowel disease. **1999**, 13, 159-62

15

2155 Technology to obtain sustained release characteristics of drugs after delivered to the colon. **1999**, 6, 439-48

23

2154 Acute pancreatitis secondary to 5-aminosalicylic acid therapy in a patient with ulcerative colitis. **1999**, 25, 217-21

18

2153 Medical therapy for inflammatory bowel disease. **1999**, 28, 297-321

66

2152 Medical therapy of specific clinical presentations. **1999**, 28, 353-70, viii

7

2151 Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease. **1999**, 57, 383-408

54

2150 Transdermal nicotine decreases mucosal IL-8 expression but has no effect on mucin gene expression in ulcerative colitis. **1999**, 5, 174-81

18

2149 Gastrointestinal spread of oral prolonged-release mesalazine microgranules (Pentasa) dosed as either tablets or sachet. **2000**, 14, 163-9

35

2148 Serum transforming growth factor-beta1 levels increase in response to successful anti-inflammatory therapy in ulcerative colitis. **2000**, 14, 1443-9

11

2147 Sequential group trial to determine gastrointestinal site of absorption and systemic exposure of azathioprine. **2000**, 45, 1601-7

7

2146 Intravenous azathioprine in severe ulcerative colitis: a pilot study. **2000**, 95, 3463-8

26

2145 Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis. **2000**, 47, 410-4

104

2144 Tratamiento médico de la colitis ulcerosa. **2000**, 8, 288-290

2143 Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. **2000**, 119, 15-22

633

2142	5-Aminosalicylates in inflammatory bowel disease: choosing the right dose. 2001 , 33, 393-8	5
2141	An open-label trial of the PPAR α ligand rosiglitazone for active ulcerative colitis. 2001 , 96, 3323-3328	13
2140	An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitis. 2001 , 96, 3323-8	153
2139	Chemiluminescence in inflammatory bowel disease patients: a parameter of inflammatory activity. 2001 , 310, 151-6	30
2138	Tolerability of aminosalicylates in inflammatory bowel disease. 2001 , 15, 339-49	12
2137	Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study. 2001 , 15, 251-6	62
2136	5-amino-salicylate in the management of inflammatory bowel disease. 2001 , 3, 218-22	6
2135	Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. 2001 , 7, 237-42	50
2134	A prospective cohort study of practice guidelines in inflammatory bowel disease. 2001 , 96, 2401-6	22
2133	[Guidelines of the DGVS. Acute process. German Society of Digestive and Metabolic Diseases]. 2001 , 39, 33-8	2
2132	Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. 2002 , 97, 2577-84	150
2131	Update in medical therapy of ulcerative colitis: a practical approach. 2002 , 34, 397-407	11
2130	Non surgical interventions for late radiation proctitis in patients who have received radical radiotherapy to the pelvis. 2002 , CD003455	66
2129	Failure to yield: drug resistance in inflammatory bowel disease. 2002 , 122, 1165-7	7
2128	Bioequivalence testing for locally acting gastrointestinal products: what role for gamma scintigraphy?. 2002 , 42, 1200-10	11
2127	Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis. 2002 , 97, 2939-41	81
2126	Role of mesalazine in acute and long-term treatment of ulcerative colitis and its complications. 2002 , 42-7	19
2125	[Therapy of chronic inflammatory bowel diseases]. 2002 , 91, 2029-39	

2124	Assessing disease activity and disease activity indices for inflammatory bowel disease. 2002 , 4, 490-6	12
2123	Systematic review for non-surgical interventions for the management of late radiation proctitis. 2002 , 87, 134-43	107
2122	Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review. 2002 , 47, 471-88	78
2121	Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. 2003 , 7, 48-59	212
2120	Combined scintigraphic and pharmacokinetic investigation of enteric-coated mesalazine micropellets in healthy subjects. 2003 , 17, 1153-62	37
2119	Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial. 2003 , 17, 1355-64	76
2118	Long-term results of low-dose intravenous ciclosporin for acute severe ulcerative colitis. 2003 , 18, 303-8	46
2117	Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. 2003 , 18, 65-75	94
2116	Ten common errors in the management of inflammatory bowel disease. 2003 , 9, 205-9	14
2115	Maintenance therapy for inflammatory bowel disease. 2003 , 98, S6-S17	49
2114	Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. 2003 , 125, 1025-31	348
2113	Effect of ulcerative colitis treatment on transforming growth factor beta(1) in plasma and rectal mucosa. 2003 , 113, 57-61	7
2112	The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. 2003 , 1, 36-43	89
2111	Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study. 2003 , 1, 28-35	171
2110	Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. 2003 , 52, 1286-90	74
2109	Fluorescence endoscopy for the detection of low and high grade dysplasia in ulcerative colitis using systemic or local 5-aminolaevulinic acid sensitisation. 2003 , 52, 1003-7	85
2108	Urinalysis for interleukin-8 in the non-invasive diagnosis of acute and chronic inflammatory diseases. 2003 , 79, 159-63	21
2107	Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. 2003 , 52, 998-1002	241

2106	Treatment of ulcerative colitis with balsalazide: response to editorial by Drs. Farrell and Peppercorn and letter to the editor by Dr. Hanauer. 2003 , 98, 216-9	6
2105	Oral 5-aminosalicylic acid for inducing remission in ulcerative colitis. 2000 , CD000543	31
2104	Endoscopy in Inflammatory Bowel Diseases. 573-581	
2103	Antisense oligonucleotide treatment of inflammatory bowel diseases. 2005 , 106, 295-305	0
2102	[Ulcerative colitis. Acute episode]. 2004 , 42, 994-8	1
2101	Medical treatment of ulcerative colitis. 2004 , 17, 7-19	37
2100	An important pitfall in diagnosing gall bladder cancer. 2004 , 53, 1651, 1664	1
2099	Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis. 2004 , 70, 36-44	108
2098	A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis. 2004 , 99, 1122-8	97
2097	Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. 2004 , 99, 1371-85	514
2096	Antisense Therapeutics. 2004 ,	1
2095	A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis. 2004 , 53, 1646-51	116
2094	Rofecoxib and early relapse of inflammatory bowel disease: an open-label trial. 2004 , 19, 755-64	28
2093	Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. 2004 , 19, 1089-98	19
2092	How effective are the usual treatments for ulcerative colitis?. 2004 , 20, 143-9	42
2091	Review article: the management of mild to severe acute ulcerative colitis. 2004 , 20 Suppl 4, 88-92	23
2090	Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis--results from a randomized-controlled trial. 2004 , 20, 1353-63	22
2089	Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. 2004 , 19, 179-89	142

2088	Prospective evaluation of intestinal homing memory T cells in ulcerative colitis. 2004 , 10, 496-503	12
2087	Pharmacokinetics of mesalazine pellets in children with inflammatory bowel disease. 2004 , 10, 626-31	15
2086	Comparison of a disease activity index and patients' self-reported symptom severity in ulcerative colitis. 2004 , 10, 632-6	23
2085	[The treatment of distal ulcerative colitis]. 2004 , 28, 964-73	2
2084	Surface characterization and dissolution properties of high amylose corn starchpectin coatings. 2004 , 18, 29-37	36
2083	Choosing Therapy on the Basis of Disease Classifications in Inflammatory Bowel Disease. 2004 , 7, 169-179	
2082	Synthesis and evaluation of new linear azo-polymers for colonic targeting. 2004 , 7, 351-359	9
2081	Linear Type Azo-Containing Polyurethanes for Colon-Specific Drug Delivery. 2004 , 19, 45-53	20
2080	Mesalamine derivatives in the treatment of Crohn's disease. 2004 , 33, 303-17, ix-x	15
2079	General principles of medical therapy of inflammatory bowel disease. 2004 , 33, 191-208, viii	32
2078	Management of refractory inflammatory bowel disease. 2004 , 33, 319-34, x	3
2077	Medical therapy for ulcerative colitis 2004. 2004 , 126, 1582-92	145
2076	Study of high amylose corn starch as food grade enteric coating in a microcapsule model system. 2004 , 5, 93-100	55
2075	Update in medical therapy of ulcerative colitis: newer concepts and therapies. 2005 , 39, 557-69	20
2074	Mesalamine delivery systems: do they really make much difference?. 2005 , 57, 281-302	65
2073	A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. 2005 , 11, 421-7	110
2072	Clinical course of distal ulcerative colitis in relation to appendiceal orifice inflammation status. 2005 , 11, 366-71	48
2071	RDP58 is a novel and potentially effective oral therapy for ulcerative colitis. 2005 , 11, 713-9	84

2070	Optimizing therapy in patients with pancolitis. 2005 , 11, 937-46	6
2069	Design issues and outcomes in IBD clinical trials. 2005 , 11 Suppl 1, S22-8	28
2068	State of the art: IBD therapy and clinical trials in IBD. 2005 , 11 Suppl 1, S3-12	68
2067	Transforming growth factor beta1 and prostaglandin E2 concentrations are associated with bone formation markers in ulcerative colitis patients. 2005 , 78, 160-8	8
2066	[S3 guideline by the German Society of Digestive and Metabolic Diseases and the Competence Network of Chronic Inflammatory Bowel diseases on diagnosis and therapy of ulcerative colitis. An update]. 2005 , 100, 43-50	3
2065	Rebamipide enemas-new effective treatment for patients with corticosteroid dependent or resistant ulcerative colitis. 2005 , 50 Suppl 1, S119-23	18
2064	Rhinosinusitis derived Staphylococcal enterotoxin B possibly associates with pathogenesis of ulcerative colitis. 2005 , 5, 28	21
2063	[Ulcerative colitis? Guidelines 2004]. 2005 , 94, 1599-604	
2062	Medical management of ulcerative colitis. 2003 , 605-629	
2061	Clinical pharmacology in inflammatory bowel disease: optimizing current medical therapy. 2003 , 495-521	1
2060	An unusual cause of soft tissue infection. 2005 , 54, 965, 993	1
2059	TARGIT technology: coated starch capsules for site-specific drug delivery into the lower gastrointestinal tract. 2005 , 2, 159-67	24
2058	Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. 2005 , 100, 2478-85	242
2057	Dissolution of pH responsive formulations in media resembling intestinal fluids: bicarbonate versus phosphate buffers. 2005 , 15, 273-279	56
2056	Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. 2005 , 54, 782-8	168
2055	Management of acute severe colitis. 2005 , 75-76, 131-44	52
2054	Severe colitis in children. 2005 , 41, 375-85	15
2053	Is endoscopy necessary for the measurement of disease activity in ulcerative colitis?. 2005 , 100, 355-61	94

2052	Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. <i>New England Journal of Medicine</i> , 2005 , 352, 2499-507	59.2	633
2051	Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. 2005 , 54, 960-5		238
2050	Advances in colonic drug delivery. 2005 , 65, 1991-2007		153
2049	How important is onset of action in ulcerative colitis therapy?. 2005 , 65, 2069-83		3
2048	Characteristics of intestinal dendritic cells in inflammatory bowel diseases. 2005 , 129, 50-65		369
2047	Infliximab for induction and maintenance therapy for ulcerative colitis. <i>New England Journal of Medicine</i> , 2005 , 353, 2462-76	59.2	2906
2046	Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. 2006 , 4, 203-11		149
2045	Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. 2006 , CD005112		87
2044	Pediatric Colon Surgery: Challenges, Functional Outcome and Quality of Life. 2006 , 17, 43-48		0
2043	Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. 2006 , 55, 1568-74		105
2042	Medical Treatment of Inflammatory Bowel Disease. 2006 , 49, 1164		
2041	Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. 2006 , CD000543		68
2040	Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn disease. 2006 , 40, 482-9		29
2039	Plasma total homocysteine in the active stage of ulcerative colitis. 2006 , 21, 739-43		21
2038	New lessons: classic treatments, expanding options in ulcerative colitis. 2006 , 8 Suppl 1, 20-4		14
2037	Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial. 2006 , 23, 1403-13		87
2036	Systematic review: the use of mesalazine in inflammatory bowel disease. 2006 , 23, 841-55		84
2035	Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease. 2006 , 23, 1435-42		89

2034	Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis. 2006 , 23, 1427-34	50
2033	A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis. 2006 , 23, 1415-25	101
2032	Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis. 2006 , 24 Suppl 3, 37-40	38
2031	Review article: induction therapy for patients with active ulcerative colitis. 2006 , 24 Suppl 1, 10-6	33
2030	Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study. 2006 , 24, 1087-97	69
2029	The quantitative validation of non-endoscopic disease activity indices in ulcerative colitis. 2007 , 25, 333-42	16
2028	Outcomes of placebo therapy in inflammatory bowel disease. 2006 , 12, 328-33	14
2027	Galectin-3 modulates T cell activity and is reduced in the inflamed intestinal epithelium in IBD. 2006 , 12, 588-97	45
2026	An investigation into the in vivo performance variability of pH responsive polymers for ileo-colonic drug delivery using gamma scintigraphy in humans. 2006 , 95, 2760-6	72
2025	Combined oral and topical mesalazine treatment for extensive ulcerative colitis. 2006 , 3, 290-3	4
2024	[Aminosalicylates and steroids in the treatment of chronic inflammatory bowel diseases--consensus paper of the Working Group for Chronic Inflammatory Bowel Diseases of the OGGH]. 2006 , 44, 525-38; discussion 539	5
2023	[Endoscopy in IBD. A Consensus Report of the IBD Working of the Austrian Association of Gastroenterology and Hepatology]. 2006 , 44, 1183-92	3
2022	Catastrophic lower gastrointestinal complications following spinal surgery. 2006 , 55, 1262, 1289	0
2021	Correlated expression of high-sensitivity C-reactive protein in relation to disease activity in inflammatory bowel disease: lack of differences between Crohn's disease and ulcerative colitis. 2006 , 73, 205-9	31
2020	A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. 2006 , 55, 1255-62	313
2019	CD4+CD25(int) T cells in inflammatory diseases refractory to treatment with glucocorticoids. 2007 , 179, 7941-8	32
2018	Preferential induction of peripheral lymph node addressin on high endothelial venule-like vessels in the active phase of ulcerative colitis. 2007 , 102, 1499-509	58
2017	Omega 3 fatty acids (fish oil) for maintenance of remission in ulcerative colitis. 2007 , CD006443	29

2016	Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. 2007 , 56, 1706-13	144
2015	Management of inflammatory bowel disease. 2007 , 46, 359-64	1
2014	Type I interferons for induction of remission in ulcerative colitis. 2007 ,	
2013	Part III: Colorectal Disorders. 2007 , 439-474	
2012	Omega 3 fatty acids (fish oil) for maintenance of remission in ulcerative colitis. 2007 ,	12
2011	"Mind the Gap": an unmet need for new therapy in IBD. 2007 , 41, 799-809	16
2010	Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease. 2007 , 44, 414-22	100
2009	Modified-release solid formulations for colonic delivery. 2007 , 1, 53-63	42
2008	A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. 2007 , 132, 763-86	724
2007	Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. 2007 , 5, 209-14	184
2006	The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. 2007 , 102, 794-802	139
2005	Inflammatory bowel disease is not associated with increased intimal media thickening. 2007 , 102, 1050-5	55
2004	Continuous infusion versus bolus administration of steroids in severe attacks of ulcerative colitis: a randomized, double-blind trial. 2007 , 102, 601-8	77
2003	The risks and the benefits of mesalazine as a treatment for ulcerative colitis. 2007 , 6, 99-107	35
2002	Current medical therapy for chronic inflammatory bowel diseases. 2007 , 87, 697-725	15
2001	Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. 2007 , 132, 66-75; quiz 432-3	272
2000	A randomized, placebo-controlled, phase II study of tetomilast in active ulcerative colitis. 2007 , 132, 76-86	45
1999	A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. 2007 , 132, 516-26	112

1998	American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. 2007 , 133, 312-39	167
1997	Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. 2007 , 133, 423-32	675
1996	A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. 2007 , 133, 1414-22	104
1995	Diagnostics of inflammatory bowel disease. 2007 , 133, 1670-89	285
1994	Tumour necrosis factor alpha down-regulation parallels inflammatory regression in ulcerative colitis patients treated with infliximab. 2007 , 39, 811-7	25
1993	Inflammatory Bowel Disease. 2007 , 613-642	
1992	Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. 2007 , 21, 827-34	121
1991	Depression and anxiety levels in therapy-naive patients with inflammatory bowel disease and cancer of the colon. 2007 , 13, 438-43	34
1990	Clinical features and natural history of ulcerative colitis in Korea. 2007 , 13, 278-83	93
1989	Predictors of early response to infliximab in patients with ulcerative colitis. 2007 , 13, 123-8	134
1988	5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review. 2007 , 13, 629-38	144
1987	Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis. 2007 , 13, 1135-40	71
1986	Usefulness of quantitative real-time PCR assay for early detection of cytomegalovirus infection in patients with ulcerative colitis refractory to immunosuppressive therapies. 2007 , 13, 1516-21	113
1985	Outcome measurement in clinical trials for Ulcerative Colitis: towards standardisation. 2007 , 8, 17	95
1984	11beta-hydroxysteroid dehydrogenase 1 and 2 expression in colon from patients with ulcerative colitis. 2007 , 22, 1019-23	37
1983	Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn's disease. 2007 , 4, 55-64	36
1982	Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man. 1990 , 4, 523-33	57
1981	Review article: new developments in the use of 5-aminosalicylic acid in patients with inflammatory bowel disease. 1991 , 5, 449-70	33

1980	Is topical therapy necessary in acute distal colitis? Double-blind comparison of high-dose oral mesalazine versus steroid enemas in the treatment of active distal ulcerative colitis. 1991 , 5, 513-22	15
1979	An Eudragit-coated prednisolone preparation for ulcerative colitis: pharmacokinetics and preliminary therapeutic use. 1992 , 6, 31-40	22
1978	Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: long-term results. 2007 , 25, 419-27	43
1977	MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. 2007 , 26, 205-15	125
1976	Review article: increasing the dose of oral mesalazine therapy for active ulcerative colitis does not improve remission rates. 2007 , 26, 1179-86	10
1975	The role of probiotics in inflammatory bowel disease. 2007 , 52, 607-11	29
1974	Accuracy of four fecal assays in the diagnosis of colitis. 2007 , 50, 1697-706	72
1973	The production of interferon-gamma-inducible protein 10 by granulocytes and monocytes is associated with ulcerative colitis disease activity. 2007 , 42, 947-56	21
1972	Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. 2007 , 22, 429-37	165
1971	Optimizing drug therapy in inflammatory bowel disease. 2007 , 9, 513-20	10
1970	Interplay between intestinal pH, transit time and feed status on the in vivo performance of pH responsive ileo-colonic release systems. 2008 , 25, 1828-35	162
1969	Increased expression of long pentraxin PTX3 in inflammatory bowel diseases. 2008 , 53, 1910-6	24
1968	Racial differences in disease extent and severity in patients with ulcerative colitis: a retrospective cohort study. 2008 , 53, 2754-60	14
1967	Meta-analysis of the placebo response in ulcerative colitis. 2008 , 53, 875-91	20
1966	A critical review of endoscopic indices in ulcerative colitis: inter-observer variation of the endoscopic index. 2008 , 1, 40-45	6
1965	Colite aiguë grave au cours des MICI: l'âge diagnostique. 2008 , 2, 5-9	1
1964	Phagocyte-specific S100 proteins are released from affected mucosa and promote immune responses during inflammatory bowel disease. 2008 , 216, 183-92	130
1963	Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. 2008 , 14, 32-9	192

1962	Phenotypical and functional study of ghrelin and its receptor in the pathogenesis of Crohn's disease. 2008 , 14, 1205-13	37
1961	Impairment of the in vitro drug release behaviour of oral modified release preparations in the presence of alcohol. 2008 , 360, 171-6	33
1960	Multivariate analysis for factors predicting rapid response of leukocytapheresis in patients with steroid-resistant ulcerative colitis: a multicenter prospective open-label study. 2008 , 12, 484-90	19
1959	Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease. 2008 , 83, 70-6	54
1958	Comparative analysis of Bayer wide-range C-reactive protein (wr-CRP) and the Dade-Behring high sensitivity C-reactive protein (hs-CRP) in patients with inflammatory bowel disease. 2008 , 9, 140-3	14
1957	Correlations among total colonoscopic findings, clinical symptoms, and laboratory markers in ulcerative colitis. 2008 , 23 Suppl 2, S262-7	66
1956	Increased pentosidine, an advanced glycation end-product, in urine and tissue reflects disease activity in inflammatory bowel diseases. 2008 , 23 Suppl 2, S140-5	13
1955	Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. 2008 , 28, 674-88	76
1954	Clinical trial: a multicentre, randomized, double-blind, placebo-controlled, dose-finding, phase II study of subcutaneous interferon-beta-la in moderately active ulcerative colitis. 2008 , 28, 758-67	34
1953	Review article: new drug formulations, chemical entities and therapeutic approaches for the management of ulcerative colitis. 2008 , 28, 815-29	14
1952	A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis. 2008 , 28, 1230-9	52
1951	An in vivo comparison of intestinal pH and bacteria as physiological trigger mechanisms for colonic targeting in man. 2008 , 130, 154-60	99
1950	Improving delivery of aminosalicylates in ulcerative colitis: effect on patient outcomes. 2008 , 68, 1089-103	24
1949	Steroid-refractory severe ulcerative colitis: what are the available treatment options?. 2008 , 68, 1157-67	18
1948	Effect of 5-aminosalicylates on renal function in patients with inflammatory bowel disease: 4-year follow-up study. 2008 , 31, 477-84	17
1947	Identification of symptom domains in ulcerative colitis that occur frequently during flares and are responsive to changes in disease activity. 2008 , 6, 69	19
1946	Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis. 2008 , CD007216	26
1945	Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. 2008 , 134, 688-95	173

1944	A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. 2008 , 135, 400-9	167
1943	European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. 2008 , 2, 1-23	402
1942	European evidence-based Consensus on the management of ulcerative colitis: Current management. 2008 , 2, 24-62	371
1941	Long-term outcome after infliximab for refractory ulcerative colitis. 2008 , 2, 219-25	163
1940	Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. 2008 , 103, 162-9	451
1939	Dynamics of the mucosa-associated flora in ulcerative colitis patients during remission and clinical relapse. 2008 , 46, 3510-3	66
1938	Therapeutic options in acute severe ulcerative colitis. 2008 , 2, 357-70	12
1937	Cost-effectiveness of 5-aminosalicylic acid therapy for maintenance of remission in ulcerative colitis. 2008 , 103, 3094-105	24
1936	Starch as an encapsulation material to control digestion rate in the delivery of active food components. 2008 , 279-293	6
1935	Type I interferons for induction of remission in ulcerative colitis. 2008 , CD006790	18
1934	Real-time PCR quantification analysis of five mucosal transcripts in patients with Crohn's disease. 2008 , 20, 290-6	10
1933	Oral 5-ASA therapy in ulcerative colitis: what are the implications of the new formulations?. 2008 , 42, 338-44	26
1932	Review and clinical perspectives for the use of infliximab in ulcerative colitis. 2008 , 22, 261-72	7
1931	Infliximab in ulcerative colitis. 2008 , 2, 379-88	21
1930	The role of Asacol in the treatment of patients with ulcerative colitis. 2008 , 6, 8-14	
1929	A clinical trial of combined use of rosiglitazone and 5-aminosalicylate for ulcerative colitis. 2008 , 14, 114-9	41
1928	Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn's disease. 2009 , 2, 139-47	5
1927	A Review of Multimatrix System (MMX) Mesalazine in the Management of Ulcerative Colitis. 2009 , 1, CMT.S38	0

1926	Renal effects of long-term treatment with 5-aminosalicylic acid. 2009 , 23, 170-6	52
1925	The effects of cytokines on suppression of lymphocyte proliferation by dexamethasone. 2009 , 183, 164-71	53
1924	Infliximab for the treatment of ulcerative colitis. 2009 , 3, 219-29	5
1923	An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. 2009 , 104, 2990-5	96
1922	Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study. 2009 , 104, 1452-9	35
1921	Medical management of ulcerative colitis. 2009 , 27, 542-9	14
1920	The placebo response rate in irritable bowel syndrome and inflammatory bowel disease. 2009 , 27 Suppl 1, 68-75	19
1919	Treatment of ulcerative colitis in the elderly. 2009 , 27, 327-34	31
1918	TNF alpha inhibition as treatment modality for certain rheumatologic and gastrointestinal diseases. 2009 , 9, 295-314	25
1917	Infliximab therapy for patients with inflammatory bowel disease: 10 years on. 2009 , 623 Suppl 1, S17-25	19
1916	Fabrication and in vivo evaluation of highly pH-responsive acrylic microparticles for targeted gastrointestinal delivery. 2009 , 37, 284-90	38
1915	Local application of tacrolimus in distal colitis: feasible and safe. 2009 , 15, 193-8	49
1914	Pouchitis, similar to active ulcerative colitis, is associated with impaired butyrate oxidation by intestinal mucosa. 2009 , 15, 335-40	28
1913	Voting With their Feet (VWF) endpoint: a meta-analysis of an alternative endpoint in clinical trials, using 5-ASA induction studies in ulcerative colitis. 2009 , 15, 422-8	4
1912	Therapeutic strategies for the management of ulcerative colitis. 2009 , 15, 935-50	56
1911	Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: a pilot study. 2009 , 15, 760-8	96
1910	Positron emission tomography (PET) used to image subclinical inflammation associated with ulcerative colitis (UC) in remission. 2009 , 15, 750-5	24
1909	GlcNAc6ST-1-mediated decoration of MADCAM-1 protein with L-selectin ligand carbohydrates directs disease activity of ulcerative colitis. 2009 , 15, 697-706	44

1908	Antinuclear antibodies: a marker associated with steroid dependence in patients with ulcerative colitis. 2009 , 15, 1039-43	17
1907	Controversies in mucosal healing in ulcerative colitis. 2009 , 15, 796-800	22
1906	Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. 2009 , 15, 1302-7	90
1905	Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. 2009 , 15, 1851-8	216
1904	Physiological bicarbonate buffers: stabilisation and use as dissolution media for modified release systems. 2009 , 382, 56-60	83
1903	Home telemanagement for patients with ulcerative colitis (UC HAT). 2009 , 54, 2463-72	36
1902	Does CT influence the decision to perform colectomy in patients with severe ulcerative colitis?. 2009 , 13, 504-7	11
1901	Les scores endoscopiques des MICI. 2009 , 3, 101-106	
1900	Detection of galectin-3 in patients with inflammatory bowel diseases: new serum marker of active forms of IBD?. 2009 , 58, 503-12	31
1899	Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. 2009 , 65, 1211-28	229
1898	Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. 2009 , 30, 210-26	161
1897	Fecal lactoferrin, myeloperoxidase and serum C-reactive are effective biomarkers in the assessment of disease activity and severity in patients with idiopathic ulcerative colitis. 2009 , 24, 1768-74	46
1896	The robustness and flexibility of an emulsion solvent evaporation method to prepare pH-responsive microparticles. 2009 , 377, 135-41	27
1895	Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn's disease. 2009 , 206, 1883-97	315
1894	Mathematical weighting of a clinimetric index (Pediatric Ulcerative Colitis Activity Index) was superior to the judgmental approach. 2009 , 62, 738-44	11
1893	Long term efficacy and safety of allopurinol and azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease. 2009 , 3, 162-7	54
1892	Predictive value of time-intensity curves obtained with contrast-enhanced ultrasonography (CEUS) in the follow-up of 30 patients with Crohn's disease. 2009 , 12, 151-9	9
1891	Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. 2009 , 137, 1250-60; quiz 1520	377

1890	Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. 2009 , 137, 1934-43.e1-3	120
1889	Accidentally ASCENDING into comparative effective research for inflammatory bowel disease. 2009 , 137, 1880-2	6
1888	Inflammatory bowel diseases: controversies in the use of diagnostic procedures. 2009 , 27, 269-77	46
1887	Repeat endoscopy affects patient management in pediatric inflammatory bowel disease. 2009 , 104, 722-7	19
1886	Colonic treatments and targets: issues and opportunities. 2009 , 17, 335-63	68
1885	Epithelial apoptosis: cause or consequence of ulcerative colitis?. 2009 , 44, 1429-34	21
1884	A combination of pH-sensitive caplet coatings may be an effective noninvasive strategy to deliver bioactive substances, nutrients, or their precursors to the colon. 2009 , 34, 893-900	2
1883	A systematic prospective comparison of noninvasive disease activity indices in ulcerative colitis. 2009 , 7, 1081-8	127
1882	Evolving inflammatory bowel disease treatment paradigms: top-down versus step-up. 2009 , 38, 577-94	19
1881	Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. 2009 , 7, 762-9	100
1880	Patient reported symptoms during an ulcerative colitis flare: a Qualitative Focus Group Study. 2009 , 21, 558-64	35
1879	Role of sulfated O-glycans expressed by high endothelial venule-like vessels in pathogenesis of chronic inflammatory gastrointestinal diseases. 2009 , 32, 774-9	11
1878	Kurzdarstellung der Therapieleitlinien zur Colitis ulcerosa. 2009 , 25, 187-192	
1877	Impact of narcotic use on the requirement for colectomy in inpatients with ulcerative colitis. 2010 , 53, 1295-300	8
1876	Histopathology predictors of medically refractory ulcerative colitis. 2010 , 53, 1280-6	12
1875	Anti-inflammatory effects of 5-aminosalicylic acid conjugates with chenodeoxycholic acid and ursodeoxycholic acid on carrageenan-induced colitis in guinea-pigs. 2001 , 53, 1711-20	15
1874	Novel endoscopic activity index is useful for choosing treatment in severe active ulcerative colitis patients. 2010 , 45, 936-43	30
1873	Mucosal healing in inflammatory bowel disease: where do we stand?. 2010 , 12, 471-8	39

1872	Importance of mucosal healing in ulcerative colitis. 2010 , 16, 338-46	161
1871	Comparison of several activity indices for the evaluation of endoscopic activity in UC: inter- and intraobserver consistency. 2010 , 16, 192-7	51
1870	Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis. 2010 , 16, 620-9	33
1869	Assessing disease activity in ulcerative colitis: patients or their physicians?. 2010 , 16, 651-6	32
1868	Genome-wide gene expression analysis of mucosal colonic biopsies and isolated colonocytes suggests a continuous inflammatory state in the lamina propria of patients with quiescent ulcerative colitis. 2010 , 16, 999-1007	31
1867	Exogenous alkaline phosphatase for the treatment of patients with moderate to severe ulcerative colitis. 2010 , 16, 1180-6	76
1866	Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study. 2010 , 16, 1567-74	46
1865	Direct comparison of two different mesalamine formulations for the maintenance of remission in patients with ulcerative colitis: a double-blind, randomized study. 2010 , 16, 1575-82	20
1864	Impaired erythrocyte antioxidant defense in active inflammatory bowel disease: impact of anemia and treatment. 2010 , 16, 1467-75	29
1863	N-3 polyunsaturated fatty acid diet therapy for patients with inflammatory bowel disease. 2010 , 16, 1696-707	72
1862	Efficacy and safety of mesalamine suppositories for treatment of ulcerative proctitis in children and adolescents. 2010 , 16, 1931-9	20
1861	Clinical scenarios in IBD: optimizing the use of conventional and biologic agents. 2010 , 16 Suppl 1, S1-11	14
1860	IL-33 is upregulated in colonocytes of ulcerative colitis. 2010 , 128, 80-5	114
1859	Ulcerative colitis and irritable bowel patients exhibit distinct abnormalities of the gut microbiota. 2010 , 10, 134	155
1858	Clinical trial: colectomy after rescue therapy in ulcerative colitis - 3-year follow-up of the Swedish-Danish controlled infliximab study. 2010 , 32, 984-9	134
1857	Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis - a 6-month placebo-controlled trial. 2010 , 32, 990-9	46
1856	Efficacy of antibiotic combination therapy in patients with active ulcerative colitis, including refractory or steroid-dependent cases. 2010 , 25 Suppl 1, S62-6	17
1855	Validity of activity indices in ulcerative colitis: comparison of clinical and endoscopic indices. 2010 , 22, 39-44	18

1854	Tolerability and usefulness of mercaptopurine in azathioprine-intolerant Japanese patients with ulcerative colitis. 2010 , 22, 289-96	8
1853	Profits from biological treatment in inflammatory bowel disease patients. 2010 , 2, 68-76	
1852	Effect of probiotics on pro-inflammatory cytokines and NF-kappaB activation in ulcerative colitis. 2010 , 16, 4145-51	161
1851	[The usefulness of Doppler sonography in the assessment of disease activity of ulcerative colitis]. 2010 , 56, 346-52	1
1850	A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspective. 2010 , 13, 148-61	17
1849	Oral budesonide for induction of remission in ulcerative colitis. 2010 , CD007698	30
1848	Newly developed antibiotic combination therapy for ulcerative colitis: a double-blind placebo-controlled multicenter trial. 2010 , 105, 1820-9	92
1847	The -A2518G polymorphism of monocyte chemoattractant protein-1 is associated with Crohn's disease. 2010 , 105, 1586-94	21
1846	Topical rosiglitazone treatment improves ulcerative colitis by restoring peroxisome proliferator-activated receptor-gamma activity. 2010 , 105, 1595-603	49
1845	Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. 2010 , CD004115	56
1844	Supportive therapy in IBD: what additional diagnoses and conditions must be treated?. 2010 , 28, 452-62	8
1843	Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-alpha treatment. 2010 , 95, 199-205	116
1842	Immunohistochemical analysis of carbohydrate antigens in chronic inflammatory gastrointestinal diseases. 2010 , 479, 271-89	8
1841	Clinical pharmacology of 5-ASA compounds in inflammatory bowel disease. 2010 , 39, 559-99	32
1840	Evolving inflammatory bowel disease treatment paradigms: top-down versus step-up. 2010 , 94, 1-18	26
1839	Usefulness of oral beclometasone dipropionate in the treatment of active ulcerative colitis in clinical practice: the RECLICU Study. 2010 , 4, 629-36	22
1838	Sustained remission after steroids and leukocytapheresis induced response in steroid-dependent ulcerative colitis: results at 1 year. 2010 , 42, 432-5	11
1837	Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. 2010 , 105, 501-23; quiz 524	917

1836	Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. 2010 , 138, 1286-96, 1296.e1-3	101
1835	A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. 2010 , 139, 1844-1854.e1	73 ¹
1834	Metabonomics in ulcerative colitis: diagnostics, biomarker identification, and insight into the pathophysiology. 2010 , 9, 954-62	127
1833	Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. 2010 , 59, 49-54	404
1832	Nutritional status in patients with active inflammatory bowel disease: prevalence of malnutrition and methods for routine nutritional assessment. 2010 , 21, 315-9	119
1831	Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). 2010 , 59, 666-89	843
1830	Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis. 2010 , 59, 1485-92	55
1829	How rapidly should remission be achieved?. 2010 , 28, 548-55	22
1828	Clinical implications of mucosal healing for the management of IBD. 2010 , 7, 15-29	347
1827	Cellular sources of MMP-7, MMP-13 and MMP-28 in ulcerative colitis. 2010 , 45, 1186-96	33
1826	Scoring systems in inflammatory bowel disease. 2010 , 4, 513-21	8
1825	[Mucosal healing: a realistic aim or marketing myth?]. 2011 , 34 Suppl 3, 4-11	
1824	Symptoms in patients with ulcerative colitis in remission are associated with visceral hypersensitivity and mast cell activity. 2011 , 46, 981-7	43
1823	Evaluation of p38 MAPK pathway as a molecular signature in ulcerative colitis. 2011 , 10, 2216-25	35
1822	Dysregulated upregulation of T-cell immunoglobulin and mucin domain-3 on mucosal T helper 1 cells in patients with Crohn's disease. 2011 , 46, 701-9	15
1821	Treatment of acute ulcerative colitis with infliximab, a retrospective study from three Danish hospitals. 2011 , 5, 28-33	30
1820	Evolution and predictive factors of relapse in ulcerative colitis patients treated with mesalazine after a first course of corticosteroids. 2011 , 5, 196-202	21
1819	C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) or both? A systematic evaluation in pediatric ulcerative colitis. 2011 , 5, 423-9	48

1818	Results of the 2nd part Scientific Workshop of the ECCO. II: Measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease. 2011 , 5, 484-98	78
1817	The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease. 2011 , 43, 1-20	101
1816	Ultrasonographic assessment of colonic wall in moderate-severe ulcerative colitis: comparison with endoscopic findings. 2011 , 43, 703-6	25
1815	An evidence-based systematic review on medical therapies for inflammatory bowel disease. 2011 , 106 Suppl 1, S2-25; quiz S26	205
1814	Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. 2011 , 141, 1194-201	646
1813	Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis. 2011 , 60, 1520-6	81
1812	Colon-specific drug delivery using ethylcellulose and chitosan in the coat of compression-coated tablets. 2011 , 37, 945-53	14
1811	Behavioral interventions may prolong remission in patients with inflammatory bowel disease. 2011 , 49, 145-50	32
1810	Mucosal healing for predicting clinical outcome in patients with ulcerative colitis using thiopurines in monotherapy. 2011 , 22, 621-5	26
1809	Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. 2011 , 60, 780-7	576
1808	Guidelines for the management of inflammatory bowel disease in adults. 2011 , 60, 571-607	927
1807	Drug Delivery to the Colon. 2011 , 385-399	1
1806	Mucosal healing in ulcerative colitis: where do we stand?. 2011 , 12, 1417-23	15
1805	Changes in immunohistochemical levels and subcellular localization after therapy and correlation and colocalization with CD68 suggest a pathogenetic role of Hsp60 in ulcerative colitis. 2011 , 19, 552-61	28
1804	Natural history of ulcerative colitis: current knowledge. 2011 , 12, 1390-5	13
1803	Leukocytapheresis in pediatric patients with ulcerative colitis. 2011 , 53, 34-9	11
1802	Is sigmoidoscopy sufficient for evaluating inflammatory status of ulcerative colitis patients?. 2011 , 26, 683-7	18
1801	Clinical outcomes and factors for response prediction after the first course of corticosteroid therapy in patients with active ulcerative colitis. 2011 , 26, 1114-22	15

1800	Increased proportion of CD16(+) NK cells in the colonic lamina propria of inflammatory bowel disease patients, but not after azathioprine treatment. 2011 , 33, 115-26	47
1799	Inflammatory manifestations at colonoscopy in patients with colonic diverticular disease. 2011 , 33, 358-65	41
1798	Review article: defining remission in ulcerative colitis. 2011 , 34, 113-24	145
1797	Kinetics of butyrate metabolism in the normal colon and in ulcerative colitis: the effects of substrate concentration and carnitine on the oxidation pathway. 2011 , 34, 526-32	21
1796	Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis--additional results from two controlled studies. 2011 , 34, 747-56	25
1795	Increased numbers of immature plasma cells in peripheral blood specifically overexpress chemokine receptor CXCR3 and CXCR4 in patients with ulcerative colitis. 2011 , 163, 215-24	39
1794	Upregulated mRNA expression of major histocompatibility complex class I chain-related gene A in colon and activated natural killer cells of Chinese patients with ulcerative colitis. 2011 , 12, 82-9	6
1793	Mucoadhesive platforms for targeted delivery to the colon. 2011 , 420, 11-9	29
1792	Gene expression profiling and response signatures associated with differential responses to infliximab treatment in ulcerative colitis. 2011 , 106, 1272-80	66
1791	Correlation of C-reactive protein with clinical and endoscopic activity in patients with ulcerative colitis. 2011 , 56, 1801-5	35
1790	Clinical trial: Effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study. 2011 , 46, 46-56	25
1789	Genes of intestinal Escherichia coli and their relation to the inflammatory activity in patients with ulcerative colitis and Crohn's disease. 2011 , 56, 367-72	8
1788	Presence of intestinal Mycobacterium avium subspecies paratuberculosis (MAP) DNA is not associated with altered MMP expression in ulcerative colitis. 2011 , 11, 34	17
1787	Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine. 2011 , 11, 157	13
1786	Development, validation, and responsiveness of a novel disease activity index for intestinal Behçet's disease. 2011 , 17, 605-13	68
1785	Anti-TNF treatment of ulcerative colitis associated with idiopathic thrombocytopenic purpura. 2011 , 17, 864-5	11
1784	Measurement of disease activity in ulcerative colitis: interobserver agreement and predictors of severity. 2011 , 17, 1257-64	37
1783	Optimal apheresis treatment volume for the efficacy and safety of leukocytapheresis with CellSORBA in patients with active ulcerative colitis. 2011 , 26, 326-31	2

1782	Looking beyond symptom relief: evolution of mucosal healing in inflammatory bowel disease. 2011 , 4, 129-43	37
1781	Infliximab therapy downregulation of basic fibroblast growth factor/syndecan 1 link: a possible molecular pathway of mucosal healing in ulcerative colitis. 2011 , 64, 968-72	10
1780	H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. 2011 , 60, 456-62	60
1779	Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers. 2011 , 46, 1081-91	97
1778	Ileal pouch anal anastomosis with close rectal dissection using automated vessel sealers for ulcerative colitis: a promising alternative. 2011 , 28, 345-51	12
1777	The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study. 2011 , 60, 1068-75	114
1776	Exacerbation of bloody diarrhea as a side effect of mesalamine treatment of active ulcerative colitis. 2011 , 5, 159-65	22
1775	Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. 2011 , 106, 601-16	176
1774	Is there any association between impaired health-related quality of life and non-adherence to medical therapy in inflammatory bowel disease?. 2012 , 47, 1298-303	13
1773	Oral high dose Beclomethasone dipropionate for treatment of active ulcerative colitis. 2012 , 4, 9	1
1772	Calcineurin inhibitors or anti-TNF- α agents in severe ulcerative colitis: available options and limitations. 2012 , 50, 396-406	3
1771	The impact of matrix metalloproteinases and their tissue inhibitors in inflammatory bowel diseases. 2012 , 30, 289-95	66
1770	Once-daily MMX(\square) mesalamine for endoscopic maintenance of remission of ulcerative colitis. 2012 , 107, 1064-77	31
1769	Role of biological therapy for inflammatory bowel disease in developing countries. 2012 , 61, 706-12	23
1768	Endoscopic Assessment of Disease Activity and Mucosal Healing in Inflammatory Bowel Disease. 2012 , 321-331	
1767	Proteomic analysis of colonic mucosal tissue from tuberculous and ulcerative colitis patients. 2012 , 16, 193-8	5
1766	Medical management of ulcerative colitis with a specific focus on 5-aminosalicylates. 2012 , 5, 77-83	5
1765	The valuable role of endoscopy in inflammatory bowel disease. 2012 , 2012, 467979	13

1764	Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. 2012 , 10, CD000543	90
1763	Editorial (Hot Topic :Randomized Clinical Trials in Inflammatory Bowel Disease). 2012 , 7, 255-255	
1762	Imaging in inflammatory bowel disease mucosal healing in ulcerative colitis: relevance for clinical outcomes. 2012 , 13, 1234-44	1
1761	Randomized Controlled Trials in Maintenance of Remission in Crohn's Disease. 2012 , 7, 270-283	
1760	Mucosal healing restores normal health and quality of life in patients with inflammatory bowel disease. 2012 , 24, 762-9	77
1759	The prevalence and efficacy of ganciclovir on steroid-refractory ulcerative colitis with cytomegalovirus infection: a prospective multicenter study. 2012 , 46, 51-6	71
1758	Evaluation of inflammatory activity in Crohn's disease and ulcerative colitis. 2012 , 18, 872-81	67
1757	Colitis ulcerosa. 2012 , 11, 266-274	
1756	Immunosuppressive and biologic therapy for ulcerative colitis. 2012 , 17, 449-67	12
1755	Ulcerative colitis. 2012 , 380, 1606-19	1036
1754	Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. 2012 , 380, 1909-15	394
1753	Magnetic resonance colonography in severe attacks of ulcerative colitis. 2012 , 22, 1963-71	8
1752	Endoscopic assessment of inflammatory bowel disease: colonoscopy/esophagogastroduodenoscopy. 2012 , 41, 271-90	18
1751	Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. 2012 , 10, 391-9.e1	185
1750	Mucosal healing in inflammatory bowel diseases: a systematic review. 2012 , 61, 1619-35	511
1749	Efficacy and safety of Fufangkushen colon-coated capsule in the treatment of ulcerative colitis compared with mesalazine: a double-blinded and randomized study. 2012 , 141, 592-8	37
1748	TNF- β induced down-regulation of CDX2 suppresses MEP1A expression in colitis. 2012 , 1822, 843-51	25
1747	Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. <i>New England Journal of Medicine</i> , 2012 , 367, 616-24	59.2 576

1746	Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. 2012 , 142, 257-65.e1-3	842
1745	Abatacept for Crohn's disease and ulcerative colitis. 2012 , 143, 62-69.e4	105
1744	Basiliximab does not increase efficacy of corticosteroids in patients with steroid-refractory ulcerative colitis. 2012 , 143, 356-64.e1	30
1743	Once-daily budesonide MMX [®] extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. 2012 , 143, 1218-1226.e2	167
1742	Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease. 2012 , 143, 1461-9	39
1741	Hepatobiliary disorders among naïve patients with ulcerative colitis in Upper Egypt. 2012 , 13, 71-6	3
1740	Clostridium difficile infection is associated with worse long term outcome in patients with ulcerative colitis. 2012 , 6, 330-6	92
1739	Severe disease on endoscopy and steroid use increase the risk for bowel perforation during colonoscopy in inflammatory bowel disease patients. 2012 , 6, 470-5	59
1738	Neuroimmune interactions in patients with inflammatory bowel diseases: disease activity and clinical behavior based on Substance P serum levels. 2012 , 6, 563-70	19
1737	Results of the 2nd scientific workshop of the ECCO (IV): therapeutic strategies to enhance intestinal healing in inflammatory bowel disease. 2012 , 6, 492-502	27
1736	Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. 2012 , 6, 965-90	592
1735	Duration and severity of primary sclerosing cholangitis is not associated with risk of neoplastic changes in the colon in patients with ulcerative colitis. 2012 , 75, 1045-1054.e1	27
1734	Rectocolite hémorragique : épidémiologie, physiopathologie, diagnostic, histoire naturelle et stratégie thérapeutique. 2012 , 7, 1-19	1
1733	Mucosal healing with anti-TNF antibodies. 2012 , 86 Suppl 1, 16-22	15
1732	Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing. 2012 , 107, 1684-92	181
1731	Canadian Association of Gastroenterology consensus guidelines on safety and quality indicators in endoscopy. 2012 , 26, 17-31	74
1730	[Effect of a probiotic preparation (VSL#3) in patients with mild to moderate ulcerative colitis]. 2012 , 60, 94-101	13
1729	[Guidelines for the management of ulcerative colitis]. 2012 , 59, 118-40	25

1728	Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. 2012 , 18, 201-11	146
1727	Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: a prospective, multicenter study. 2012 , 18, 1006-10	89
1726	Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis. 2012 , 18, 803-8	139
1725	Impaired butyrate oxidation in ulcerative colitis is due to decreased butyrate uptake and a defect in the oxidation pathway. 2012 , 18, 1127-36	56
1724	Study of sexual, urinary, and fecal function in females following restorative proctocolectomy. 2012 , 18, 1601-7	16
1723	One-year investigator-blind randomized multicenter trial comparing Asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitis. 2012 , 18, 1885-93	17
1722	Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNF α blocking agents. 2012 , 18, 2011-7	132
1721	Can endoscopy be avoided in the assessment of ulcerative colitis in clinical trials?. 2012 , 18, 2056-62	27
1720	Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. 2012 , 18, 2218-24	524
1719	Decreased mucosal sulfide detoxification is related to an impaired butyrate oxidation in ulcerative colitis. 2012 , 18, 2371-80	31
1718	Two distinct lymphocyte homing systems involved in the pathogenesis of chronic inflammatory gastrointestinal diseases. 2012 , 34, 401-13	14
1717	Association between red cell distribution width and disease activity in patients with inflammatory bowel disease. 2012 , 57, 1033-8	84
1716	Evaluation of fecal myeloperoxidase as a biomarker of disease activity and severity in ulcerative colitis. 2012 , 57, 1336-40	26
1715	Leukocytapheresis for steroid-dependent ulcerative colitis in clinical practice: results of a nationwide Spanish registry. 2012 , 47, 359-65	21
1714	The impact of MMX mesalazine on disease-specific health-related quality of life in ulcerative colitis patients. 2012 , 35, 1386-96	12
1713	Normal response to vaccines in inflammatory bowel disease patients treated with thiopurines. 2012 , 18, 261-8	64
1712	Inflammatory bowel disease in patients with primary sclerosing cholangitis: clinical characterization in liver transplanted and nontransplanted patients. 2012 , 18, 536-45	85
1711	Cancer prevention in ulcerative colitis: long-term outcome following fluorescence-guided colonoscopy. 2012 , 18, 489-95	11

1710	MDCT assessment of ulcerative colitis: radiologic analysis with clinical, endoscopic, and pathologic correlation. 2012 , 37, 61-9	17
1709	Impact of MMX mesalamine on improvement and maintenance of health-related quality of life in patients with ulcerative colitis. 2013 , 19, 386-96	7
1708	ERK controls epithelial cell death receptor signalling and cellular FLICE-like inhibitory protein (c-FLIP) in ulcerative colitis. 2013 , 91, 839-49	16
1707	Urinary NMR metabolomic profiles discriminate inflammatory bowel disease from healthy. 2013 , 7, e42-8	83
1706	Backwash ileitis and the risk of colon neoplasia in ulcerative colitis patients undergoing restorative proctocolectomy. 2013 , 58, 2019-27	8
1705	A novel coating concept for ileo-colonic drug targeting: proof of concept in humans using scintigraphy. 2013 , 84, 573-7	30
1704	Relationship of Mindfulness, Quality of Life, and Psychiatric Symptoms Among Patients with Ulcerative Colitis. 2013 , 4, 296-300	12
1703	Deep remission in inflammatory bowel disease: looking beyond symptoms. 2013 , 15, 315	91
1702	Histologic markers of inflammation in patients with ulcerative colitis in clinical remission. 2013 , 11, 991-6	87
1701	Flare up of ulcerative colitis during pregnancy treated by adsorptive granulocyte and monocyte apheresis: therapeutic outcomes in three pregnant patients. 2013 , 288, 341-7	16
1700	Vedolizumab as induction and maintenance therapy for ulcerative colitis. <i>New England Journal of Medicine</i> , 2013 , 369, 699-710	59.2 1465
1699	Noninvasive evaluation of mucosal healing in inflammatory bowel diseases. 2013 , 6, 1-7	3
1698	Evaluation of mucosal healing of ulcerative colitis by a quantitative fecal immunochemical test. 2013 , 108, 83-9	69
1697	Definition and evaluation of mucosal healing in clinical practice. 2013 , 45, 969-77	87
1696	Budesonide MMX and mesalamine to induce remission in patients with ulcerative colitis. 2013 , 144, e23	0
1695	Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. 2013 , 108, 1620-30	254
1694	European evidence based consensus for endoscopy in inflammatory bowel disease. 2013 , 7, 982-1018	560
1693	A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED). 2013 , 108, 1877-88	96

1692	Influence of NADPH oxidase on inflammatory response in primary intestinal epithelial cells in patients with ulcerative colitis. 2013 , 13, 159	15
1691	Severe disease activity and cytomegalovirus colitis are predictive of a nonresponse to infliximab in patients with ulcerative colitis. 2013 , 58, 3592-9	38
1690	Common and specific signatures of gene expression and protein-protein interactions in autoimmune diseases. 2013 , 14, 67-82	67
1689	The influence of anti-TNF therapy on the course of chronic hepatitis C virus infection in patients with inflammatory bowel disease. 2013 , 58, 1149-56	20
1688	Rapid fecal calprotectin correlates with clinical and endoscopic severity of inflammatory bowel diseases. 2013 , 48, 1359-60	5
1687	Multicenter prospective study for clinical and endoscopic efficacies of leukocytapheresis therapy in patients with ulcerative colitis. 2013 , 48, 412-8	5
1686	Clinical efficacy of infliximab in moderate to severe ulcerative colitis in a latin american referral population. 2013 , 88, 222-8	4
1685	Nano- and microscaled particles for drug targeting to inflamed intestinal mucosa: a first in vivo study in human patients. 2013 , 165, 139-45	143
1684	Transcriptional analysis of the intestinal mucosa of patients with ulcerative colitis in remission reveals lasting epithelial cell alterations. 2013 , 62, 967-76	146
1683	Neutrophil-lymphocyte ratio as a predictor of disease severity in ulcerative colitis. 2013 , 27, 72-6	136
1682	Mucosal healing with oral tacrolimus is associated with favorable medium- and long-term prognosis in steroid-refractory/dependent ulcerative colitis patients. 2013 , 7, e609-14	35
1681	Through the looking glass: a journey toward optimal endoscopic assessment of disease activity in ulcerative colitis. 2013 , 11, 55-6	2
1680	The GETECCU clinical guideline for the treatment of ulcerative colitis: A guideline created using GRADE methodology. 2013 , 36, 483.e1-483.e46	
1679	The value of experimental models of colitis in predicting efficacy of biological therapies for inflammatory bowel diseases. 2013 , 305, G763-85	69
1678	Anxiety is associated with impaired tolerance of colonoscopy preparation in inflammatory bowel disease and controls. 2013 , 7, e580-7	22
1677	Relationship between levels of angiogenic and lymphangiogenic factors and the endoscopic, histological and clinical activity, and acute-phase reactants in patients with inflammatory bowel disease. 2013 , 7, e569-79	21
1676	Adalimumab in active ulcerative colitis: a "real-life" observational study. 2013 , 45, 738-43	57
1675	[Therapeutic guidelines on ulcerative colitis: a GRADE methodology based effort of GETECCU]. 2013 , 36, e1-47	21

1674	Effect of intensive granulocyte and monocyte adsorptive apheresis in patients with ulcerative colitis positive for cytomegalovirus. 2013 , 7, 803-11	28
1673	Immunosuppression after liver transplantation for primary sclerosing cholangitis influences activity of inflammatory bowel disease. 2013 , 11, 517-23	37
1672	Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. 2013 , 11, 49-54.e1	95
1671	One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. 2013 , 37, 204-13	99
1670	Reply: risk of colorectal cancer. 2013 , 144, e22-3	1
1669	Cicatrisation muqueuse endoscopique. 2013 , 43, 123-128	1
1668	Achievement of deep remission during scheduled maintenance therapy with TNF β blocking agents in IBD. 2013 , 7, 730-5	79
1667	A new paradigm in ulcerative colitis: regulatory T cells are key factor which induces/exacerbates UC through an immune imbalance. 2013 , 54, 173-80	8
1666	Development of a novel tablet-in-capsule formulation of mesalamine for inflammatory bowel disease. 2013 , 18, 390-400	9
1665	Death-associated protein kinase controls STAT3 activity in intestinal epithelial cells. 2013 , 182, 1005-20	22
1664	Relationship between neutrophil gelatinase-associated lipocalin (NGAL) levels and inflammatory bowel disease type and activity. 2013 , 58, 2587-93	23
1663	Life-event stress induced by the Great East Japan Earthquake was associated with relapse in ulcerative colitis but not Crohn's disease: a retrospective cohort study. 2013 , 3,	27
1662	Protocol for a prospective multicentre cohort study to develop and validate two new outcome measures for patients with inflammatory bowel disease. 2013 , 3,	2
1661	Endoscopy as a prognostic marker in inflammatory bowel disease. 2013 , 31, 351-6	3
1660	Pre- and posttherapy assessment of intestinal soluble mediators in IBD: where we stand and future perspectives. 2013 , 2013, 391473	4
1659	A randomised phase I study of etrolizumab (rhuMAb \bar{I}) in moderate to severe ulcerative colitis. 2013 , 62, 1122-30	108
1658	Clinical Study of the Relation between Mucosal Healing and Long-Term Outcomes in Ulcerative Colitis. 2013 , 2013, 192794	51
1657	The characteristics of ulcerative colitis associated with autoimmune pancreatitis. 2013 , 47, 520-5	31

1656	Short-term stress, but not mucosal healing nor depression was predictive for the risk of relapse in patients with ulcerative colitis: a prospective 12-month follow-up study. 2013 , 19, 2380-6	55
1655	Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study. 2013 , 19, 2568-76	170
1654	Pharmacokinetics of infliximab in children with moderate-to-severe ulcerative colitis: results from a randomized, multicenter, open-label, phase 3 study. 2013 , 19, 2753-62	55
1653	Serum IL-17A in newly diagnosed treatment-naive patients with ulcerative colitis reflects clinical disease severity and predicts the course of disease. 2013 , 19, 2433-9	28
1652	Are endoscopic endpoints reliable in therapeutic trials of ulcerative colitis?. 2013 , 19, 2611-5	7
1651	Treatment of Ulcerative Colitis in the Elderly: A Systematic Review. 2013 , 6, 1-26	3
1650	Colon Mucosa Exhibits Loss of Ectopic MUC5AC Expression in Patients with Ulcerative Colitis Treated with Oral Tacrolimus. 2013 , 2013, 304894	13
1649	Meta-analysis using individual patient data: efficacy and durability of topical alicaforsen for the treatment of active ulcerative colitis. 2013 , 38, 284-93	29
1648	Comparison of Xilei-san, a Chinese herbal medicine, and dexamethasone in mild/moderate ulcerative proctitis: a double-blind randomized clinical trial. 2013 , 19, 838-42	24
1647	Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation -- a placebo-controlled study. 2013 , 38, 264-73	46
1646	Characterization of IBS-like symptoms in patients with ulcerative colitis in clinical remission. 2013 , 25, 756-e578	53
1645	Butyricococcus pullicaecorum in inflammatory bowel disease. 2013 , 62, 1745-52	186
1644	Andrographis paniculata extract (HMPL-004) for active ulcerative colitis. 2013 , 108, 90-8	107
1643	Clinical aspects of mucosal healing in inflammatory bowel diseases: what is it and what is the real value for the everyday practice?. 2013 , 9, 871-82	
1642	The efficacy of oral tacrolimus in patients with moderate/severe ulcerative colitis not receiving concomitant corticosteroid therapy. 2013 , 52, 15-20	14
1641	Ulcerative Colitis associated with Sclerosing Cholangitis and Autoimmune Hepatitis. 2013 , 59, 115-120	
1640	Virtual chromoendoscopy for prediction of severity and disease extent in patients with inflammatory bowel disease: a randomized controlled study. 2013 , 19, 1935-42	39
1639	Procedure time and the determination of polypoid abnormalities with experience: implementation of a chromoendoscopy program for surveillance colonoscopy for ulcerative colitis. 2013 , 19, 1913-20	73

1638	Correlation between the endoscopic and histologic score in assessing the activity of ulcerative colitis. 2013 , 19, 1194-201	93
1637	Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis. 2013 , 19, 2155-65	183
1636	Predictors of endoscopic inflammation in patients with ulcerative colitis in clinical remission. 2013 , 19, 779-84	61
1635	Aberrant expression of circulating Th17, Th1 and Tc1 cells in patients with active and inactive ulcerative colitis. 2013 , 31, 989-97	23
1634	Infliximab salvage therapy for patients with ulcerative colitis who failed to respond to tacrolimus. 2013 , 25, 714-8	10
1633	52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants. 2013 , 19, 1700-9	54
1632	Clinical implications of histologic abnormalities in colonic biopsy specimens from patients with ulcerative colitis in clinical remission. 2013 , 19, 1477-82	23
1631	Video capsule endoscopy in patients with nonresponsive celiac disease. 2013 , 47, 393-9	25
1630	Mucosal healing in inflammatory bowel disease. 2013 , 47, 212-21	41
1629	Periappendiceal inflammation in pediatric ulcerative colitis. 2013 , 19, 1617-21	2
1628	Fecal calprotectin levels predict the clinical course in patients with new onset of ulcerative colitis. 2013 , 19, 576-81	44
1627	High expression of the "A Disintegrin And Metalloprotease" 19 (ADAM19), a sheddase for TNF- α in the mucosa of patients with inflammatory bowel diseases. 2013 , 19, 501-11	16
1626	New and emerging treatments for ulcerative colitis: a focus on vedolizumab. 2013 , 7, 123-30	17
1625	Guidelines for the management of ulcerative colitis. Recommendations of the Working Group of the Polish National Consultant in Gastroenterology and the Polish Society of Gastroenterology. 2013 , 1, 1-20	1
1624	Adalimumab treatment in Crohn's disease: an overview of long-term efficacy and safety in light of the EXTEND trial. 2013 , 6, 153-60	15
1623	Serum glycan markers for evaluation of disease activity and prediction of clinical course in patients with ulcerative colitis. 2013 , 8, e74861	38
1622	Inducible CYP2J2 and its product 11,12-EET promotes bacterial phagocytosis: a role for CYP2J2 deficiency in the pathogenesis of Crohn's disease?. 2013 , 8, e75107	31
1621	Endoscopy reporting standards. 2013 , 27, 286-92	11

1620	miR-20b, miR-98, miR-125b-1*, and let-7e* as new potential diagnostic biomarkers in ulcerative colitis. 2013 , 19, 4289-99	67
1619	Inflammatory Bowel Diseases. 2014 , 1297-1304	1
1618	Rate and predictors of mucosal healing in patients with inflammatory bowel disease treated with anti-TNF-alpha antibodies. 2014 , 9, e99293	21
1617	Mucosal healing did not predict sustained clinical remission in patients with IBD after discontinuation of one-year infliximab therapy. 2014 , 9, e110797	32
1616	Atypical distribution of inflammation in newly diagnosed ulcerative colitis is not rare. 2014 , 28, 125-30	25
1615	Physician global assessments or blood tests do not predict mucosal healing in ulcerative colitis. 2014 , 28, 325-9	22
1614	Serrated adenoma prevalence in inflammatory bowel disease surveillance colonoscopy, and characteristics revealed by chromoendoscopy and virtual chromoendoscopy. 2014 , 28, 589-94	19
1613	Current approaches to the management of new-onset ulcerative colitis. 2014 , 7, 111-32	30
1612	Designing biologic selectivity for inflammatory bowel disease--role of vedolizumab. 2015 , 9, 147-54	6
1611	Endoscopic Findings during the Early Induction Phase of Infliximab Therapy may Predict its Efficacy for Refractory Ulcerative Colitis. 2014 , 05,	
1610	Golimumab for the treatment of ulcerative colitis. 2014 , 7, 53-9	19
1609	Treatment of Ulcerative Colitis Patients by Local Application of the Toll like Receptor-9 Agonist DIMS0150. 2014 , 04,	1
1608	Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn's disease?. 2014 , 7, 163-72	21
1607	Differential expression of interleukin-1/Toll-like receptor signaling regulators in microscopic and ulcerative colitis. 2014 , 20, 12249-59	28
1606	Interventions for induction of mucosal healing in ulcerative colitis. 2014 ,	
1605	Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. 2014 , 63, 442-50	136
1604	The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis. 2015 , 9, 26-32	106
1603	Opposing roles of prostaglandin D2 receptors in ulcerative colitis. 2014 , 193, 827-39	24

1602	Efficacy of zinc-carnosine chelate compound, Polaprezinc, enemas in patients with ulcerative colitis. 2014 , 49, 164-72	12
1601	Evaluation of cardiac function by two-dimensional speckle tracking echocardiography in ulcerative colitis patients. 2014 , 59, 3004-11	11
1600	Soluble epoxide hydrolase as an anti-inflammatory target of the thrombolytic stroke drug SMTP-7. 2014 , 289, 35826-38	32
1599	Scores endoscopiques des maladies inflammatoires chroniques de l'intestin. 2014 , 44, 408-409	
1598	Peroxisome proliferator-activated receptors family is involved in the response to treatment and mild clinical course in patients with ulcerative colitis. 2014 , 2014, 932530	21
1597	Central endoscopy reads in inflammatory bowel disease clinical trials: The role of the imaging core lab. 2014 , 2, 201-6	8
1596	Endoscopic scoring systems for inflammatory bowel disease: pros and cons. 2014 , 8, 543-54	19
1595	Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies. 2014 , 6, 963-71	28
1594	[Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis (Spanish version)]. 2014 , 79, 263-89	11
1593	Endoscopic assessment of the duodenum in dogs with inflammatory bowel disease. 2014 , 28, 1442-6	13
1592	Adjunct antibiotic combination therapy for steroid-refractory or -dependent ulcerative colitis: an open-label multicentre study. 2014 , 39, 949-56	24
1591	Managing ambulatory ulcerative colitis patients with infliximab: a long term follow-up study in primary gastroenterology centers. 2014 , 25, 757-61	14
1590	Validated gene expression biomarker analysis for biopsy-based clinical trials in ulcerative colitis. 2014 , 40, 477-85	7
1589	Expression of interleukin (IL)-19 and IL-24 in inflammatory bowel disease patients: a cross-sectional study. 2014 , 177, 64-75	49
1588	The gap between scientific evidence and clinical practice: 5-aminosalicylates are frequently used for the treatment of Crohn's disease. 2014 , 40, 930-7	31
1587	Assessment of the validity of a multigene analysis in the diagnostics of inflammatory bowel disease. 2014 , 275, 484-93	13
1586	Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy. 2014 , 44, 464-70	20
1585	Long-term outcome of inflammatory bowel diseases with cytomegalovirus colitis: effect of antiviral treatment. 2014 , 26, 1146-51	22

1584	Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease. 2014 , 2, 30-7	91
1583	Role of HMGB1 as a suitable biomarker of subclinical intestinal inflammation and mucosal healing in patients with inflammatory bowel disease. 2014 , 20, 1448-57	48
1582	Increased pulse wave velocity and relationship with inflammation, insulin, and insulin resistance in inflammatory bowel disease. 2014 , 26, 725-32	25
1581	High- and low-dose oral delayed-release mesalamine in children with mild-to-moderately active ulcerative colitis. 2014 , 59, 767-72	12
1580	Surveillance in ulcerative colitis: is chromoendoscopy-guided endomicroscopy always better than conventional colonoscopy? A randomized trial. 2014 , 20, 2038-45	21
1579	Patient preferences for surgical versus medical therapy for ulcerative colitis. 2014 , 20, 103-14	57
1578	Osteopathy decreases the severity of IBS-like symptoms associated with Crohn's disease in patients in remission. 2014 , 26, 1392-8	13
1577	An optimized patient-reported ulcerative colitis disease activity measure derived from the Mayo score and the simple clinical colitis activity index. 2014 , 20, 1070-8	24
1576	Current role of endoscopy in inflammatory bowel disease diagnosis and management. 2014 , 30, 370-7	11
1575	Prostaglandin E-major urinary metabolite as a reliable surrogate marker for mucosal inflammation in ulcerative colitis. 2014 , 20, 1208-16	34
1574	Accuracy of advanced endoscopy and fecal calprotectin for prediction of relapse in ulcerative colitis: a prospective study. 2014 , 20, 1187-93	41
1573	Alternate endpoints and clinical outcome assessments in pediatric ulcerative colitis registration trials. 2014 , 58, 12-7	9
1572	Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. 2014 , 147, 1296-1307.e5	233
1571	Fatigue severity and factors associated with high fatigue levels in Korean patients with inflammatory bowel disease. 2014 , 8, 148-53	17
1570	Colonoscopic evaluation in ulcerative colitis. 2014 , 2, 161-8	39
1569	Does fecal calprotectin predict short-term relapse after stopping TNF β -blocking agents in inflammatory bowel disease patients in deep remission?. 2015 , 9, 33-40	66
1568	The Importance of Mucosal Healing in Ulcerative Colitis. 2014 , 45-54	
1567	Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. 2014 , 7, 473-87	192

1566	Proximal disease extension and related predicting factors in ulcerative proctitis. 2014 , 49, 177-83	36
1565	A randomized controlled trial of mindfulness-based stress reduction to prevent flare-up in patients with inactive ulcerative colitis. 2014 , 89, 142-55	69
1564	Fecal hemoglobin and calprotectin are equally effective in identifying patients with inflammatory bowel disease with active endoscopic inflammation. 2014 , 20, 307-14	41
1563	Faecal analysis and plasma complement factor 3c levels at admission for an acute attack of ulcerative colitis are predictive of the need for colectomy. 2014 , 26, 295-300	2
1562	Outcome after discontinuation of TNF α -blocking therapy in patients with inflammatory bowel disease in deep remission. 2014 , 20, 1021-8	56
1561	Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis. 2014 , 20, 1368-74	45
1560	Opposite effects of interferon regulatory factor 1 and osteopontin on the apoptosis of epithelial cells induced by TNF α in inflammatory bowel disease. 2014 , 20, 1950-61	25
1559	Transcriptional analysis of left-sided colitis, pancolitis, and ulcerative colitis-associated dysplasia. 2014 , 20, 2340-52	18
1558	Clinical pharmacology of AMG 181, a gut-specific human anti-IL-17 monoclonal antibody, for treating inflammatory bowel diseases. 2014 , 78, 1315-33	28
1557	Clinical features and course of ulcerative colitis diagnosed in asymptomatic subjects. 2014 , 8, 1254-60	7
1556	Expression of T-cell KV1.3 potassium channel correlates with pro-inflammatory cytokines and disease activity in ulcerative colitis. 2014 , 8, 1378-91	31
1555	Daily sodium butyrate enema for the prevention of radiation proctitis in prostate cancer patients undergoing radical radiation therapy: results of a multicenter randomized placebo-controlled dose-finding phase 2 study. 2014 , 89, 518-24	22
1554	Prevalence of serum celiac antibody in patients with IBD in Japan. 2014 , 49, 825-34	29
1553	Correlations of C-reactive protein levels and erythrocyte sedimentation rates with endoscopic activity indices in patients with ulcerative colitis. 2014 , 59, 829-37	48
1552	Colonic mucosal immune activity in irritable bowel syndrome: comparison with healthy controls and patients with ulcerative colitis. 2014 , 59, 1001-11	34
1551	Clinical Gastrointestinal Endoscopy. 2014 ,	1
1550	Integration of transcriptomics and metabonomics: improving diagnostics, biomarker identification and phenotyping in ulcerative colitis. 2014 , 10, 280-290	20
1549	Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. 2014 , 49, 283-94	105

1548	Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. 2014 , 39, 660-71	114
1547	Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics. 2014 , 15 Suppl 1, S121-8	28
1546	Defective expression of SIRT1 contributes to sustain inflammatory pathways in the gut. 2014 , 7, 1467-79	47
1545	Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. 2014 , 146, 96-109.e1	482
1544	Dysregulation of T cell receptor N-glycosylation: a molecular mechanism involved in ulcerative colitis. 2014 , 23, 2416-27	39
1543	Clinical utility of cytomegalovirus antigenemia assay and blood cytomegalovirus DNA PCR for cytomegaloviral colitis patients with moderate to severe ulcerative colitis. 2014 , 8, 693-701	40
1542	Targeting TNF- α for the treatment of inflammatory bowel disease. 2014 , 14, 75-101	94
1541	Inter-observer agreement in endoscopic scoring systems: preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG-IBD). 2014 , 46, 969-73	58
1540	Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year. 2014 , 46, 974-9	48
1539	Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation. 2014 , 63, 744-52	222
1538	Increased expression of CXCL16, a bacterial scavenger receptor, in the colon of children with ulcerative colitis. 2014 , 8, 1222-6	4
1537	An update on anti-TNF agents in ulcerative colitis. 2014 , 43, 479-94	13
1536	Fecal calprotectin-guided dosing of mesalamine in ulcerative colitis: concept proved but more data needed. 2014 , 12, 1894-6	2
1535	The role of mucosal healing in the treatment of patients with inflammatory bowel disease. 2014 , 12, 103-17	24
1534	Successful treatment for ulcerative proctitis with rectal tacrolimus in an 8-year-old girl with intolerance to mesalamine. 2014 , 7, 320-3	2
1533	[New biologics for treatment of chronic inflammatory bowel diseases]. 2014 , 55, 367-76	1
1532	Colectomy for patients with ulcerative colitis and primary sclerosing cholangitis - what next?. 2014 , 8, 421-30	18
1531	Biopharmaceutical considerations and characterizations in development of colon targeted dosage forms for inflammatory bowel disease. 2014 , 4, 187-202	17

1530	Biomarkers can predict potential clinical responders to DIMS0150 a toll-like receptor 9 agonist in ulcerative colitis patients. 2014 , 14, 79	17
1529	Mucosal healing as a target of therapy for colonic inflammatory bowel disease and methods to score disease activity. 2014 , 24, 367-78	74
1528	Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. 2014 , 384, 309-18	331
1527	Ultrasonography of the colon in pediatric ulcerative colitis: a prospective, blind, comparative study with colonoscopy. 2014 , 165, 78-84.e2	46
1526	Osteopathy and low back pain, acupuncture and in vitro fertilization, Tai Chi and osteoarthritis, Andrographis paniculata and ulcerative colitis, and acupressure and vertigo. 2014 , 10, 62-6	
1525	Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. 2014 , 146, 392-400.e3	593
1524	Bolus administration of steroid therapy is more favorable than the conventional use in preventing decrease of bone density and the increase of body fat percentage in patients with inflammatory bowel disease. 2014 , 8, 992-7	7
1523	A large-scale, prospective, observational study of leukocytapheresis for ulcerative colitis: treatment outcomes of 847 patients in clinical practice. 2014 , 8, 981-91	33
1522	Current overview of extrinsic and intrinsic factors in etiology and progression of inflammatory bowel diseases. 2014 , 66, 766-75	67
1521	Prospective validation study of the International Classification of Functioning, Disability and Health score in Crohn's disease and ulcerative colitis. 2014 , 8, 1237-45	39
1520	A randomized clinical trial of mesalazine suppository: the usefulness and problems of central review of evaluations of colonic mucosal findings. 2014 , 8, 1444-53	6
1519	Comparing disease activity indices in ulcerative colitis. 2014 , 8, 318-25	67
1518	Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. 2014 , 146, 85-95; quiz e14-5	572
1517	Case-control study of factors that trigger inflammatory bowel disease flares. 2014 , 20, 4329-34	23
1516	Integrated miRNA and mRNA expression profiling in inflamed colon of patients with ulcerative colitis. 2014 , 9, e116117	48
1515	Prognosis of ulcerative colitis differs between patients with complete and partial mucosal healing, which can be predicted from the platelet count. 2014 , 20, 18367-74	39
1514	DNA methylation status of epithelial-mesenchymal transition (EMT)--related genes is associated with severe clinical phenotypes in ulcerative colitis (UC). 2014 , 9, e107947	16
1513	Interventions for maintenance of mucosal healing in ulcerative colitis. 2014 ,	

1512	Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. 2014 , 160, 704-11	158
1511	Crohn's Disease is Associated with Restless Legs Syndrome. 2014 , 20, 1471	
1510	A systematic review of the measurement of endoscopic healing in ulcerative colitis clinical trials: recommendations and implications for future research. 2014 , 20, 1465-71	57
1509	A systematic review of measurement of endoscopic disease activity and mucosal healing in Crohn's disease: recommendations for clinical trial design. 2014 , 20, 1850-61	40
1508	Comparison of outcomes for patients with primary sclerosing cholangitis associated with ulcerative colitis and Crohn's disease. 2016 , 4, 43-9	16
1507	The severity of inflammation at onset of ulcerative colitis is not associated with IBS-like symptoms during clinical remission. 2015 , 9, 776-83	9
1506	Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis. 2015 , 42, 504-14	51
1505	Successful Use of Adalimumab for Treating Pyoderma Gangrenosum with Ulcerative Colitis under Corticosteroid-tapering Conditions. 2015 , 54, 2167-72	13
1504	Does Pre-Operative Multiple Immunosuppressive Therapy Associate with Surgical Site Infection in Surgery for Ulcerative Colitis. 2015 , 92, 121-9	13
1503	Clinical application of faecal calprotectin in ulcerative colitis patients. 2015 , 27, 1418-24	23
1502	Systematic Review of the Clinical Disease Severity Indices for Inflammatory Bowel Disease. 2015 , 21, 2460-6	9
1501	Alpha-1 antitrypsin and granulocyte colony-stimulating factor as serum biomarkers of disease severity in ulcerative colitis. 2015 , 21, 1077-88	12
1500	Extent of Early Clinical Response to Infliximab Predicts Long-term Treatment Success in Active Ulcerative Colitis. 2015 , 21, 2090-6	19
1499	Type I interferons for induction of remission in ulcerative colitis. 2015 , CD006790	9
1498	Inflammation decreases keratin level in ulcerative colitis; inadequate restoration associates with increased risk of colitis-associated cancer. 2015 , 2, e000024	12
1497	Potential utility of a new ulcerative colitis segmental endoscopic index combining disease severity and the extent of inflammation. 2015 , 49, 401-6	5
1496	Low-dose Infliximab for Induction and Maintenance Treatment in Chinese Patients With Moderate to Severe Active Ulcerative Colitis. 2015 , 49, 582-8	34
1495	Monocytosis and a Low Lymphocyte to Monocyte Ratio Are Effective Biomarkers of Ulcerative Colitis Disease Activity. 2015 , 21, 1769-75	32

1494	Cultured blood T-cell responses predict anti-TNF therapy response in patients with ulcerative colitis. 2015 , 41, 1149-61	7
1493	High within-day variability of fecal calprotectin levels in patients with active ulcerative colitis: what is the best timing for stool sampling?. 2015 , 21, 1072-6	70
1492	Colon Cleansing for Colonoscopy in Patients with Ulcerative Colitis: Efficacy and Acceptability of a 2-L PEG Plus Bisacodyl Versus 4-L PEG. 2015 , 21, 2137-44	16
1491	Detection of Cytomegalovirus in Patients with Inflammatory Bowel Disease: Where to Biopsy and How Many Biopsies?. 2015 , 21, 2833-8	72
1490	Oral budesonide for induction of remission in ulcerative colitis. 2015 , CD007698	34
1489	Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials. 2015 , 42, 1200-10	71
1488	Effect of Thalidomide on Clinical Remission in Children and Adolescents with Ulcerative Colitis Refractory to Other Immunosuppressives: Pilot Randomized Clinical Trial. 2015 , 21, 1739-49	21
1487	Clinical remission as defined by the Mayo Score: do we deceive ourselves?. 2015 , 21, E2-3	3
1486	Different Profile of Efficacy of Thiopurines in Ulcerative Colitis and Crohn's Disease. 2015 , 21, 2570-5	8
1485	Assessment of Circulating MicroRNAs for the Diagnosis and Disease Activity Evaluation in Patients with Ulcerative Colitis by Using the Nanostring Technology. 2015 , 21, 2533-9	53
1484	Reduced Dendritic Cells Expressing CD200R1 in Children with Inflammatory Bowel Disease: Correlation with Th17 and Regulatory T Cells. 2015 , 16, 28998-9010	21
1483	Use of Cyclo-Oxygenase Inhibitors Is Not Associated with Clinical Relapse in Inflammatory Bowel Disease: A Case-Control Study. 2015 , 8, 512-24	9
1482	Central Reading of Endoscopy Endpoints in Inflammatory Bowel Disease Trials. 2015 , 21, 2475-82	23
1481	LOWER LEVELS OF VITAMIN D CORRELATE WITH CLINICAL DISEASE ACTIVITY AND QUALITY OF LIFE IN INFLAMMATORY BOWEL DISEASE. 2015 , 52, 260-5	29
1480	Low Level Engraftment and Improvement following a Single Colonoscopic Administration of Fecal Microbiota to Patients with Ulcerative Colitis. 2015 , 10, e0133925	41
1479	Differential Expression of MUC12, MUC16, and MUC20 in Patients with Active and Remission Ulcerative Colitis. 2015 , 2015, 659018	22
1478	Procoagulatory state in inflammatory bowel diseases is promoted by impaired intestinal barrier function. 2015 , 2015, 189341	15
1477	Altered chemokine signalling in endothelial progenitor cells from acute ulcerative colitis patients. 2015 , 2015, 843980	3

1476	An Evaluation of the Correlation between Hepcidin Serum Levels and Disease Activity in Inflammatory Bowel Disease. 2015 , 2015, 810942	15
1475	Evaluation of a multiplex PCR assay for detection of cytomegalovirus in stool samples from patients with ulcerative colitis. 2015 , 21, 12667-75	14
1474	Clinical Presentation of Ulcerative Colitis in Pakistani Adults. 2015 , 5, 127-130	1
1473	Usefulness of the cytomegalovirus antigenemia assay in patients with ulcerative colitis. 2015 , 13, 50-9	20
1472	Evaluation of Mucosal Healing in Ulcerative Colitis by Fecal Calprotectin Vs. Fecal Immunochemical Test. 2015 , 110, 873-80	78
1471	Systematic review with meta-analysis: infliximab and immunosuppressant therapy vs. infliximab alone for active ulcerative colitis. 2015 , 41, 603-12	25
1470	Rediscovery of the Anti-Pancreatic Antibodies and Evaluation of their Prognostic Value in a Prospective Clinical Cohort of Crohn's Patients: The Importance of Specific Target Antigens [GP2 and CUZD1]. 2015 , 9, 659-68	30
1469	The diagnostic value of a new fecal marker, matrix metalloprotease-9, in different types of inflammatory bowel diseases. 2015 , 9, 231-7	35
1468	Bariatric surgery in patients with inflammatory bowel disease: an accessible path? Report of a case series and review of the literature. 2015 , 9, 185-90	26
1467	Extent of disease is a major outcome predictor in patients with ulcerative colitis and pregnancy. 2015 , 34, 108-11	5
1466	Is mucosal healing more common than clinical remission in ulcerative colitis? - Is it the truth or only a myth coming from the studies?. 2015 , 50, 985-90	4
1465	Level of Fecal Calprotectin Correlates With Endoscopic and Histologic Inflammation and Identifies Patients With Mucosal Healing in Ulcerative Colitis. 2015 , 13, 1929-36.e1	98
1464	The 2 + 1 paradigm: an efficient algorithm for central reading of Mayo endoscopic subscores in global multicenter phase 3 ulcerative colitis clinical trials. 2016 , 4, 35-8	6
1463	Fatigue in Newly Diagnosed Inflammatory Bowel Disease. 2015 , 9, 725-30	47
1462	Biological therapy for ulcerative colitis. 2015 , 3, 103-9	27
1461	Frequency and risk factors of low immunoglobulin levels in patients with inflammatory bowel disease. 2015 , 3, 115-21	22
1460	Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases. 2015 , 14, 1915-34	3
1459	Biologics in inflammatory bowel disease: what are the data?. 2015 , 3, 419-28	79

1458	Pharmacological intervention based on fecal calprotectin levels in patients with ulcerative colitis at high risk of a relapse: A prospective, randomized, controlled study. 2015 , 3, 72-9	36
1457	Rapid Fecal Calprotectin Testing Predicts Mucosal Healing Better than C-reactive Protein and Serum Tumor Necrosis Factor α in Patients with Ulcerative Colitis. 2015 , 53, 253-60	1
1456	Response to infliximab therapy in ulcerative colitis is associated with decreased monocyte activation, reduced CCL2 expression and downregulation of Tenascin C. 2015 , 9, 56-65	25
1455	Accuracy of Rapid Fecal Calprotectin Test in Monitoring Inflammatory Bowel Diseases Under Treatment with TNF α Antagonists. 2015 , 60, 1406-13	7
1454	IL-33 promotes GATA-3 polarization of gut-derived T cells in experimental and ulcerative colitis. 2015 , 50, 180-90	37
1453	Mucosal healing in the era of biologic agents in treatment of inflammatory bowel disease. 2015 , 50, 43-52	22
1452	Anrakinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study. 2015 , 64, 894-900	111
1451	Development and validation of an endoscopic activity score for canine inflammatory bowel disease. 2015 , 203, 290-5	25
1450	Histological inflammation in ulcerative colitis in deep remission under treatment with infliximab. 2015 , 39, 107-13	10
1449	Ulcerative Colitis: What is the Optimal Treatment Goal and How Do We Achieve It?. 2015 , 13, 130-42	7
1448	Does neutrophil-to-lymphocyte ratio predict active ulcerative colitis?. 2015 , 127, 262-5	56
1447	Progress with anti-tumor necrosis factor therapeutics for the treatment of inflammatory bowel disease. 2015 , 7, 175-90	12
1446	Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis. 2015 , 148, 740-750.e2	73
1445	Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis. 2015 ,	2
1444	The risk of colorectal cancer in patients with ulcerative colitis. 2015 , 60, 492-501	30
1443	Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial. 2015 , 13, 1444-9.e1	258
1442	Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. 2015 , 148, 1035-1058.e3	251
1441	The relationship among multiple patient-reported outcomes measures for patients with ulcerative colitis receiving treatment with MMX \square formulated delayed-release mesalamine. 2015 , 24, 671-83	7

1440	Extracorporeal photopheresis for the treatment of Crohn's disease. 2015 , 52, 183-6	3
1439	The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS]. 2015 , 9, 607-16	40
1438	Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn's disease and ulcerative colitis - experiences from a single center. 2015 , 15, 1257-62	71
1437	The Toxin-Producing Pathobiont <i>Klebsiella oxytoca</i> Is Not Associated with Flares of Inflammatory Bowel Diseases. 2015 , 60, 3393-8	14
1436	Long-term efficacy and safety of azathioprine in ulcerative colitis. 2015 , 9, 191-7	18
1435	The Modified Mayo Endoscopic Score (MMES): A New Index for the Assessment of Extension and Severity of Endoscopic Activity in Ulcerative Colitis Patients. 2015 , 9, 846-52	71
1434	Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis. 2015 , 149, 350-5.e2	254
1433	The role of endoscopy in inflammatory bowel disease. 2015 , 81, 1101-21.e1-13	216
1432	Clinical usefulness of endocytoscopy in the remission stage of ulcerative colitis: a pilot study. 2015 , 50, 1087-93	17
1431	Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis. 2015 , 149, 110-118.e4	571
1430	Development and validation of an endoscopic classification of diverticular disease of the colon: the DICA classification. 2015 , 33, 68-76	46
1429	Oral prolonged release beclomethasone dipropionate and prednisone in the treatment of active ulcerative colitis: results from a double-blind, randomized, parallel group study. 2015 , 110, 708-15	38
1428	Colonic mucosal expression of heat-shock proteins may have a potential prognostic value in ulcerative colitis. 2015 , 16, 20-4	9
1427	Antibody and cell-mediated immune response to whole virion and split virion influenza vaccine in patients with inflammatory bowel disease on maintenance immunosuppressive and biological therapy. 2015 , 50, 174-81	6
1426	Inflammatory bowel disease. 2015 , 50, 748-62	23
1425	Management of ulcerative colitis: a clinical update. 2015 , 35, 230-237	8
1424	Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea. 2015 , 9 Suppl 1, 35-44	87
1423	Complete mucosal healing defined by endoscopic Mayo subscore still demonstrates abnormalities by novel high definition colonoscopy and refined histological gradings. 2015 , 47, 726-34	42

1422	Risk factors and clinical implication of superimposed <i>Campylobacter jejuni</i> infection in patients with underlying ulcerative colitis. 2016 , 4, 287-292	15
1421	Regulation of antiapoptotic and cytoprotective pathways in colonic epithelial cells in ulcerative colitis. 2015 , 50 Suppl 1, 1-29	30
1420	Low muscle mass and sarcopenia: common and predictive of osteopenia in inflammatory bowel disease. 2015 , 41, 895-906	75
1419	Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes. 2015 , 15, 14	67
1418	Safety and Efficacy of AJM300, an Oral Antagonist of α 4 Integrin, in Induction Therapy for Patients With Active Ulcerative Colitis. 2015 , 149, 1775-1783.e2	88
1417	Symptomatic sensorineural hearing loss in patients with ulcerative colitis. 2015 , 19, 729-31	9
1416	[Joint opinion of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) and the German Society for Internal Medicine (DGIM) to Vedolizumab-benefit assessment according to § 35a SGB V the G-BA]. 2015 , 53, 54-8	1
1415	Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. 2015 , 110, 1324-38	1024
1414	Diagnostic Modalities for Inflammatory Bowel Disease: Serologic Markers and Endoscopy. 2015 , 95, 1123-41, v	3
1413	A model for identifying cytomegalovirus in patients with inflammatory bowel disease. 2015 , 13, 131-7; quiz e7	51
1412	Development and validation of a new disease severity index: the Inflammatory Bowel Disease Index (IBDEX). 2015 , 6, 161-168	5
1411	Fecal calprotectin and the clinical activity index are both useful to monitor medical treatment in patients with ulcerative colitis. 2015 , 60, 485-91	23
1410	A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis. 2015 , 13, 531-8	119
1409	Converging goals of treatment of inflammatory bowel disease from clinical trials and practice. 2015 , 148, 37-51.e1	162
1408	Faecal metabolite profiling identifies medium-chain fatty acids as discriminating compounds in IBD. 2015 , 64, 447-58	116
1407	Effects of antiviral therapy for patients with inflammatory bowel disease and a positive intestinal biopsy for cytomegalovirus. 2015 , 13, 949-55	64
1406	Integrative transcriptomic and metabolomic molecular profiling of colonic mucosal biopsies indicates a unique molecular phenotype for ulcerative colitis. 2015 , 14, 479-90	10
1405	Metabonomics of human fecal extracts characterize ulcerative colitis, Crohn's disease and healthy individuals. 2015 , 11, 122-133	144

1404	Telomere length in non-neoplastic colonic mucosa in ulcerative colitis (UC) and its relationship to the severe clinical phenotypes. 2015 , 15, 327-32	16
1403	Microparticles as controlled drug delivery carrier for the treatment of ulcerative colitis: A brief review. 2016 , 24, 458-72	68
1402	Ulcerative colitis patients in clinical remission demonstrate correlations between fecal immunochemical test results, mucosal healing, and risk of relapse. 2016 , 22, 5079-87	17
1401	The effects of psychiatric treatment on depression, anxiety, quality of life, and sexual dysfunction in patients with inflammatory bowel disease. 2016 , 12, 673-83	34
1400	Benefit-risk assessment of golimumab in the treatment of refractory ulcerative colitis. 2016 , 8, 1-7	3
1399	Clinical relevance of endoscopic assessment of inflammation in ulcerative colitis: Can endoscopic evaluation predict outcomes?. 2016 , 22, 9324-9332	16
1398	Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study. 2016 , 2016, 2079582	12
1397	Tacrolimus for Remission Induction and Maintenance Therapy in Patients with Ulcerative Colitis: A Retrospective Evaluation Study. 2016 , 2016, 5956316	3
1396	Diagnosis of inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 2(nd) Asian Organization for Crohn's and Colitis (AOCC) meeting in Seoul. 2016 , 14, 224-30	8
1395	Serum Fatty Acids Are Correlated with Inflammatory Cytokines in Ulcerative Colitis. 2016 , 11, e0156387	38
1394	Over-reaching beyond disease activity: the influence of anxiety and medical economic burden on health-related quality of life in patients with inflammatory bowel disease. 2017 , 11, 23-31	13
1393	Applicability of endoscopic indices in the determination of disease activity in patients with ulcerative colitis. 2016 , 28, 722-30	2
1392	Assessing Colonic Exposure, Safety, and Clinical Activity of SRT2104, a Novel Oral SIRT1 Activator, in Patients with Mild to Moderate Ulcerative Colitis. 2016 , 22, 607-14	20
1391	Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease. 2016 , 22, 623-30	103
1390	NOD2 Is Regulated By Mir-320 in Physiological Conditions but this Control Is Altered in Inflamed Tissues of Patients with Inflammatory Bowel Disease. 2016 , 22, 315-26	40
1389	Performance of Common Disease Activity Markers as a Reflection of Inflammatory Burden in Ulcerative Colitis. 2016 , 22, 1384-90	1
1388	L-Arginine Availability and Metabolism Is Altered in Ulcerative Colitis. 2016 , 22, 1847-58	36
1387	A Novel Decision Aid for Surgical Patients with Ulcerative Colitis: Results of a Pilot Study. 2016 , 59, 520-8	8

1386	PNPLA3 148M Carriers with Inflammatory Bowel Diseases Have Higher Susceptibility to Hepatic Steatosis and Higher Liver Enzymes. 2016 , 22, 134-40	18
1385	Correlation of Serum Vitamin A Levels with Disease Activity Indices and Colonic IL-23R and FOXP3 mRNA Expression in Ulcerative Colitis Patients. 2016 , 84, 110-7	10
1384	Ulcerative colitis endoscopic index of severity is associated with long-term prognosis in ulcerative colitis patients treated with infliximab. 2016 , 28, 665-70	20
1383	Faecal lactoferrin is a useful biomarker for mucosal healing in patients with ulcerative colitis during granulocyte and monocyte adsorptive apheresis therapy. 2016 , 18, 696-702	1
1382	Complementary and Alternative Medicine. 2016 , 22, 1523-30	10
1381	Plasma intestinal fatty acid-binding protein fails to predict endoscopic disease activity in inflammatory bowel disease patients. 2016 , 28, 807-13	7
1380	Efficacy of a Novel Granulocyte Monocyte Apheresis Adsorber Device in the Treatment of Inflammatory Bowel Diseases: A Pilot Study. 2016 , 20, 668-676	1
1379	Evolving strategies to reduce colectomy rates in primary sclerosing cholangitis-inflammatory bowel disease: clinical remission of corticosteroid refractory colitis post-liver transplant with vedolizumab. 2016 , 7, 271-274	4
1378	Sleep disturbances in Japanese patients with inflammatory bowel disease and their impact on disease flare. 2016 , 5, 1792	17
1377	Care of inflammatory bowel disease patients in remission. 2016 , 4, 261-271	11
1376	Drug development in IBD: from novel target identification to early clinical trials. 2016 , 65, 1233-9	27
1375	UEG Week 2016 Poster Presentations. 2016 , 4, A157-A720	12
1374	Accuracy of Diffusion-weighted Magnetic Resonance Colonography in Assessing Mucosal Healing and the Treatment Response in Patients with Ulcerative Colitis. 2017 , 11, 716-723	12
1373	Efficacy and Usefulness of New Single-Needle Intensive Granulocyte and Monocyte Adsorptive Apheresis in Active Ulcerative Colitis Patients Without Corticosteroids and Biologics. 2016 , 20, 383-9	7
1372	IBS-like Symptoms in Patients with Ulcerative Colitis in Deep Remission Are Associated with Increased Levels of Serum Cytokines and Poor Psychological Well-being. 2016 , 22, 2630-2640	58
1371	Fecal HMGB1 Reveals Microscopic Inflammation in Adult and Pediatric Patients with Inflammatory Bowel Disease in Clinical and Endoscopic Remission. 2016 , 22, 2886-2893	28
1370	Confocal laser endomicroscopy in ulcerative colitis: a longitudinal study of endomicroscopic changes and response to medical therapy (with videos). 2016 , 84, 279-286.e1	25
1369	Anti-TNF Therapy Response in Patients with Ulcerative Colitis Is Associated with Colonic Antimicrobial Peptide Expression and Microbiota Composition. 2016 , 10, 943-52	83

1368	French national consensus clinical guidelines for the management of ulcerative colitis. 2016 , 48, 726-33	14
1367	The Ulcerative Colitis Endoscopic Index of Severity is Useful to Predict Medium- to Long-Term Prognosis in Ulcerative Colitis Patients with Clinical Remission. 2016 , 10, 1303-1309	45
1366	Active cytomegalovirus infection diagnosed by real-time PCR in patients with inflammatory bowel disease: a prospective, controlled observational study (.). 2016 , 51, 1075-80	11
1365	Current approaches for optimizing the benefit of biologic therapy in ulcerative colitis. 2016 , 9, 548-59	13
1364	Indole compounds may be promising medicines for ulcerative colitis. 2016 , 51, 853-61	62
1363	Increased levels of circulating platelet derived microparticles in Crohn's disease patients. 2016 , 51, 1184-92	8
1362	AVX-470, an Orally Delivered Anti-Tumour Necrosis Factor Antibody for Treatment of Active Ulcerative Colitis: Results of a First-in-Human Trial. 2016 , 10, 631-40	46
1361	Clinical Effects of a Topically Applied Toll-like Receptor 9 Agonist in Active Moderate-to-Severe Ulcerative Colitis. 2016 , 10, 1294-1302	45
1360	Current evidence supporting mucosal healing and deep remission as important treatment goals for inflammatory bowel disease. 2016 , 10, 915-27	56
1359	Effects of AVX-470, an Oral, Locally Acting Anti-Tumour Necrosis Factor Antibody, on Tissue Biomarkers in Patients with Active Ulcerative Colitis. 2016 , 10, 641-9	19
1358	TNFAIP6 is a potential biomarker of disease activity in inflammatory bowel disease. 2016 , 10, 473-83	8
1357	Assessment of disease activity in pediatric ulcerative colitis. 2016 , 10, 1127-1134	4
1356	Adalimumab for Moderately to Severely Active Ulcerative Colitis: A Systematic Review and Meta-Analysis. 2016 , 30, 207-17	8
1355	IBD Diagnosis and Evaluation. 2016 , 771-786	
1354	Medical Management of Chronic Ulcerative Colitis. 2016 , 787-806	
1353	Mesalazine Modified-Release Tablet in the Treatment of Ulcerative Colitis in the Active Phase: A Chinese, Multicenter, Single-Blind, Randomized Controlled Study. 2016 , 33, 400-9	4
1352	Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2016 , 374, 1754-62	59.2 276
1351	Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis. 2016 , 10, 1273-1278	56

1350	Impact of Low Immunoglobulin G Levels on Disease Outcomes in Patients with Inflammatory Bowel Diseases. 2016 , 61, 3270-3277	11
1349	Fecal Human Neutrophil Peptide Levels Correlate with Intestinal Inflammation in Ulcerative Colitis. 2016 , 93, 300-8	8
1348	Recent advances in the endoscopic assessment of ulcerative colitis. 2016 , 18, 116-122	1
1347	Recent trends and future directions for the medical treatment of ulcerative colitis. 2016 , 9, 329-336	22
1346	Once- Versus Twice-daily Mesalazine to Induce Remission in Paediatric Ulcerative Colitis: A Randomised Controlled Trial. 2017 , 11, 527-533	5
1345	Training Programs on Endoscopic Scoring Systems for Inflammatory Bowel Disease Lead to a Significant Increase in Interobserver Agreement Among Community Gastroenterologists. 2017 , 11, 556-561	21
1344	Challenges Faced by Cross-sectional Imaging and Histological Endpoints in Clinical Trials. 2017 , 11, S586-S592	7
1343	Accuracy of Faecal Calprotectin and Neutrophil Gelatinase B-associated Lipocalin in Evaluating Subclinical Inflammation in UlceRaTIVE Colitis-the ACERTIVE study. 2017 , 11, 435-444	18
1342	Clinical outcome after discontinuation of infliximab in patients with ulcerative colitis in deep remission. 2016 , 39, 442-448	1
1341	Safety and Tolerability of Nafamostat Mesilate and Heparin as Anticoagulants in Leukocytapheresis for Ulcerative Colitis: Post Hoc Analysis of a Large-Scale, Prospective, Observational Study. 2016 , 20, 197-204	11
1340	Letter: effectiveness of golimumab to induce remission in outpatient ulcerative colitis in Italy. 2016 , 43, 657-8	2
1339	Letter: abnormal bone densitometry in patients with coeliac disease -beyond malabsorption and sunlight exposure. 2016 , 43, 658-9	1
1338	Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial. 2016 , 28, 67-74	94
1337	Circulating memory B cells and plasmablasts are associated with the levels of serum immunoglobulin in patients with ulcerative colitis. 2016 , 20, 804-14	11
1336	Current best practice for disease activity assessment in IBD. 2016 , 13, 567-79	117
1335	A Simplified Geboes Score for Ulcerative Colitis. 2017 , 11, 305-313	29
1334	Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis. 2016 , 44, 157-69	37
1333	Mesalazine allergy in a boy with ulcerative colitis: clinical usefulness of mucosal biopsy criteria. 2016 , 9, 302-5	3

1332	The 100 classic papers in ulcerative colitis: a bibliometric analysis. 2016 , 10, 1187-1195	7
1331	Rapid faecal tests for detecting disease activity in colonic inflammatory bowel disease. 2016 , 46, 825-32	9
1330	Double benefit of long-acting somatostatin analogs in a patient with coexistence of acromegaly and ulcerative colitis. 2016 , 41, 559-62	3
1329	How to Assess and Document Endoscopies in IBD Patients by Including Standard Scoring Systems. 2016 , 22, 1010-9	4
1328	Pectin enhances the effect of fecal microbiota transplantation in ulcerative colitis by delaying the loss of diversity of gut flora. 2016 , 16, 255	43
1327	Patient Reported Outcome Measures (PROMs) in Inflammatory Bowel Disease: New Data. 2017 , 11, S576-S585	30
1326	Head-to-head Comparative Studies: Challenges and Opportunities?. 2017 , 11, S567-S575	5
1325	Randomised, Double-blind, Placebo-controlled Trial of CCR9-targeted Leukapheresis Treatment of Ulcerative Colitis Patients. 2017 , 11, 534-542	8
1324	IBD Integrin Identifies Subsets of Pro-Inflammatory Colonic CD4+ T Lymphocytes in Ulcerative Colitis. 2017 , 11, 610-620	33
1323	Loss of interleukin 33 expression in colonic crypts - a potential marker for disease remission in ulcerative colitis. 2016 , 6, 35403	14
1322	Peripheral and Intestinal T-regulatory Cells are Upregulated in Children with Inflammatory Bowel Disease at Onset of Disease. 2016 , 45, 787-796	5
1321	Clinical Efficacy and Safety of Oral Qing-Dai in Patients with Ulcerative Colitis: A Single-Center Open-Label Prospective Study. 2016 , 93, 193-201	58
1320	Usefulness of sulfasalazine for patients with refractory-ulcerative colitis. 2016 , 3, e000103	6
1319	Hyperbaric oxygen therapy stimulates colonic stem cells and induces mucosal healing in patients with refractory ulcerative colitis: a prospective case series. 2016 , 3, e000082	14
1318	Observation on the effects of different partitioned moxibustion in treating ulcerative colitis. 2016 , 14, 231-241	0
1317	Distinct Anti-IFI16 and Anti-GP2 Antibodies in Inflammatory Bowel Disease and Their Variation with Infliximab Therapy. 2016 , 22, 2977-2987	14
1316	Increased Rates of Clostridium difficile Infection and Poor Outcomes in Patients with IBD with Cytomegalovirus. 2016 , 22, 2688-2693	41
1315	Effect of Early Versus Late Azathioprine Therapy in Pediatric Ulcerative Colitis. 2016 , 22, 1647-54	13

1314	Validation of a Simple 0 to 10 Numerical Score (IBD-10) of Patient-reported Inflammatory Bowel Disease Activity for Routine Clinical Use. 2016 , 22, 1902-7	5
1313	Novel CD8+ T-Cell Subsets Demonstrating Plasticity in Patients with Inflammatory Bowel Disease. 2016 , 22, 1596-608	17
1312	Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies. 2016 , 22, 1881-6	7
1311	Downregulation of MicroRNA-21 in Colonic CD3+ T Cells in UC Remission. 2016 , 22, 2788-2793	21
1310	Serum 25-hydroxyvitamin D concentration is inversely associated with mucosal inflammation in patients with ulcerative colitis. 2016 , 104, 113-20	57
1309	Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study. 2016 , 14, 1426-1432.e1	28
1308	Effectiveness of golimumab in inducing remission and clinical response in outpatient ulcerative colitis. 2016 , 40, e61-e63	8
1307	Fecal calprotectin level correlated with both endoscopic severity and disease extent in ulcerative colitis. 2016 , 16, 47	24
1306	Conventional treatment regimens for ulcerative colitis alleviate fatigue - an observational cohort study. 2016 , 51, 1213-9	7
1305	Regional gastrointestinal transit times in severe ulcerative colitis. 2016 , 28, 217-24	32
1304	Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. 2016 , 4, CD000543	51
1303	The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study. 2016 , 65, 249-55	143
1302	Non-surgical porto-mesenteric vein thrombosis is associated with worse long-term outcomes in inflammatory bowel diseases. 2016 , 4, 210-5	6
1301	Understanding Endoscopic Disease Activity in IBD: How to Incorporate It into Practice. 2016 , 18, 5	19
1300	Epithelial IL-1R2 acts as a homeostatic regulator during remission of ulcerative colitis. 2016 , 9, 950-9	24
1299	The Ulcerative Colitis Endoscopic Index of Severity More Accurately Reflects Clinical Outcomes and Long-term Prognosis than the Mayo Endoscopic Score. 2016 , 10, 286-95	78
1298	The Concept of Mucosal Healing in Ulcerative Colitis: Time and Reasons for a Reappraisal. 2016 , 10, 3-4	3
1297	Endoscopic scores for inflammatory bowel disease in the era of 'mucosal healing': Old problem, new perspectives. 2016 , 48, 703-8	11

1296	Histology Grade Is Independently Associated With Relapse Risk in Patients With Ulcerative Colitis in Clinical Remission: A Prospective Study. 2016 , 111, 685-90	101
1295	Ulcerative Colitis Is Characterized by a Decrease in Regulatory B Cells. 2016 , 10, 1212-23	24
1294	Fecal calprotectin is a clinically relevant biomarker of mucosal healing in patients with quiescent ulcerative colitis. 2016 , 31, 93-8	43
1293	Consecutive Measurements by Faecal Immunochemical Test in Quiescent Ulcerative Colitis Patients Can Detect Clinical Relapse. 2016 , 10, 687-94	20
1292	Regional Specialisation of T Cell Subsets and Apoptosis in the Human Gut Mucosa: Differences Between Ileum and Colon in Healthy Intestine and Inflammatory Bowel Diseases. 2016 , 10, 1042-54	9
1291	[Clinical outcome after discontinuation of infliximab in patients with ulcerative colitis in deep remission]. 2016 , 39, 442-8	1
1290	Efficient Early Drug Development for Ulcerative Colitis. 2016 , 150, 1056-1060	13
1289	Timing for dose-down of 5-ASA depends on mucosal status with ulcerative colitis. 2016 , 51, 827-34	7
1288	Prostaglandin E-Major Urinary Metabolite as a Biomarker for Inflammation in Ulcerative Colitis: Prostaglandins Revisited. 2016 , 93, 32-9	15
1287	Mucosal Healing Is Associated With Improved Long-term Outcomes of Patients With Ulcerative Colitis: A Systematic Review and Meta-analysis. 2016 , 14, 1245-1255.e8	158
1286	Adrenomedullin Therapy in Patients with Refractory Ulcerative Colitis: A Case Series. 2016 , 61, 872-80	26
1285	Circulating MicroRNA223 is a New Biomarker for Inflammatory Bowel Disease. 2016 , 95, e2703	34
1284	Effect of mucosal healing (Mayo 0) on clinical relapse in patients with ulcerative colitis in clinical remission. 2016 , 51, 1069-74	23
1283	Diversion neovaginitis after sigmoid vaginoplasty: endoscopic and clinical characteristics. 2016 , 105, 834-839.e1	27
1282	Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. 2016 , 10, 607-18	23
1281	Core Fucosylation on T Cells, Required for Activation of T-Cell Receptor Signaling and Induction of Colitis in Mice, Is Increased in Patients With Inflammatory Bowel Disease. 2016 , 150, 1620-1632	58
1280	Protocolo diagnóstico y terapéutico de un brote grave de colitis ulcerosa. 2016 , 12, 256-259	
1279	Association Between Response to Etrolizumab and Expression of Integrin β and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis. 2016 , 150, 477-87.e9	101

1278	Systemic and intestinal levels of factor XIII-A: the impact of inflammation on expression in macrophage subtypes. 2016 , 51, 796-807	9
1277	Evaluation of the Risk of Relapse in Ulcerative Colitis According to the Degree of Mucosal Healing (Mayo 0 vs 1): A Longitudinal Cohort Study. 2016 , 10, 13-9	107
1276	Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice. 2016 , 10, 402-9	74
1275	Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study. 2016 , 10, 418-28	38
1274	Gastrointestinal Features of Chronic Granulomatous Disease Found During Endoscopy. 2016 , 14, 395-402.e5	43
1273	Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis. 2016 , 14, 251-8.e1-2	125
1272	EPA- and DHA-derived resolvins' actions in inflammatory bowel disease. 2016 , 785, 156-164	54
1271	Agreement Between Rectosigmoidoscopy and Colonoscopy Analyses of Disease Activity and Healing in Patients With Ulcerative Colitis. 2016 , 150, 389-95.e3	30
1270	Mucosal Healing in Ulcerative Colitis--When Zero is Better. 2016 , 10, 20-5	41
1269	First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis--results from a multicenter prospective randomized controlled trial and its post hoc analysis. 2016 , 51, 241-51	75
1268	Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. 2016 , 14, 348-354.e17	17
1267	Cohort Profile: The Inflammatory Bowel Disease South Limburg Cohort (IBDSL). 2017 , 46, e7	30
1266	Development and validation of a histological index for UC. 2017 , 66, 50-58	151
1265	Assessment of Small Intestinal Transit Times in Ulcerative Colitis and Crohn's Disease Patients with Different Disease Activity Using Video Capsule Endoscopy. 2017 , 18, 404-409	24
1264	Regulation of Laminin α Expression by CDX2 in Colonic Epithelial Cells Is Impaired During Active Inflammation. 2017 , 118, 298-307	3
1263	Mucosal Healing in Ulcerative Colitis: A Comprehensive Review. 2017 , 77, 159-173	56
1262	Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus. 2017 , 45, 801-813	64
1261	Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease. 2017 , 49, 604-617	34

1260	Polymer-based drug delivery: the quest for local targeting of inflamed intestinal mucosa. 2017 , 25, 582-596	20
1259	Diagnosis and treatment of inflammatory bowel disease: First Latin American Consensus of the Pan American Crohn's and Colitis Organisation. 2017 , 82, 46-84	2
1258	Evaluation of the severity of ulcerative colitis using endoscopic dual red imaging targeting deep vessels. 2017 , 5, E76-E82	13
1257	Prevalence of Apical Periodontitis in Patients with Inflammatory Bowel Diseases: A Retrospective Clinical Study. 2017 , 43, 389-394	23
1256	Alterations in the epithelial stem cell compartment could contribute to permanent changes in the mucosa of patients with ulcerative colitis. 2017 , 66, 2069-2079	95
1255	Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. 2017 , 389, 1218-1228	623
1254	Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study). 2017 , 52, 1101-1111	37
1253	Reviewing treatments and outcomes in the evolving landscape of ulcerative colitis. 2017 , 129, 538-553	15
1252	Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. 2017 , 11, 649-670	837
1251	Emerging treatments for ulcerative colitis: a systematic review. 2017 , 52, 923-931	9
1250	Oligoclonal T-cell Receptor Repertoire in Colonic Biopsies of Patients with Microscopic Colitis and Ulcerative Colitis. 2017 , 23, 932-945	6
1249	Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. 2017 , 389, 2304-2316	488
1248	Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2017 , 376, 1723-1736	59.2 771
1247	Efficacy and Factors Associated with Treatment Response of Intravenous Immunoglobulin in Inpatients with Refractory Inflammatory Bowel Diseases. 2017 , 23, 1080-1087	11
1246	Ulcerative colitis. 2017 , 389, 1756-1770	1146
1245	Looking into Enteric Virome in Patients with IBD: Defining Guilty or Innocence?. 2017 , 23, 1278-1284	21
1244	Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial. 2017 , 390, 135-144	119
1243	Therapeutic Drug Monitoring to Guide Infliximab Dose Adjustment is Associated with Better Endoscopic Outcomes than Clinical Decision Making Alone in Active Inflammatory Bowel Disease. 2017 , 23, 1202-1209	51

1242	Calprotectin and the Magnitude of Antibodies to Infliximab in Clinically-stable Ulcerative Colitis Patients are More Relevant Than Infliximab Trough Levels and Pharmacokinetics for Therapeutic Escalation. 2017 , 21, 123-130	6
1241	Prostaglandin E-major Urinary Metabolite as a Biomarker for Pediatric Ulcerative Colitis Activity. 2017 , 64, 955-961	11
1240	Long-term outcomes of infliximab treatment and predictors of response in 195 patients with ulcerative colitis: a hospital-based cohort study from Korea. 2017 , 52, 857-863	7
1239	Comprehensive DNA Methylation Profiling of Inflammatory Mucosa in Ulcerative Colitis. 2017 , 23, 165-173	8
1238	Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis. 2017 , 46, 292-302	20
1237	The Mucosal Antibacterial Response Profile and Fecal Microbiota Composition Are Linked to the Disease Course in Patients with Newly Diagnosed Ulcerative Colitis. 2017 , 23, 956-966	11
1236	Development of a core outcome set for clinical trials in inflammatory bowel disease: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. 2017 , 7, e016146	26
1235	Vedolizumab Induces Long-term Mucosal Healing in Patients With Crohn's Disease and Ulcerative Colitis. 2017 , 11, 1085-1089	41
1234	Objective Assessment of Clinical Disease Activity. 2017 , 259-266	
1233	Adjunctive herbal medicine therapy for inflammatory bowel disease: A systematic review and meta-analysis. 2017 , 12, 12-22	5
1232	Endoscopic and Histologic Healing in Children With Inflammatory Bowel Diseases Treated With Thalidomide. 2017 , 15, 1382-1389.e1	14
1231	Biologic Therapy in Moderate-to-Severe Ulcerative Colitis: Infliximab. 2017 , 429-433	0
1230	Development and reliability of the new endoscopic virtual chromoendoscopy score: the PICaSSO (Paddington International Virtual ChromoendoScopy ScOre) in ulcerative colitis. 2017 , 86, 1118-1127.e5	35
1229	Beyond white light: optical enhancement in conjunction with magnification colonoscopy for the assessment of mucosal healing in ulcerative colitis. 2017 , 49, 553-559	28
1228	Objective Assessment of Endoscopic Disease Activity and Mucosal Healing. 2017 , 267-277	2
1227	High Percentage of IBD Patients with Indefinite Fecal Calprotectin Levels: Additional Value of a Combination Score. 2017 , 62, 465-472	18
1226	TWEAK is not elevated in patients with newly diagnosed inflammatory bowel disease. 2017 , 52, 420-424	5
1225	Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study. 2017 , 112, 120-131	66

1224	Diagnosis and treatment of inflammatory bowel disease: First Latin American Consensus of the Pan American Crohn's and Colitis Organisation. 2017 , 82, 46-84	15
1223	Subcutaneous Golimumab in Pediatric Ulcerative Colitis: Pharmacokinetics and Clinical Benefit. 2017 , 23, 2227-2237	27
1222	Mindfulness-Based Interventions in Inflammatory Bowel Disease. 2017 , 46, 859-874	74
1221	Rapid Fecal Calprotectin Test and Symptom Index in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease. 2017 , 62, 3123-3130	20
1220	Clinical, endoscopic and histological correlation and measures of association in ulcerative colitis. 2017 , 18, 634-641	10
1219	Factors associated with early outcomes following standardised therapy in children with ulcerative colitis (PROTECT): a multicentre inception cohort study. 2017 , 2, 855-868	41
1218	Impact of Histological and Endoscopic Remissions on Clinical Recurrence and Recurrence-free Time in Ulcerative Colitis. 2017 , 23, 2238-2244	27
1217	Nanoparticulate Drug Delivery Systems Targeting Inflammation for Treatment of Inflammatory Bowel Disease. 2017 , 16, 82-96	78
1216	Contribution of Extracellular Matrix and Signal Mechanotransduction to Epithelial Cell Damage in Inflammatory Bowel Disease Patients: A Proteomic Study. 2017 , 17, 1700164	20
1215	Endoscopic and Histological Mucosal Healing in Ulcerative Colitis in the First Year of Diagnosis: Results from a Population-based Inception Cohort from Six Countries in Asia. 2017 , 11, 1440-1448	8
1214	Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn's disease and ulcerative colitis - experiences from a single center. 2017 , 17, 1325-1332	13
1213	RIP3 AND pMLKL promote necroptosis-induced inflammation and alter membrane permeability in intestinal epithelial cells. 2017 , 49, 1201-1210	38
1212	Race/Ethnicity-Specific Disparities in the Severity of Disease at Presentation in Adults with Ulcerative Colitis: A Cross-Sectional Study. 2017 , 62, 2876-2881	8
1211	Ratio of Circulating Estrogen Receptors Beta and Alpha (ER β /ER α) Indicates Endoscopic Activity in Patients with Crohn's Disease. 2017 , 62, 2744-2754	20
1210	The prognostic value of histology in ulcerative colitis in clinical remission with mesalazine. 2017 , 10, 749-759	21
1209	Diagnosis of Cytomegalovirus Infection during Exacerbation of Ulcerative Colitis. 2017 , 96, 142-148	17
1208	Clinical performance of an infliximab rapid quantification assay. 2017 , 10, 651-660	13
1207	Histologic Correlates of Clinical and Endoscopic Severity in Children Newly Diagnosed With Ulcerative Colitis. 2017 , 41, 1491-1498	20

1206	Cytapheresis (CAP) with leukocyte removal filter/bead column as one therapeutic option for inflammatory bowel disease. 2017 , 56, 689-697	1
1205	A prospective study on second-generation colon capsule endoscopy to detect mucosal lesions and disease activity in ulcerative colitis (with video). 2017 , 86, 1139-1146.e6	18
1204	Speckle Tracking Stress Echocardiography Uncovers Early Subclinical Cardiac Involvement in Pediatric Patients with Inflammatory Bowel Diseases. 2017 , 7, 2966	12
1203	Usefulness of Transcriptional Blood Biomarkers as a Non-invasive Surrogate Marker of Mucosal Healing and Endoscopic Response in Ulcerative Colitis. 2017 , 11, 1335-1346	26
1202	Tripeptide K(D)PT Is Well Tolerated in Mild-to-moderate Ulcerative Colitis: Results from a Randomized Multicenter Study. 2017 , 23, 261-271	7
1201	Short-term treatment with eicosapentaenoic acid improves inflammation and affects colonic differentiation markers and microbiota in patients with ulcerative colitis. 2017 , 7, 7458	39
1200	MFSD2A Promotes Endothelial Generation of Inflammation-Resolving Lipid Mediators and Reduces Colitis in Mice. 2017 , 153, 1363-1377.e6	34
1199	Gallstone prevalence and risk factors in patients with ulcerative colitis in Korean population. 2017 , 96, e7653	5
1198	PiCaSSO: a predictive score for endoscopic findings in ulcerative colitis that sounds like art but is all science. 2017 , 86, 1128-1130	1
1197	Detection of calprotectin in inflammatory bowel disease: Fecal and serum levels and immunohistochemical localization. 2018 , 41, 107-118	30
1196	Blood biomarkers reflect integration of severity and extent of endoscopic inflammation in ulcerative colitis. 2017 , 1, 98-104	9
1195	The shifted balance between circulating follicular regulatory T cells and follicular helper T cells in patients with ulcerative colitis. 2017 , 131, 2933-2945	16
1194	Management of acute severe ulcerative colitis in children. 2017 , 26, 367-372	15
1193	Comparison of 4-L Polyethylene Glycol and 2-L Polyethylene Glycol Plus Ascorbic Acid in Patients with Inactive Ulcerative Colitis. 2017 , 62, 2489-2497	6
1192	Nurse in patients' health status assessment: Data from a pilot study assessing agreement among nurse and gastroenterologist in computing IBD-clinical scores. 2017 , 49, 1110-1114	6
1191	Accuracy of Faecal Immunochemical Test to Predict Endoscopic and Histological Healing in Ulcerative Colitis: A Prospective Study Based on Validated Histological Scores. 2017 , 11, 1071-1077	19
1190	A comparison of approaches for adjudicating outcomes in clinical trials. 2017 , 18, 266	22
1189	Comparison of non-invasive biomarkers faecal BAFF, calprotectin and FOBT in discriminating IBS from IBD and evaluation of intestinal inflammation. 2017 , 7, 2669	19

1188	Inflammatory Bowel Disease. 2017,	2
1187	Tricks of the Trade: Treating Your Patient with Moderate-to-Severe IBD. 2017, 147-182	
1186	State of the Art and Future Predictions: Isn't There a Test for That? Diagnosing IBD. 2017, 45-59	
1185	Noninvasive Fecal Immunochemical Testing and Fecal Calprotectin Predict Mucosal Healing in Inflammatory Bowel Disease: A Prospective Cohort Study. 2017, 23, 1643-1649	28
1184	Implementing the Concept of Continuous Clinical Response Into Clinical Practice for Ulcerative Colitis. 2017, 15, 1154-1161.e1	6
1183	Advances in Use of Endoscopy, Radiology, and Biomarkers to Monitor Inflammatory Bowel Diseases. 2017, 152, 362-373.e3	57
1182	Mucoadhesive chitosan hydrogels as rectal drug delivery vessels to treat ulcerative colitis. 2017, 48, 247-257	82
1181	Skeletal muscle depletion correlates with disease activity in ulcerative colitis and is reversed after colectomy. 2017, 36, 1586-1592	27
1180	Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNF-blocking agents. 2017, 52, 284-290	12
1179	Leucine-rich Alpha-2 Glycoprotein is a Serum Biomarker of Mucosal Healing in Ulcerative Colitis. 2017, 11, 84-91	51
1178	Fecal calprotectin in inflammatory bowel diseases: update and perspectives. 2017, 55, 474-483	50
1177	Gut and liver T-cells of common clonal origin in primary sclerosing cholangitis-inflammatory bowel disease. 2017, 66, 116-122	27
1176	Lessons to be learned from serum biomarkers in psoriasis and IBD - the potential role in SpA. 2017, 13, 333-344	13
1175	Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD "AGED study". 2017, 49, 17-23	26
1174	Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies. 2017, 11, 35-46	76
1173	Fecal neutrophil gelatinase-associated lipocalin as a biomarker for inflammatory bowel disease. 2017, 32, 128-135	42
1172	Urinary potassium is a potential biomarker of disease activity in Ulcerative colitis and displays in vitro immunotolerant role. 2017, 7, 18068	1
1171	Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis. 2017, 9, CD011572	12

1170	ADALIMUMAB FOR ULCERATIVE COLITIS: RESULTS OF A BRAZILIAN MULTICENTER OBSERVATIONAL STUDY. 2017 , 54, 321-327	3
1169	Distinct gut microbiota profiles in patients with primary sclerosing cholangitis and ulcerative colitis. 2017 , 23, 4548-4558	157
1168	[Management of severe ulcerative colitis: An up-to-date]. 2017 , 145, 75-84	2
1167	Management of Crohn's disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease. 2017 , 15, 285-310	22
1166	Characterization of Growth Hormone Resistance in Experimental and Ulcerative Colitis. 2017 , 18,	12
1165	Oleuropein Decreases Cyclooxygenase-2 and Interleukin-17 Expression and Attenuates Inflammatory Damage in Colonic Samples from Ulcerative Colitis Patients. 2017 , 9,	38
1164	Anti-TNF-Mediated Modulation of Prohepcidin Improves Iron Availability in Inflammatory Bowel Disease, in an IL-6-Mediated Fashion. 2017 , 2017, 6843976	17
1163	Fecal Calprotectin: A Reliable Predictor of Mucosal Healing after Treatment for Active Ulcerative Colitis. 2017 , 2017, 2098293	15
1162	Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease. 2017 , 15, 266-284	25
1161	[Prognostic factors of ulcerative colitis at the moment of diagnosis]. 2017 , 145, 1319-1329	5
1160	Clinical Efficacy of Beclomethasone Dipropionate in Korean Patients with Ulcerative Colitis. 2017 , 58, 144-149	3
1159	PCR detection of human herpesviruses in colonic mucosa of individuals with inflammatory bowel disease: Comparison with individuals with immunocompetency and HIV infection. 2017 , 12, e0184699	12
1158	Fecal calprotectin predicts complete mucosal healing and better correlates with the ulcerative colitis'endoscopic index of severity than with the Mayo endoscopic subscore in patients with ulcerative colitis. 2017 , 17, 110	32
1157	Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease. 2017 , 15, 184	22
1156	Listeria Monocytogenes Septicemia and Meningitis Caused by Listeria Enteritis Complicating Ulcerative Colitis. 2017 , 56, 2655-2659	11
1155	BODY COMPOSITION IN PATIENTS WITH CROHN'S DISEASE AND ULCERATIVE COLITIS. 2017 , 54, 109-114	17
1154	Low dose oral curcumin is not effective in induction of remission in mild to moderate ulcerative colitis: Results from a randomized double blind placebo controlled trial. 2017 , 8, 147-154	42
1153	Eosinophilic colitis in children. 2017 , 34, 52-59	7

1152	Adsorptive Granulocyte and Monocyte Apheresis in the Treatment of Ulcerative Colitis: The First Multicenter Study in China. 2017 , 11, 216-225	9
1151	Inflammatory bowel diseases activity in patients undergoing pelvic radiation therapy. 2017 , 8, 173-179	8
1150	Burden of Ulcerative Colitis on Functioning and Well-being: A Systematic Literature Review of the SF-36 Health Survey. 2018 , 12, 600-609	21
1149	Endoscopic score vs. fecal biomarkers for predicting relapse in patients with ulcerative colitis after clinical remission and mucosal healing. 2018 , 9, 136	25
1148	Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study. 2018 , 24, 1099-1105	15
1147	Outcomes of Endoscopic Resections of Large Laterally Spreading Colorectal Lesions in Inflammatory Bowel Disease: a Single United Kingdom Center Experience. 2018 , 24, 1196-1203	15
1146	Methotrexate and Thioguanine Rescue Therapy for Conventional Thiopurine Failing Ulcerative Colitis Patients: A Multi-center Database Study on Tolerability and Effectiveness. 2018 , 24, 1558-1565	3
1145	Disagreement Among Gastroenterologists Using the Mayo and Rutgeerts Endoscopic Scores. 2018 , 24, 254-260	11
1144	Symptoms Do Not Correlate With Findings From Colonoscopy in Children With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis. 2018 , 16, 1098-1105.e1	23
1143	Ultrasound for Assessing Disease Activity in IBD Patients: A Systematic Review of Activity Scores. 2018 , 12, 920-929	37
1142	Accelerated Clearance of Infliximab is Associated With Treatment Failure in Patients With Corticosteroid-Refractory Acute Ulcerative Colitis. 2018 , 12, 662-669	33
1141	Combined Infection of Human Herpes Viruses: A Risk Factor for Subsequent Colectomy in Ulcerative Colitis. 2018 , 24, 1307-1315	6
1140	Ulcerative Colitis Endoscopic Index of Severity (UCEIS) versus Mayo Endoscopic Score (MES) in guiding the need for colectomy in patients with acute severe colitis. 2018 , 6, 38-44	50
1139	Endoscopy in Pediatric Inflammatory Bowel Disease. 2018 ,	
1138	Health-Related Quality of Life and Work-Related Outcomes for Patients With Mild-to-Moderate Ulcerative Colitis and Remission Status Following Short-Term and Long-Term Treatment With Multimatrix Mesalamine: A Prospective, Open-Label Study. 2018 , 24, 450-463	8
1137	Eicosapentaenoic Acid Reduces Fecal Levels of Calprotectin and Prevents Relapse in Patients With Ulcerative Colitis. 2018 , 16, 1268-1275.e2	30
1136	Non-alcoholic fatty liver disease phenotypes in patients with inflammatory bowel disease. 2018 , 9, 87	39
1135	Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease. 2018 , 47, 753-762	45

1134	Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. 2018 , 3, e000278	136
1133	Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis. 2018 , 1, CD011450	48
1132	Rescue Diverting Loop Ileostomy: An Alternative to Emergent Colectomy in the Setting of Severe Acute Refractory IBD-Colitis. 2018 , 61, 214-220	9
1131	Evidence-based clinical practice guidelines for inflammatory bowel disease. 2018 , 53, 305-353	249
1130	Quantitative contrast-enhanced ultrasound for monitoring vedolizumab therapy in inflammatory bowel disease patients: a pilot study. 2018 , 59, 1149-1156	6
1129	Simultaneous Measurements of Faecal Calprotectin and the Faecal Immunochemical Test in Quiescent Ulcerative Colitis Patients Can Stratify Risk of Relapse. 2018 , 12, 71-76	17
1128	Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission in patients with inflammatory bowel disease. 2018 , 50, 452-456	19
1127	Alterations in Lipid, Amino Acid, and Energy Metabolism Distinguish Crohn's Disease from Ulcerative Colitis and Control Subjects by Serum Metabolomic Profiling. 2018 , 14, 17	66
1126	High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO). 2018 , 53, 158-167	23
1125	Efficacy of Indigo Naturalis in a Multicenter Randomized Controlled Trial of Patients With Ulcerative Colitis. 2018 , 154, 935-947	85
1124	Evaluation of Brain Activity Using Near-infrared Spectroscopy in Inflammatory Bowel Disease Patients. 2018 , 8, 402	13
1123	Efficacy and Safety of Adalimumab in Pediatric Ulcerative Colitis: A Real-life Experience from the SIGENP-IBD Registry. 2018 , 66, 920-925	16
1122	Development and Validation of a Confocal Laser Endomicroscopy-Based Score for In Vivo Assessment of Mucosal Healing in Ulcerative Colitis Patients. 2017 , 24, 35-44	19
1121	Assessment of Histological Remission in Ulcerative Colitis: Discrepancies Between Daily Practice and Expert Opinion. 2018 , 12, 425-431	12
1120	Psychological distress, iron deficiency, active disease and female gender are independent risk factors for fatigue in patients with ulcerative colitis. 2018 , 6, 148-158	13
1119	Expression Patterns of TNF α , MAdCAM1, and STAT3 in Intestinal and Skin Manifestations of Inflammatory Bowel Disease. 2018 , 12, 347-354	25
1118	The Effect of Vitamin D on Intestinal Inflammation and Faecal Microbiota in Patients with Ulcerative Colitis. 2018 , 12, 963-972	52
1117	Colorectal dysplasia and adenocarcinoma in patients with ulcerative colitis: an experience from a tertiary care hospital. 2018 , 16, 81	1

1116	Endoscopic submucosal injection of adipose-derived mesenchymal stem cells ameliorates TNBS-induced colitis in rats and prevents stenosis. 2018 , 9, 95	10
1115	Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis. 2018 , 47, 1578-1596	19
1114	Efficacy and safety of granulocyte adsorption apheresis in elderly patients with ulcerative colitis. 2018 , 33, 514-520	10
1113	REDD1/Autophagy Pathway Is Associated with Neutrophil-Driven IL-1 β Inflammatory Response in Active Ulcerative Colitis. 2018 , 200, 3950-3961	52
1112	Comparison of Small Bowel Lesions Using Capsule Endoscopy in Ulcerative Colitis and Crohn's Disease: A Single-Center Retrospective Analysis. 2018 , 98, 119-126	6
1111	Adalimumab treatment of anti-TNF-naïve patients with ulcerative colitis: Deep remission and response factors. 2018 , 50, 812-819	5
1110	Endoscopic Surveillance in Inflammatory Bowel Disease. 2018 , 34, 66-71	7
1109	Immunogenicity of Quadrivalent Influenza Vaccine for Patients with Inflammatory Bowel Disease Undergoing Immunosuppressive Therapy. 2018 , 24, 1082-1091	27
1108	Increased epoxyeicosatrienoic acids may be part of a protective mechanism in human ulcerative colitis, with increased CYP2J2 and reduced soluble epoxide hydrolase expression. 2018 , 136, 9-14	5
1107	Irritable Bowel-like Symptoms in Ulcerative Colitis are as Common in Patients in Deep Remission as in Inflammation: Results From a Population-based Study [the IBSEN Study]. 2018 , 12, 389-393	31
1106	Chromoendoscopy versus autofluorescence imaging for neoplasia detection in patients with longstanding ulcerative colitis (FIND-UC): an international, multicentre, randomised controlled trial. 2018 , 3, 305-316	21
1105	The Paddington International Virtual Chromoendoscopy Score in ulcerative colitis exhibits very good inter-rater agreement after computerized module training: a multicenter study across academic and community practice (with video). 2018 , 88, 95-106.e2	17
1104	Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety. 2018 , 24, 849-860	24
1103	Endocytoscopic classification can be predictive for relapse in ulcerative colitis. 2018 , 97, e0107	18
1102	Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial. 2018 , 67, 818-826	64
1101	Development of an index to define overall disease severity in IBD. 2018 , 67, 244-254	73
1100	Disease activity and mucosal healing in inflammatory bowel disease: a new role for histopathology?. 2018 , 472, 99-110	26
1099	A multicenter, retrospective, observational study of the clinical outcomes and risk factors for relapse of ulcerative colitis at 1 year after leukocytapheresis. 2018 , 53, 387-396	8

1098	PET/MRI for evaluating subclinical inflammation of ulcerative colitis. 2018 , 47, 737-745	11
1097	Severe ulcerative colitis: predictors of response and algorithm proposal for rescue therapy. 2018 , 187, 385-392	8
1096	The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis. 2018 , 47, 67-77	85
1095	Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set. 2018 , 16, 637-647.e13	27
1094	Psychometric validation of the SF-36 Health Survey in ulcerative colitis: results from a systematic literature review. 2018 , 27, 273-290	16
1093	Endoscopic Indices for Ulcerative Colitis. 2018 , 163-172	
1092	Mucosal Healing in Ulcerative Colitis. 2018 , 183-191	
1091	Does Azathioprine induce endoscopic and histologic healing in pediatric inflammatory bowel disease? A prospective, observational study. 2018 , 50, 240-246	10
1090	The endoscopic surveillance of the transplanted small intestine: a single center experience and a proposal for a grading score. 2018 , 53, 134-139	10
1089	Serial semi-quantitative measurement of fecal calprotectin in patients with ulcerative colitis in remission. 2018 , 53, 152-157	9
1088	Of mice and men: a novel dietary supplement for the treatment of ulcerative colitis. 2018 , 11, 1756283X17741864	
1087	Alicaforsen, an Antisense Inhibitor of Intercellular Adhesion Molecule-1, in the Treatment for Left-Sided Ulcerative Colitis and Ulcerative Proctitis. 2018 , 36, 123-129	11
1086	A Randomized Trial Comparing High Definition Colonoscopy Alone With High Definition Dye Spraying and Electronic Virtual Chromoendoscopy for Detection of Colonic Neoplastic Lesions During IBD Surveillance Colonoscopy. 2018 , 113, 225-234	69
1085	Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis Frequently Have Subclinical Inflammation in the Proximal Colon. 2018 , 16, 68-74	26
1084	p53 and miR-34b/c genetic variation and their impact on ulcerative colitis susceptibility. 2018 , 75, 46-49	4
1083	Limited uptake of ulcerative colitis "treat-to-target" recommendations in real-world practice. 2018 , 33, 599-607	21
1082	Recommended drug therapies for inflammatory bowel disease. 2018 , 29, 17-22	1
1081	Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence. 2018 , 24, 2457-2467	46

1080	Effectiveness and safety of adalimumab to treat outpatient ulcerative colitis: A real-life multicenter, observational study in primary inflammatory bowel disease centers. 2018 , 97, e11897	15
1079	[Usefulness of therapeutic monitoring of infliximab in the treatment of inflammatory bowel disease]. 2018 , 146, 1241-1251	
1078	Colonic hypereosinophilia in ulcerative colitis may help to predict the failure of steroid therapy. 2018 , 22, 941-946	6
1077	Risk of recurrence of primary sclerosing cholangitis after liver transplantation is associated with inflammatory bowel disease. 2018 , 24, 4939-4949	8
1076	Psychometric validation of the work productivity and activity impairment questionnaire in ulcerative colitis: results from a systematic literature review. 2018 , 2, 62	10
1075	Symptomatic Effects of Smoking in Ulcerative Colitis: A Clinical Dilemma. 2018 , 03,	
1074	Faecal secretogranin and chromogranin levels persist over time and are unrelated to disease history and outcome in patients with ulcerative colitis. 2018 , 5, 1484602	1
1073	Oral Adjuvant Curcumin Therapy for Attaining Clinical Remission in Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 2018 , 10,	30
1072	A Simple Noninvasive Score Predicts Disease Activity and Deep Remission in Ulcerative Colitis. 2018 , 3, 16-24	6
1071	Transcription Factor ZNF281: A Novel Player in Intestinal Inflammation and Fibrosis. 2018 , 9, 2907	7
1070	Sustained Clinical Efficacy and Mucosal Healing of Thiopurine Maintenance Treatment in Ulcerative Colitis: A Real-Life Study. 2018 , 2018, 4195968	6
1069	Tacrolimus Suppositories in Therapy-Resistant Ulcerative Proctitis. 2019 , 3, 116-124	14
1068	Real-life chromoendoscopy for dysplasia surveillance in ulcerative colitis. 2018 , 24, 4069-4076	2
1067	[Updated S3-Guideline Colitis ulcerosa. German Society for Digestive and Metabolic Diseases (DGVS) - AWMF Registry 021/009]. 2018 , 56, 1087-1169	35
1066	Evaluation of interleukin 23 (IL-23) as a non-invasive test of disease severity in patients with ulcerative colitis. 2018 , 19, 116-120	5
1065	Vitamin A supplementation decreases disease activity index in patients with ulcerative colitis: A randomized controlled clinical trial. 2018 , 41, 215-219	11
1064	Algorithms to facilitate shared decision-making for the management of mild-to-moderate ulcerative colitis. 2018 , 12, 1079-1100	8
1063	Does Medical Acceleration Improve Outcomes in Ulcerative Colitis Patients Who Are in Clinical Remission but Have Endoscopic Inflammation?. 2018 , 63, 3041-3048	2

1062	Italian cohort of patients affected by inflammatory bowel disease is characterised by variation in glycerophospholipid, free fatty acids and amino acid levels. 2018 , 14, 140	18
1061	The emerging role of histologic disease activity assessment in ulcerative colitis. 2018 , 88, 887-898	53
1060	Algoritmos de tratamiento de la colitis ulcerosa desde una experiencia local. 2018 , 29, 570-579	
1059	Protocol for faecal microbiota transplantation in ulcerative colitis (FMTUC): a randomised feasibility study. 2018 , 8, e021987	3
1058	Fecal calprotectin correlates with active colonic inflammatory bowel disease but not with small intestinal Crohn's disease activity. 2018 , 2, 201-206	18
1057	38 Inflammatory Bowel Disease and Microscopic Colitis. 2018 ,	
1056	Affective temperament in inflammatory bowel diseases: Another brick in the wall of differentiation. 2018 , 13, e0205606	2
1055	Endoscopic progression of ulcerative proctitis to proximal disease. Can we identify predictors of progression?. 2018 , 53, 1286-1290	2
1054	Systematic review with network meta-analysis: the impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life. 2018 , 48, 1174-1185	23
1053	Diagnostic Accuracy of Endoscopic Trimodal Imaging and Chromoendoscopy for Lesion Characterization in Ulcerative Colitis. 2018 , 12, 1438-1447	8
1052	Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative Colitis. 2018 , 155, 1008-1011.e8	29
1051	Safety and efficacy of intravenous iron isomaltoside for correction of anaemia in patients with inflammatory bowel disease in everyday clinical practice. 2018 , 53, 1059-1065	8
1050	Altered intestinal antibacterial gene expression response profile in irritable bowel syndrome is linked to bacterial composition and immune activation. 2018 , 30, e13468	8
1049	The Transient Receptor Potential Vanilloid 1 Is Associated with Active Inflammation in Ulcerative Colitis. 2018 , 2018, 6570371	7
1048	Sleep Quality in Ulcerative Colitis: Associations with Inflammation, Psychological Distress, and Quality of Life. 2018 , 25, 517-525	12
1047	Paradoxical arthritis occurring during anti-TNF in patients with inflammatory bowel disease: histological and immunological features of a complex synovitis. 2018 , 4, e000667	11
1046	Tryptophan Metabolism through the Kynurenine Pathway is Associated with Endoscopic Inflammation in Ulcerative Colitis. 2018 , 24, 1471-1480	43
1045	Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease. 2018 , 12, S653-S668	34

1044	Role of endoscopy in inflammatory bowel disease. 2018 , 6, 75-82	17
1043	Assessment of Quality of Life in Chinese Patients With Inflammatory Bowel Disease and their Caregivers. 2018 , 24, 2039-2047	14
1042	Impact of Obesity on Short- and Intermediate-Term Outcomes in Inflammatory Bowel Diseases: Pooled Analysis of Placebo Arms of Infliximab Clinical Trials. 2018 , 24, 2278-2284	6
1041	Long-term course of inflammatory bowel disease after the Great East Japan Earthquake. 2018 , 33, 1956-1960	3
1040	Evolution of the Randomized Controlled Trial in Inflammatory Bowel Disease: Current Challenges and Future Solutions. 2018 , 24, 2155-2164	2
1039	Establishment of a Novel Scoring System for Colon Capsule Endoscopy to Assess the Severity of Ulcerative Colitis-Capsule Scoring of Ulcerative Colitis. 2018 , 24, 2641-2647	10
1038	Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. 2018 , 67, 257-291	145
1037	Clinical efficacy of the Toll-like receptor 9 agonist cobitolimod using patient-reported-outcomes defined clinical endpoints in patients with ulcerative colitis. 2018 , 50, 1019-1029	12
1036	Effectiveness of Disease-Specific Cognitive Behavioral Therapy on Anxiety, Depression, and Quality of Life in Youth With Inflammatory Bowel Disease: A Randomized Controlled Trial. 2018 , 43, 967-980	22
1035	Granulocyte and monocyte apheresis in inflammatory bowel disease: The patients' point of view. 2018 , 41, 423-431	3
1034	The sensitivity of fecal calprotectin in predicting deep remission in ulcerative colitis. 2018 , 53, 825-830	23
1033	All disease begins in the gut: Influence of gastrointestinal disorders and surgery on oral drug performance. 2018 , 548, 408-422	37
1032	The regulatory role of Nrf2 in antioxidants phase2 enzymes and IL-17A expression in patients with ulcerative colitis. 2018 , 214, 1149-1155	21
1031	Biological therapy and surgery rates in inflammatory bowel diseases - Data analysis of almost 1000 patients from a Hungarian tertiary IBD center. 2018 , 13, e0200824	2
1030	Effect of fermented vegetable beverage containing in patients with mild to moderate ulcerative colitis. 2018 , 9, 74-80	5
1029	The expression analysis of Fra-1 gene and IL-11 protein in Iranian patients with ulcerative colitis. 2018 , 19, 17	7
1028	[Evolving Therapeutic Strategies in the Inflammatory Bowel Disease]. 2018 , 71, 61-68	3
1027	Relapse Prevention in Ulcerative Colitis by Plant-Based Diet Through Educational Hospitalization: A Single-Group Trial. 2018 , 22, 17-167	11

1026	What can we learn from top-cited articles in inflammatory bowel disease? A bibliometric analysis and assessment of the level of evidence. 2018 , 8, e021233	7
1025	Reduction in TIMP-2 serum levels predicts remission of inflammatory bowel diseases. 2018 , 48, e13002	8
1024	Caspase recruitment domain (CARD) family (CARD9, CARD10, CARD11, CARD14 and CARD15) are increased during active inflammation in patients with inflammatory bowel disease. 2018 , 15, 13	10
1023	A multicenter retrospective study aiming to identify patients who respond well to adsorptive granulomonocytapheresis in moderately to severely active ulcerative colitis. 2018 , 9, 170	12
1022	How disease extent can be included in the endoscopic activity index of ulcerative colitis: the panMayo score, a promising scoring system. 2018 , 18, 7	6
1021	Evaluation of interleukin-6 and its soluble receptor components sIL-6R and sgp130 as markers of inflammation in inflammatory bowel diseases. 2018 , 33, 927-936	19
1020	Serologic Reactivity Reflects Clinical Expression of Ulcerative Colitis in Children. 2018 , 24, 1335-1343	10
1019	Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses. 2018 , 3, 742-753	22
1018	Optimal cut-off value of fecal calprotectin for the evaluation of ulcerative colitis: An unsolved issue?. 2018 , 2, 207-213	12
1017	Endoscopy in Pediatric Inflammatory Bowel Disease: A Position Paper on Behalf of the Porto IBD Group of the European Society for Pediatric Gastroenterology, Hepatology and Nutrition. 2018 , 67, 414-430	37
1016	Granulocyte and monocyte apheresis in inflammatory bowel disease: The patients' point of view. 2018 , 41, 423-431	0
1015	Extensive Disease Subtypes in Adult Patients with Ulcerative Colitis: Non-pancolitis Versus Pancolitis. 2018 , 63, 3097-3104	3
1014	Case-Control Study of Inflammatory Bowel Disease Patients with and without Clostridium difficile Infection and Poor Outcomes in Patients Coinfected with C. difficile and Cytomegalovirus. 2018 , 63, 3074-3083	10
1013	Accuracy of Humanitas Ultrasound Criteria in Assessing Disease Activity and Severity in Ulcerative Colitis: A Prospective Study. 2018 , 12, 1385-1391	40
1012	Faecal calprotectin level for assessing endoscopic activity and predicting future clinical course in patients with moderately active ulcerative colitis undergoing granulomonocytapheresis: a prospective cohort study. 2018 , 18, 120	5
1011	Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases. 2018 , 9, 1700	21
1010	Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study. 2018 , 12, 1079-1088	41
1009	Obesity and Response to Infliximab in Patients with Inflammatory Bowel Diseases: Pooled Analysis of Individual Participant Data from Clinical Trials. 2018 , 113, 883-889	26

1008	Clinical disease activity is associated with anxiety and depressive symptoms in adolescents and young adults with inflammatory bowel disease. 2018 , 48, 358-369	22
1007	Mesenchymal stem cell expression of interleukin-35 protects against ulcerative colitis by suppressing mucosal immune responses. 2018 , 20, 911-918	13
1006	Significance of serological markers in the disease course of ulcerative colitis in a prospective clinical cohort of patients. 2018 , 13, e0194166	14
1005	Golimumab effectiveness and safety in clinical practice for moderately active ulcerative colitis. 2018 , 30, 1019-1026	7
1004	Altered Polyamine Profiles in Colorectal Cancer. 2018 , 38, 3601-3607	14
1003	Potential of Fecal Calprotectin as an Objective Marker to Discriminate Hospitalized Patients with Acute Severe Colitis from Outpatients with Less Severe Disease. 2018 , 63, 2747-2753	1
1002	Putative biomarkers of vedolizumab resistance and underlying inflammatory pathways involved in IBD. 2018 , 5, e000208	21
1001	Gastrix. A Guide to Gastroenterology and Hepatology. 2018 , 1-346	
1000	Novel score predicts risk for cytomegalovirus infection in ulcerative colitis. 2018 , 105, 103-108	11
999	Long-Term Benefit of Golimumab for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension. 2018 , 12, 1053-1066	13
998	Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study. 2018 , 12, 1158-1169	70
997	Endoscopic Diagnosis and Staging of Inflammatory Bowel Disease. 2019 , 425-434.e2	
996	Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease. 2019 , 17, 486-493	53
995	Real-World Outcomes of Vedolizumab Therapy in Ulcerative Colitis and Crohn's Disease at a Tertiary Referral Center. 2019 , 37, 33-44	5
994	ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. 2019 , 13, 273-284	132
993	Prospective cohort study of appendicectomy for treatment of therapy-refractory ulcerative colitis. 2019 , 106, 1697-1704	14
992	Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review. 2019 , 25, 1142-1157	42
991	The retinal foveal avascular zone as a systemic biomarker to evaluate inflammatory bowel disease control. 2019 , 5, 16	3

990	Performance of tacrolimus in hospitalized patients with steroid-refractory acute severe ulcerative colitis. 2019 , 25, 1603-1617	9
989	Diagnostic utility of linked color imaging in the evaluation of colonic mucosal inflammation in ulcerative colitis: a pilot study. 2019 , 7, E937-E943	4
988	An update on treatment of ulcerative colitis. 2019 , 7, 295-304	1
987	Prediction of clinical effects of infliximab administered for inflammatory bowel disease based on pharmacokinetic and pharmacodynamic modeling. 2019 , 40, 250-261	2
986	Inflammatory Bowel Disease. 2019 , 373-424	
985	The efficacy of maintenance therapy after remission induction with tacrolimus in ulcerative colitis with and without previous tumor necrosis factor- α inhibitor. 2019 , 3, 217-223	2
984	PREVENTION OF INFLAMMATORY BOWEL DISEASE COMPLICATIONS AND RECURRENCE. 2019 , 30, 339-343	
983	Infliximab for pediatric patients with ulcerative colitis: a phase 3, open-label, uncontrolled, multicenter trial in Japan. 2019 , 19, 351	1
982	Budesonide treatment for microscopic colitis from immune checkpoint inhibitors. 2019 , 7, 292	27
981	Improving the quality of surveillance colonoscopy in inflammatory bowel disease. 2019 , 4, 971-983	13
980	The abundance of Akkermansia muciniphila and its relationship with sulphated colonic mucins in health and ulcerative colitis. 2019 , 9, 15683	75
979	A Combined Set of Four Serum Inflammatory Biomarkers Reliably Predicts Endoscopic Disease Activity in Inflammatory Bowel Disease. 2019 , 6, 251	20
978	The influence of self-criticism on depression symptoms among ambulatory patients with inflammatory bowel disease. 2019 , 26, 743-750	5
977	Colonic mucosa-associated candida assessed by biopsy culture is associated with disease severity in ulcerative colitis: A prospective study. 2019 , 20, 642-648	4
976	Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. 2019 , 17, 285-310	41
975	Magnification endoscopy with optical chromoendoscopy shows strong correlation with histologic inflammation in patients with inflammatory bowel disease. 2019 , 7, E1018-E1026	6
974	Influence of Pharmaceutical Formulation on the Mucosal Concentration of 5-Aminosalicylic Acid and N-Acetylmethylsalicylic Acid in Japanese Patients with Ulcerative Colitis. 2019 , 42, 81-86	5
973	Serum Free Thiols Are Superior to Fecal Calprotectin in Reflecting Endoscopic Disease Activity in Inflammatory Bowel Disease. 2019 , 8,	16

972	Two-year delay in ulcerative colitis diagnosis is associated with anti-tumor necrosis factor alpha use. 2019 , 25, 989-1001	4
971	Swedish Inflammatory Bowel Disease Register (SWIBREG) - a nationwide quality register. 2019 , 54, 1089-1101	11
970	Therapeutic targets in inflammatory bowel disease. 2019 , 30, 315-322	
969	Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab. 2019 , 12, 1756284819869141	2
968	The value of mRNA expression of S100A8 and S100A9 as blood-based biomarkers of inflammatory bowel disease. 2019 , 20, 135-140	3
967	Predictors of Inadequate Response to Budesonide Multimatrix in Real-World Patients with Ulcerative Colitis. 2019 , 4, 115-122	3
966	Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2019 , 381, 1201-1214	59.2 354
965	British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. 2019 , 68, s1-s106	557
964	Difference in the clinical characteristic and prognosis of colitis-associated cancer and sporadic neoplasia in ulcerative colitis patients. 2019 , 51, 1257-1264	5
963	Retrospective analysis of Clostridium difficile infection in patients with ulcerative colitis in a tertiary hospital in China. 2019 , 19, 3	7
962	Characterization of T Cells in Intestinal Mucosa From Patients With Early-Onset or Long-Standing Inflammatory Bowel Disease and Their Correlation With Clinical Status. 2019 , 13, 873-883	13
961	Validation of a novel integral disease index for evaluating the grade of activity in Mexican patients with ulcerative colitis: A prospective cohort study. 2019 , 84, 317-325	7
960	Predictive models of disease burden at diagnosis in persons with adult-onset ulcerative colitis using health administrative data. 2019 , 19, 13	1
959	Successful outcome of the transitional process of inflammatory bowel disease from pediatric to adult age: A five years experience. 2019 , 51, 524-528	4
958	Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease. 2019 , 50, 5-23	43
957	Expression Analysis of Fibronectin Type III Domain-Containing (FNDC) Genes in Inflammatory Bowel Disease and Colorectal Cancer. 2019 , 2019, 3784172	11
956	Even non-experts identify non-dysplastic lesions in inflammatory bowel disease via chromoendoscopy: results of a screening program in real-life. 2019 , 7, E743-E750	5
955	Vedolizumab is effective and safe in real-life treatment of inflammatory bowel diseases outpatients: A multicenter, observational study in primary inflammatory bowel disease centers. 2019 , 66, 85-91	12

954	Immunologic Alterations Associated With Oral Delivery of Anti-CD3 (OKT3) Monoclonal Antibodies in Patients With Moderate-to-Severe Ulcerative Colitis. 2019 , 1, otz009	6
953	Pomegranate juice to reduce fecal calprotectin levels in inflammatory bowel disease patients with a high risk of clinical relapse: Study protocol for a randomized controlled trial. 2019 , 20, 327	7
952	Chronic Active Ulcerative Colitis. 2019 , 131-140	
951	Validation of a novel integral disease index for evaluating the grade of activity in Mexican patients with ulcerative colitis: A prospective cohort study. 2019 , 84, 317-325	0
950	New developments in ulcerative colitis: latest evidence on management, treatment, and maintenance. 2019 , 8, 212572	54
949	Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease. 2019 , 7, 741-749	10
948	Capabilities of fecal calprotectin and blood biomarkers as surrogate endoscopic markers according to ulcerative colitis disease type. 2019 , 64, 265-270	8
947	Short Health Scale: a valid and reliable measure of quality of life in Dutch speaking patients with inflammatory bowel disease. 2019 , 54, 592-596	1
946	Hyposensitization trial using salazosulfapyridine in a case of mesalamine intolerance. 2019 , 12, 578-582	1
945	Utility of Mesalazine in Familial Adenomatous Polyposis: Clinical Report of Reduction of Polyp Size in Patients with Ulcerative Colitis, and Safety Examination in Familial Adenomatous Polyposis Patients. 2019 , 104, 51-56	4
944	Haemorheological and haemostatic alterations in coeliac disease and inflammatory bowel disease in comparison with non-coeliac, non-IBD subjects (HERMES): a case-control study protocol. 2019 , 9, e026315	2
943	Performance of a Deep Learning Model vs Human Reviewers in Grading Endoscopic Disease Severity of Patients With Ulcerative Colitis. 2019 , 2, e193963	76
942	Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study. 2019 , 51, 972-977	13
941	Low Golimumab Trough Levels at Week 6 Are Associated With Poor Clinical, Endoscopic and Histological Outcomes in Ulcerative Colitis Patients: Pharmacokinetic and Pharmacodynamic Sub-analysis of the Evolution Study. 2019 , 13, 1387-1393	9
940	Treat-to-Target in Inflammatory Bowel Diseases, What Is the Target and How Do We Treat?. 2019 , 29, 421-436	28
939	Serum S100A8/A9 as a Potentially Sensitive Biomarker for Inflammatory Bowel Disease. 2019 , 50, 370-380	11
938	Single-Needle Intensive Granulocyte and Monocyte Adsorptive Apheresis Is Suitable for Elderly Patients With Active Ulcerative Colitis Taking no Corticosteroids or Biologics. 2019 , 23, 224-232	4
937	Acoustic radiation force impulse (ARFI) shear wave elastography of the bowel wall in healthy volunteers and in ulcerative colitis. 2019 , 8, 2058460119840969	5

936	A blood-based prognostic biomarker in IBD. 2019 , 68, 1386-1395	69
935	Mucosal 5-aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis. 2019 , 49, 1301-1313	18
934	Reduced CD27IgD B Cells in Blood and Raised CD27IgD B Cells in Gut-Associated Lymphoid Tissue in Inflammatory Bowel Disease. 2019 , 10, 361	14
933	Mechanistic analysis and experimental verification of bicarbonate-controlled enteric coat dissolution: Potential in vivo implications. 2019 , 139, 47-58	18
932	Clinical Parameters Correlate With Endoscopic Activity of Ulcerative Colitis: A Systematic Review. 2019 , 17, 1265-1275.e8	17
931	Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. 2019 , 34, 1296-1315	18
930	A comprehensive review and update on ulcerative colitis. 2019 , 65, 100851	103
929	Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases. 2019 , 64, 1651-1659	22
928	DUBLIN [Degree of Ulcerative colitis Burden of Luminal Inflammation] Score, a Simple Method to Quantify Inflammatory Burden in Ulcerative Colitis. 2019 , 13, 1365-1371	11
927	Structural weakening of the colonic mucus barrier is an early event in ulcerative colitis pathogenesis. 2019 , 68, 2142-2151	110
926	Symptoms compatible with functional bowel disorders are common in patients with quiescent ulcerative colitis and influence the quality of life but not the course of the disease. 2019 , 12, 1756284819827689	7
925	Depression and anxiety have unique contributions to somatic complaints in depression, irritable bowel syndrome and inflammatory bowel diseases. 2019 , 29, 418-426	2
924	Vitamin D deficiency in adult patients with ulcerative colitis: Prevalence and relationship with disease severity, extent, and duration. 2019 , 38, 6-14	9
923	Relationship between endoscopic mucosal healing and histologic inflammation during remission maintenance phase in ulcerative colitis: a retrospective study. 2019 , 7, E568-E575	16
922	Presenting symptoms in inflammatory bowel disease: descriptive analysis of a community-based inception cohort. 2019 , 19, 47	23
921	Validation of a Digital Support App to Assess Inflammatory Disease Activity and Mental Health Patient-Reported Outcomes (PROs): A Pilot Investigation. 2019 , 2019, 7618468	1
920	Clinical and biological predictors of response to standardised paediatric colitis therapy (PROTECT): a multicentre inception cohort study. 2019 , 393, 1708-1720	61
919	Mucosal and Systemic Immune Profiles Differ During Early and Late Phases of the Disease in Patients With Active Ulcerative Colitis. 2019 , 13, 1450-1458	9

918	Trial summary and protocol for a phase II randomised placebo-controlled double-blinded trial of Interleukin 1 blockade in Acute Severe Colitis: the IASO trial. 2019 , 9, e023765	17
917	Kidney transplantation in patients with inflammatory bowel diseases (IBD): analysis of transplantation outcome and IBD activity. 2019 , 32, 730-738	7
916	The Role of Biomarkers in Treatment Algorithms for Ulcerative Colitis (UC). 2019 , 25-42	
915	Weight Gain and Liver Steatosis in Patients with Inflammatory Bowel Diseases. 2019 , 11,	5
914	A User-Friendly Prediction Tool to Identify Colectomy Risk in Patients With Ulcerative Colitis. 2019 , 25, 1550-1558	8
913	A comparison of long-term healthcare utilization and costs in patients with acute severe ulcerative colitis receiving infliximab early colectomy. 2019 , 10, 2040622319825595	4
912	Intensified Infliximab Induction is Associated with Improved Response and Decreased Colectomy in Steroid-Refractory Paediatric Ulcerative Colitis. 2019 , 13, 982-989	14
911	The Impact of Raising the Bar for Clinical Trials in Ulcerative Colitis. 2019 , 13, 1217-1226	4
910	Characterization of inflammatory bowel disease management by vedolizumab and concomitant treatments in real-life clinical practice. 2019 , 58, 50-56	2
909	The clinical significance of simple endoscopic scoring of patients with rectal cancer after concurrent chemoradiotherapy. 2019 , 10, 1073-1079	
908	Correlation between Serological Biomarkers and Disease Activity in Patients with Inflammatory Bowel Disease. 2019 , 2019, 6517549	11
907	Single Needle Granulocyte and Monocyte Apheresis for Ulcerative Colitis: A Retrospective Safety Analysis. 2020 , 66, 1-7	1
906	Diffuse Large B-Cell Lymphoma Mimicking an Ulcerative Colitis Flare. 2019 , 6, 1-3	0
905	Stratification of inflammatory bowel disease outpatients by disease activity and risk of complications to guide out-of-hospital monitoring: a patient-centred quality improvement project. 2019 , 8, e000546	3
904	Retrospective investigation of tacrolimus combined with an anti-tumor necrosis factor- α antibody as remission induction therapy for refractory ulcerative colitis: Efficacy, safety, and relapse rate. 2019 , 3, 525-531	1
903	Inflammatory Bowel Disease in Children with Elevated Serum Gamma Glutamyltransferase Levels. 2019 , 215, 144-151.e3	6
902	Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease. 2019 , 7, 1189-1197	18
901	Endoscopy in Inflammatory Bowel Disease. 2019 , 99, 1063-1082	2

900	Immunosuppression for inflammatory bowel disease does not influence EpsteinBarr viral load in the short-term. 2019 , 42, 542-547	
899	Usability of IBDoc, a Novel Fecal Calprotectin Home-Based Rapid Test in Clinical Practice. 2019 , 18, 85-91	1
898	A distinct gut microbiota composition in patients with ankylosing spondylitis is associated with increased levels of fecal calprotectin. 2019 , 21, 248	22
897	Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial.. 2019 , 12, 1756284819874202	0
896	Safety and effectiveness of granulocyte and monocyte adsorptive apheresis in patients with inflammatory bowel disease in special situations: a multicentre cohort study. 2019 , 19, 196	6
895	Endoscopic score vs blood cell indices for determining timing of immunomodulator withdrawal in quiescent ulcerative colitis. 2019 , 9, 17751	4
894	Effectiveness of sigmoidoscopy for assessing ulcerative colitis disease activity and therapeutic response. 2019 , 98, e15748	4
893	Clinical implications of fecal calprotectin and fecal immunochemical test on mucosal status in patients with ulcerative colitis. 2019 , 98, e17080	11
892	UEG Week 2019 Poster Presentations. 2019 , 7, 189-1030	1
891	High-Definition Chromoendoscopy Versus High-Definition White Light Colonoscopy for Neoplasia Surveillance in Ulcerative Colitis: A Randomized Controlled Trial. 2019 , 114, 1642-1648	22
890	Top-100 highest-cited original articles in inflammatory bowel disease: A bibliometric analysis. 2019 , 98, e15718	12
889	ACG Clinical Guideline: Ulcerative Colitis in Adults. 2019 , 114, 384-413	458
888	Fibrosis Mediators in the Colonic Mucosa of Acute and Healed Ulcerative Colitis. 2019 , 10, e00082	10
887	Assessment of Long-Term Efficacy and Safety of Adalimumab in Patients with Ulcerative Colitis: Results from a 6-Year Real-World Clinical Practice. 2019 , 37, 11-20	2
886	Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn's Disease or Ulcerative Colitis: A Systematic Review and Meta-analysis. 2019 , 17, 838-846.e2	62
885	Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis. 2019 , 17, 139-147	78
884	Systematic review with meta-analysis: high prevalence and cost of continued aminosalicylate use in patients with ulcerative colitis escalated to immunosuppressive and biological therapies. 2019 , 49, 364-374	1
883	Advanced endoscopic techniques in the assessment of inflammatory bowel disease: new technology, new era. 2019 , 68, 562-572	25

882	Fully automated diagnostic system with artificial intelligence using endocytoscopy to identify the presence of histologic inflammation associated with ulcerative colitis (with video). 2019 , 89, 408-415	110
881	AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis. 2019 , 156, 748-764	92
880	Fecal calprotectin role in diagnosis of ulcerative colitis and treatment follow-up. 2019 , 39, 115-120	
879	AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis. 2019 , 156, 769-808.e29	61
878	25 Ulcerative Colitis. 2019 ,	
877	Inulin-type fructans improve active ulcerative colitis associated with microbiota changes and increased short-chain fatty acids levels. 2019 , 10, 334-357	53
876	Granulomonocytapheresis as a cell-dependent treatment option for patients with inflammatory bowel disease: Concepts and clinical features for better therapeutic outcomes. 2019 , 34, 51-60	15
875	The Prevalence and Clinical Associations of Subclinical Sacroiliitis in Inflammatory Bowel Disease. 2019 , 25, 1066-1071	16
874	Probiotics for improving quality of life in ulcerative colitis: Exploring the patient perspective. 2019 , 7, 100139	9
873	Elevation in Cell Cycle and Protein Metabolism Gene Transcription in Inactive Colonic Tissue From Icelandic Patients With Ulcerative Colitis. 2019 , 25, 317-327	4
872	Factors affecting vitamin D deficiency in active inflammatory bowel diseases. 2019 , 51, 657-662	11
871	Updated S3-Guideline Ulcerative Colitis. German Society for Digestive and Metabolic Diseases (DGVS). 2019 , 57, 162-241	25
870	Oversecretion and Overexpression of Nicotinamide Phosphoribosyltransferase/Pre-B Colony-Enhancing Factor/Visfatin in Inflammatory Bowel Disease Reflects the Disease Activity, Severity of Inflammatory Response and Hypoxia. 2019 , 20,	17
869	Correlation of Endoscopic and Histologic Severity Scores in Pediatric Ulcerative Colitis at First Presentation. 2019 , 22, 106-111	4
868	Validation and Investigation of the Operating Characteristics of the Ulcerative Colitis Endoscopic Index of Severity. 2019 , 25, 937-944	16
867	Predictors of mucosal healing during induction therapy in patients with acute moderate-to-severe ulcerative colitis. 2019 , 34, 1004-1010	3
866	Illness Perception in Inflammatory Bowel Disease Patients is Different Between Patients With Active Disease or in Remission: A Prospective Cohort Study. 2019 , 13, 417-423	22
865	Semen Quality and Sperm DNA Integrity in Patients With Severe Active Inflammatory Bowel Disease and Effects of Tumour Necrosis Factor-alpha Inhibitors. 2019 , 13, 564-571	7

864	Current Medical Therapies for Ulcerative Colitis. 2019 , 1-15	
863	Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug Development. 2019 , 17, 1673-1679.e1	13
862	Metagenomic analysis of intestinal mucosa revealed a specific eukaryotic gut virome signature in early-diagnosed inflammatory bowel disease. 2019 , 10, 149-158	36
861	Efficacy of Therapeutic Intervention for Patients With an Ulcerative Colitis Mayo Endoscopic Score of 1. 2019 , 25, 782-788	15
860	Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort-An Epi-IBD Study. 2019 , 13, 198-208	57
859	Comparison of different histological indexes in the assessment of UC activity and their accuracy regarding endoscopic outcomes and faecal calprotectin levels. 2019 , 68, 594-603	62
858	Virtual Chromoendoscopy With FICE for the Classification of Polypoid and Nonpolypoid Raised Lesions in Ulcerative Colitis. 2019 , 53, 269-276	7
857	Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. 2020 , 18, 179-187.e6	24
856	Intestinal Inflammation Modulates the Epithelial Response to Butyrate in Patients With Inflammatory Bowel Disease. 2020 , 26, 43-55	43
855	Faecal Calprotectin Predicts Endoscopic and Histological Activity in Clinically Quiescent Ulcerative Colitis. 2020 , 14, 46-52	16
854	Infants born to mothers with IBD present with altered gut microbiome that transfers abnormalities of the adaptive immune system to germ-free mice. 2020 , 69, 42-51	67
853	Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. 2020 , 158, 562-572.e12	65
852	Indigo naturalis is effective even in treatment-refractory patients with ulcerative colitis: a post hoc analysis from the INDIGO study. 2020 , 55, 169-180	11
851	Significance of Conducting 2 Types of Fecal Tests in Patients With Ulcerative Colitis. 2020 , 18, 1102-1111.e5	14
850	Discordance Between Patient-Reported Outcomes and Mucosal Inflammation in Patients With Mild to Moderate Ulcerative Colitis. 2020 , 18, 1760-1768.e1	7
849	Tofacitinib Reprograms Human Monocytes of IBD Patients and Healthy Controls Toward a More Regulatory Phenotype. 2020 , 26, 391-406	14
848	Ulcerative Colitis Patients Continue to Improve Over the First Six Months of Vedolizumab Treatment: 12-Month Clinical and Mucosal Healing Effectiveness. 2020 , 3, 74-82	1
847	Absence of Day 3 Steroid Response Predicts Colitis-Related Complications and Colectomy in Hospitalized Ulcerative Colitis Patients. 2020 , 3, 169-176	2

846	Do You See What I See? An Assessment of Endoscopic Lesions Recognition and Description by Gastroenterology Trainees and Staff Physicians. 2020 , 3, 216-221	0
845	The TLR9 Agonist Cobitolimod Induces IL10-Producing Wound Healing Macrophages and Regulatory T Cells in Ulcerative Colitis. 2020 , 14, 508-524	16
844	No Superiority of Tacrolimus Suppositories vs Beclomethasone Suppositories in a Randomized Trial of Patients With Refractory Ulcerative Proctitis. 2020 , 18, 1777-1784.e2	5
843	Using artificial intelligence to improve adequacy of inspection in gastrointestinal endoscopy. 2020 , 22, 71-79	5
842	Development of an Indigo Naturalis Suppository for Topical Induction Therapy in Patients with Ulcerative Colitis. 2020 , 101, 492-498	8
841	Colitis, Ulcerative. 2020 , 552-574	
840	Comparing the Continuous Geboes Score With the Robarts Histopathology Index: Definitions of Histological Remission and Response and their Relation to Faecal Calprotectin Levels. 2020 , 14, 169-175	12
839	Modern use of 5-aminosalicylic acid compounds for ulcerative colitis. 2020 , 20, 363-378	22
838	Psychological Outcomes of a Cognitive Behavioral Therapy for Youth with Inflammatory Bowel Disease: Results of the HAPPY-IBD Randomized Controlled Trial at 6- and 12-Month Follow-Up. 2020 , 27, 490-506	5
837	Relationship between Mayo endoscopic score and histological scores in ulcerative colitis: A prospective study. 2020 , 4, 382-386	4
836	Real-Life Effectiveness and Safety of Golimumab and Its Predictors of Response in Patients with Ulcerative Colitis. 2020 , 65, 1767-1776	5
835	Performance measures in inflammatory bowel disease surveillance colonoscopy: Implementing changes to practice improves performance. 2020 , 32, 592-599	1
834	A Phase I Trial of Berberine in Chinese with Ulcerative Colitis. 2020 , 13, 117-126	17
833	Ulcerative Colitis: Current and Emerging Treatment Strategies. 2019 , 9,	19
832	Mucosal gene transcription of ulcerative colitis in endoscopic remission. 2020 , 55, 139-147	4
831	Histological Markers of Clinical Relapse in Endoscopically Quiescent Ulcerative Colitis. 2020 , 26, 1722-1729	7
830	Systemic Inflammatory Protein Profiles Distinguish Irritable Bowel Syndrome (IBS) and Ulcerative Colitis, Irrespective of Inflammation or IBS-Like Symptoms. 2020 , 26, 874-884	9
829	Automatic, computer-aided determination of endoscopic and histological inflammation in patients with mild to moderate ulcerative colitis based on red density. 2020 , 69, 1778-1786	36

828	A novel endoscopic imaging system for quantitative evaluation of colonic mucosal inflammation in patients with quiescent ulcerative colitis. 2020 , 8, E41-E49	5
827	Serum Dipeptidyl Peptidase 4: A Predictor of Disease Activity and Prognosis in Inflammatory Bowel Disease. 2020 , 26, 1707-1719	9
826	Is there room for immunomodulators in ulcerative colitis?. 2020 , 20, 379-390	2
825	Development of a validated Chinese version of the inflammatory bowel disease disability index. 2020 , 21, 52-58	0
824	Mannose-binding lectin (MBL) in adult patients with inflammatory bowel disease. 2020 , 225, 151859	2
823	Comparative Efficacy and Speed of Onset of Action of Infliximab vs Golimumab in Ulcerative Colitis. 2020 , 18, 424-431.e7	9
822	Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis. 2020 , 52, 268-273	24
821	Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis. 2020 , 158, 550-561	63
820	Endoscopic alterations in Peyer's patches in patients with ulcerative colitis: A prospective, multicenter study. 2020 , 35, 1143-1149	2
819	Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre. 2020 , 14, 915-919	18
818	Phase I, II and III Trials in Inflammatory Bowel Diseases: A Practical Guide for the Non-specialist. 2020 , 14, 710-718	1
817	Combining faecal calprotectin and sigmoidoscopy can predict mucosal healing in paediatric ulcerative colitis. 2020 , 32, 17-21	1
816	Long-term deep remission during maintenance therapy with biological agents in inflammatory bowel diseases. 2020 , 55, 34-40	5
815	Efficacy of apheresis as maintenance therapy for patients with ulcerative colitis in an open-label prospective multicenter randomised controlled trial. 2020 , 55, 390-400	6
814	Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis. 2020 , 18, 2244-2255.e9	30
813	The Effect of Dream Anxiety on Sleep Quality in Inflammatory Bowel Diseases. 2020 , 38, 380-389	1
812	Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. 2020 , 38, 576-583	71
811	Breath Test Gas Patterns in Inflammatory Bowel Disease with Concomitant Irritable Bowel Syndrome-Like Symptoms: A Controlled Large-Scale Database Linkage Analysis. 2020 , 65, 2388-2396	2

810	The Anti-inflammatory Immune Regulation Induced by Butyrate Is Impaired in Inflamed Intestinal Mucosa from Patients with Ulcerative Colitis. 2020 , 43, 507-517	23
809	A review of endoscopic scoring systems and their importance in a treat-to-target approach in inflammatory bowel disease (with videos). 2020 , 91, 733-745	13
808	Factors associated with disability in patients with ulcerative colitis: A cross-sectional study. 2020 , 21, 81-87	4
807	Current Endpoints of Clinical Trials in Ulcerative Colitis: Are They Valid?. 2020 , 18, 15	0
806	The endoscopic diagnosis of mucosal healing and deep remission in inflammatory bowel disease. 2021 , 33, 1008-1023	3
805	Efficacy of iron supplementation in patients with inflammatory bowel disease treated with anti-tumor necrosis factor-alpha agents. 2020 , 13, 1756284820961302	2
804	Defining Endpoints and Biomarkers in Inflammatory Bowel Disease: Moving the Needle Through Clinical Trial Design. 2020 , 159, 2013-2018.e7	3
803	Artificial intelligence-assisted endoscopy changes the definition of mucosal healing in ulcerative colitis. 2021 , 33, 903-911	4
802	Assessing Severity of Disease in Patients with Ulcerative Colitis. 2020 , 49, 671-688	10
801	Week 2020 Poster Presentations. 2020 , 8, 144-887	3
800	Histologic Features of Colon Biopsies (Geboes Score) Associated With Progression of Ulcerative Colitis for the First 36 Months After Biopsy. 2021 , 19, 2567-2576.e9	2
799	Randomized, Ascending Dose, Phase 2 Study of KHK4083, an Anti-OX40 Monoclonal Antibody, in Moderately Active Ulcerative Colitis. 2020 , 2,	0
798	Maintenance Golimumab Treatment in Pediatric UC Patients With Moderately to Severely Active UC: PURSUIT PEDS PK Long-Term Study Results. 2020 , 2,	2
797	Exploratory Study of the Effectiveness of Granulocyte and Monocyte Adsorptive Apheresis Before Initiation of Steroids in Patients With Active Ulcerative Colitis (EXPECT Study): A Multicenter Prospective Clinical Trial. 2020 , 2, otaa073	1
796	Chromoendoscopy With Indigo Carmine vs Virtual Chromoendoscopy (iSCAN 1) for Neoplasia Screening in Patients With Inflammatory Bowel Disease: A Prospective Randomized Study. 2021 , 27, 1256-1262	3
795	Association between platelet count and mucosal healing in Japanese patients with ulcerative colitis: a cross-sectional study. 2020 , 20, 384	5
794	Corticosteroid exposure prior to admission and predicting need for rescue therapy in acute severe ulcerative colitis. 2020 ,	0
793	Clinical Characterization of Ulcerative Colitis in Patients with Primary Sclerosing Cholangitis. 2020 , 2020, 7969628	2

792	Adjuvant use of combination of antibiotics in acute severe ulcerative colitis: A placebo controlled randomized trial. 2021 , 19, 949-955	7
791	Enhancement of Circulating and Intestinal T Regulatory Cells and Their Expression of Helios and Neuropilin-1 in Children with Inflammatory Bowel Disease. 2020 , 13, 995-1005	6
790	Predicting a rapid response to adalimumab treatment and favorable short-term outcomes through the high platelet count in patients with ulcerative colitis: A multicenter retrospective cohort study. 2020 , 99, e23344	
789	Molecular Changes in the Non-Inflamed Terminal Ileum of Patients with Ulcerative Colitis. 2020 , 9,	2
788	Endoscopic and histologic activity assessment considering disease extent and prediction of treatment failure in ulcerative colitis. 2020 , 55, 1157-1162	2
787	Risk factors for ulcerative colitis-associated colorectal cancer: A retrospective cohort study. 2020 , 99, e21686	3
786	Development and validation of a diverticular clinical score for symptomatic uncomplicated diverticular disease after acute diverticulitis in a prospective patient cohort. 2020 , 13, 1756284820913210	2
785	Endoscopy and central reading in inflammatory bowel disease clinical trials: achievements, challenges and future developments. 2021 , 70, 418-426	8
784	Cytomegalovirus and Inflammatory Bowel Diseases (IBD) with a Special Focus on the Link with Ulcerative Colitis (UC). 2020 , 8,	9
783	Intestinal Inflammation Alters the Expression of Hepatic Bile Acid Receptors Causing Liver Impairment. 2020 , 71, 189-196	5
782	What is the appropriate cut-off value of CRP to predict endoscopic remission in patients with ulcerative colitis in clinical remission?. 2020 , 35, 2249-2255	1
781	Role of Ulcerative Colitis Endoscopic Index of Severity (UCEIS) versus Mayo Endoscopic Subscore (MES) in Predicting Patients' Response to Biological Therapy and the Need for Colectomy. 2021 , 102, 534-545	6
780	Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. 2020 , 8, CD000543	9
779	Characteristics of the Mucosal Surface on Scanning Electron Microscopy in Patients with Remitting Ulcerative Colitis. 2021 , 66, 3141-3148	1
778	Efficacies of first and second tumor necrosis factor inhibitors in refractory ulcerative colitis patients in real-world practice. 2020 , 39, 565-575	1
777	Altered serum profile of the interleukin-22 system in inflammatory bowel disease. 2020 , 136, 155264	1
776	Efficacy and safety of vedolizumab in elderly patients with inflammatory bowel disease: a matched case-control study. 2020 , 8, 306-311	3
775	Gene Expression of Transient Receptor Potential Channels in Peripheral Blood Mononuclear Cells of Inflammatory Bowel Disease Patients. 2020 , 9,	5

774	Association between Corrected QT Interval and C-Reactive Protein in Patients with Inflammatory Bowel Diseases. 2020 , 56,	
773	Colonic Mucosal Microbiota and Association of Bacterial Taxa with the Expression of Host Antimicrobial Peptides in Pediatric Ulcerative Colitis. 2020 , 21,	4
772	HyperKvasir, a comprehensive multi-class image and video dataset for gastrointestinal endoscopy. 2020 , 7, 283	71
771	Analysis of Using the Total White Blood Cell Count to Define Severe New-onset Ulcerative Colitis in Children. 2020 , 71, 354-360	2
770	Relationship Between Combined Histologic and Endoscopic Endpoints and Efficacy of Ustekinumab Treatment in Patients With Ulcerative Colitis. 2020 , 159, 2052-2064	17
769	Determinants of Sleep Quality in Inflammatory Bowel Diseases. 2020 , 9,	14
768	Ulcerative colitis. 2020 , 6, 74	182
767	Inpatient Therapy With Calcineurin Inhibitors in Severe Ulcerative Colitis. 2021 , 27, 1620-1625	3
766	Hepcidin Is a Reliable Marker of Iron Deficiency Anemia in Newly Diagnosed Patients with Inflammatory Bowel Disease. 2020 , 2020, 8523205	3
765	An Update on Pharmaceutical Strategies for Oral Delivery of Therapeutic Peptides and Proteins in Adults and Pediatrics. 2020 , 7,	7
764	Endoscopic Assessment of Inflammatory Bowel Disease Activity in Clinical Trials. 2020 ,	1
763	Early Changes in Serum Albumin Predict Clinical and Endoscopic Outcomes in Patients With Ulcerative Colitis Starting Anti-TNF Treatment. 2021 , 27, 1452-1461	4
762	Bacterial and Fungal Profiles as Markers of Infliximab Drug Response in Inflammatory Bowel Disease. 2021 , 15, 1019-1031	6
761	A dual pH and microbiota-triggered coating (Phloral [®]) for fail-safe colonic drug release. 2020 , 583, 119379	29
760	Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. 2020 , 69, 1213-1217	208
759	Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?. 2020 , 123, 207-215	16
758	Cardiovascular Risk in Individuals with Inflammatory Bowel Disease. 2020 , 13, 107-113	16
757	Clinical Significance of Hepatocyte Growth Factor and Transforming Growth Factor-Beta-1 Levels in Assessing Disease Activity in Inflammatory Bowel Disease. 2020 , 2020, 2104314	1

756	Transperineal ultrasound predicts endoscopic and histological healing in ulcerative colitis. 2020 , 51, 1373-1383	11
755	Novel Therapeutic Options for People with Ulcerative Colitis: An Update on Recent Developments with Janus Kinase (JAK) Inhibitors. 2020 , 13, 131-139	9
754	Effect of ulcerative colitis duration on the usefulness of immunochemical fecal occult blood test result as a disease activity biomarker. 2020 , 35, 1729-1739	5
753	Remission of ulcerative colitis flare-up induced by nivolumab. 2020 , 35, 1791-1795	3
752	Obesity Is More Common in Children Newly Diagnosed With Ulcerative Colitis as Compared to Those With Crohn Disease. 2020 , 70, 593-597	4
751	Endoscopic scores in inflammatory bowel disease. 2020 , 189-220	
750	British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis. 2020 , 5, 679-697	9
749	Remote ischemic conditioning in active ulcerative colitis: An explorative randomized clinical trial. 2020 , 10, 9537	2
748	Effectiveness and Nephrotoxicity of Long-Term Tacrolimus Administration in Patients with Ulcerative Colitis. 2020 , 9,	1
747	Histologic evaluation of disease activity in inflammatory bowel disease. 2020 , 221-233	
746	Heat shock transcription factor 2 predicts mucosal healing and promotes mucosal repair of ulcerative colitis. 2020 , 55, 677-686	1
745	The diagnostic role and clinical association of serum proteinase 3 anti-neutrophil cytoplasmic antibodies in Chinese patients with inflammatory bowel disease. 2020 , 55, 806-813	2
744	The treatment approach to inflammatory bowel disease in 2020. 2020 , 36, 247-256	7
743	Thromboelastography in Patients with Inflammatory Bowel Disease. 2020 , 2020, 3245657	2
742	The association among enterobacterial flora, dietary factors, and prognosis in patients with ulcerative colitis. 2020 , 66, 152-157	2
741	Biochemical Biomarkers of Mucosal Healing for Inflammatory Bowel Disease in Adults. 2020 , 10,	21
740	Segmental colectomy for ulcerative colitis: is there a place in selected patients without active colitis? An international multicentric retrospective study in 72 patients. 2020 ,	4
739	Utility of bioimpedance methods for the assessment of fat-free mass in adult outpatients with inflammatory bowel disease. 2020 , 77, 110833	3


738	Safety and efficacy of single-needle leukocyte apheresis for treatment of ulcerative colitis. 2020 , 24, 503-510	
737	Do Histologic Features Help Predict Colectomy in Pediatric Patients Presenting With Acute Severe Colitis?. 2020 , 23, 380-386	
736	Human Neutrophil Elastase Proteolytic Activity in Ulcerative Colitis Favors the Loss of Function of Therapeutic Monoclonal Antibodies. 2020 , 13, 233-243	8
735	Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis. 2020 , 8,	15
734	MicroRNA-320a Monitors Intestinal Disease Activity in Patients With Inflammatory Bowel Disease. 2020 , 11, e00134	6
733	Tacrolimus induces short-term but not long-term clinical response in inflammatory bowel disease. 2020 , 51, 870-879	4
732	Efficacy and safety of methotrexate in the management of inflammatory bowel disease: A systematic review and meta-analysis of randomized, controlled trials. 2020 , 20, 100271	13
731	Development and feasibility of a telemonitoring tool with full integration in the electronic medical record: a proof of concept study for patients with inflammatory bowel disease in remission on biological therapy. 2020 , 55, 287-293	1
730	Assessing the efficacy and safety of fecal microbiota transplantation and probiotic VSL#3 for active ulcerative colitis: A systematic review and meta-analysis. 2020 , 15, e0228846	23
729	Combined Use of Common Fecal and Blood Markers for Detection of Endoscopically Active Inflammatory Bowel Disease. 2020 , 11, e00138	9
728	Significance of Linked Color Imaging for Predicting the Risk of Clinical Relapse in Ulcerative Colitis. 2020 , 2020, 3108690	2
727	Gene Expression Profiling of Mediators Associated with the Inflammatory Pathways in the Intestinal Tissue from Patients with Ulcerative Colitis. 2020 , 2020, 9238970	11
726	Assessment of Endoscopic Healing by Using Advanced Technologies Reflects Histological Healing in Ulcerative Colitis. 2020 , 14, 1282-1289	10
725	Systematic Review of Development and Content Validity of Patient-reported Outcome Measures in Inflammatory Bowel Disease: Do We Measure What We Measure?. 2020 , 14, 1299-1315	8
724	Endocytoscopic intramucosal capillary network changes and crypt architecture abnormalities can predict relapse in patients with an ulcerative colitis Mayo endoscopic score of 1. 2020 , 32, 1082-1091	4
723	The Imbalance of Circulating Follicular Helper T Cells and Follicular Regulatory T Cells Is Associated With Disease Activity in Patients With Ulcerative Colitis. 2020 , 11, 104	13
722	Relationship between mucosal healing by tacrolimus and relapse of refractory ulcerative colitis: a retrospective study. 2020 , 20, 203	0
721	The Relationship between C-Reactive Protein/Albumin Ratio and Disease Activity in Patients with Inflammatory Bowel Disease. 2020 , 2020, 3467419	14

720	Oat Bran Increased Fecal Butyrate and Prevented Gastrointestinal Symptoms in Patients With Quiescent Ulcerative Colitis Randomized Controlled Trial. 2020 , 2,	1
719	Activated inducible co-stimulator-positive programmed cell death 1-positive follicular helper T cells indicate disease activity and severity in ulcerative colitis patients. 2020 , 202, 106-118	5
718	Efficacy and safety of adsorptive granulomocytapheresis in Chinese patients with ulcerative colitis: A retrospective analysis of 50 cases with focus on factors impacting clinical efficacy. 2020 , 35, 271-280	2
717	Ultrasonographic and clinical assessment of peripheral enthesitis and arthritis in an Italian cohort of inflammatory bowel disease patients. 2020 , 50, 436-443	2
716	Biomarkers Predictive of Response to Thiopurine Therapy in Inflammatory Bowel Disease. 2020 , 7, 8	7
715	Genetic Analysis of Ulcerative Colitis in Japanese Individuals Using Population-specific SNP Array. 2020 , 26, 1177-1187	1
714	Markers of Hypoxia Correlate with Histologic and Endoscopic Severity of Colitis in Inflammatory Bowel Disease. 2020 , 8, 1-12	3
713	Comparable Long-Term Outcomes of Cyclosporine and Infliximab in Patients With Steroid-Refractory Acute Severe Ulcerative Colitis: A Meta-Analysis. 2019 , 6, 338	8
712	Development and Validation of a Deep Neural Network for Accurate Evaluation of Endoscopic Images From Patients With Ulcerative Colitis. 2020 , 158, 2150-2157	80
711	Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis. 2020 , 8, 91-98	19
710	AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. 2020 , 158, 1450-1461	139
709	AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis. 2020 , 158, 1465-1496.e1737	
708	Comparison of the Nancy Index With Continuous Geboes Score: Histological Remission and Response in Ulcerative Colitis. 2020 , 14, 1021-1025	7
707	Increased Colonic Epithelial Permeability and Mucosal Eosinophilia in Ulcerative Colitis in Remission Compared With Irritable Bowel Syndrome and Health. 2020 , 26, 974-984	17
706	Sleep disturbance in Inflammatory Bowel Disease: prevalence and risk factors - A cross-sectional study. 2020 , 10, 507	18
705	Exploratory clinical characterization of experimentally-induced ulcerative colitis nonhuman primates. 2020 , 6, e03178	1
704	Positioning Therapies in Ulcerative Colitis. 2020 , 18, 1280-1290.e1	30
703	Population Pharmacokinetics and Exposure-Response Modeling Analyses of Ustekinumab in Adults With Moderately to Severely Active Ulcerative Colitis. 2020 , 60, 889-902	9

702	OPTICORE—an innovative and accurate colonic targeting technology. 2020 , 583, 119372	27
701	Revisiting Inflammatory Bowel Disease: Pathology, Treatments, Challenges and Emerging Therapeutics Including Drug Leads from Natural Products. 2020 , 9,	36
700	The Efficacy and Safety of Mesalamine and Probiotics in Mild-to-Moderate Ulcerative Colitis: A Systematic Review and Meta-Analysis. 2020 , 2020, 6923609	3
699	Mucosal concentrations of N-acetyl-5-aminosalicylic acid related to endoscopic activity in ulcerative colitis patients with mesalamine. 2020 , 35, 1878-1885	5
698	Inter-Observer Agreement of a New Endoscopic Score for Ulcerative Colitis Activity: Preliminary Experience. 2020 , 10,	1
697	Using Healthcare Databases to Replicate Trial Findings for Supplemental Indications: Adalimumab in Patients with Ulcerative Colitis. 2020 , 108, 874-884	1
696	Specific T-Cell Subsets Can Predict the Efficacy of Anti-TNF Treatment in Inflammatory Bowel Diseases. 2020 , 68, 12	3
695	Vedolizumab in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Safety, Efficacy, and Place of Therapy. 2020 , 15, 7-20	5
694	Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis. 2020 , 51, 1047-1066	10
693	Prostaglandin E-major urinary metabolite versus fecal immunochemical occult blood test as a biomarker for patient with ulcerative colitis. 2020 , 20, 114	6
692	Immunotherapy. 2020 ,	1
691	Prediction of treatment failure during infliximab induction therapy in inflammatory bowel disease patients based on pharmacokinetic and pharmacodynamic modeling. 2020 , 150, 105317	0
690	Diagnostic utility of the neutrophil-platelet ratio as a novel marker of activity in patients with Ulcerative Colitis. 2020 , 15, e0231988	6
689	Ulcerative Colitis: Disease Burden, Impact on Daily Life, and Reluctance to Consult Medical Professionals: Results from a Japanese Internet Survey. 2020 , 5, 27-35	4
688	Persistent Diarrhea in Patients With Crohn's Disease After Mucosal Healing Is Associated With Lower Diversity of the Intestinal Microbiome and Increased Dysbiosis. 2021 , 19, 296-304.e3	9
687	Transcriptional Signatures That Define Ulcerative Colitis in Remission. 2021 , 27, 94-105	10
686	Endoscopic and Histological Assessment, Correlation, and Relapse in Clinically Quiescent Ulcerative Colitis (MARQUEE). 2021 , 27, 207-214	9
685	Current status of colon capsule endoscopy. 2021 , 33, 529-537	11

684	Colonooids From Patients With Pediatric Inflammatory Bowel Disease Exhibit Decreased Growth Associated With Inflammation Severity and Durable Upregulation of Antigen Presentation Genes. 2021 , 27, 256-267	1
683	Development and Validation of a Clinical Decision Support Tool That Incorporates Pharmacokinetic Data to Predict Endoscopic Healing in Patients Treated With Infliximab. 2021 , 19, 1209-1217.e2	8
682	A 1-Year Cross-sectional Inflammatory Bowel Disease Surveillance Colonoscopy Cohort Comparing High-definition White Light Endoscopy and Chromoendoscopy. 2021 , 27, 594-602	2
681	A nationwide database study on colectomy and colorectal cancer in ulcerative colitis: what is the role of appendectomy?. 2021 , 23, 64-73	2
680	Fecal Calprotectin Thresholds to Predict Endoscopic Remission Using Advanced Optical Enhancement Techniques and Histological Remission in IBD Patients. 2021 , 27, 647-654	10
679	Systematic Review: Gastrointestinal Ultrasound Scoring Indices for Inflammatory Bowel Disease. 2021 , 15, 125-142	11
678	Variability in the Distribution of Histological Disease Activity in the Colon of Patients with Ulcerative Colitis. 2021 , 15, 603-608	2
677	Polysaccharides from natural resources exhibit great potential in the treatment of ulcerative colitis: A review. 2021 , 254, 117189	24
676	Accuracy of Ultrasound for Evaluation of Colorectal Segments in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. 2021 , 19, 908-921.e6	7
675	Fully automated endoscopic disease activity assessment in ulcerative colitis. 2021 , 93, 728-736.e1	18
674	Evolution of Endoscopic Lesions in Steroid-Refractory Acute Severe Ulcerative Colitis Responding to Infliximab or Cyclosporine. 2021 , 19, 1180-1188.e4	6
673	Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology practice recommendations for medical management and monitoring of inflammatory bowel disease in Asia. 2021 , 36, 637-645	9
672	Prevalence and Outcomes of COVID-19 Among Patients With Inflammatory Bowel Disease-A Danish Prospective Population-based Cohort Study. 2021 , 15, 540-550	28
671	Disease Activity Patterns in the First 5 Years After Diagnosis in Children With Ulcerative Colitis: A Population-Based Study. 2021 , 15, 367-374	0
670	Visceral hypersensitivity is together with psychological distress and female gender associated with severity of IBS-like symptoms in quiescent ulcerative colitis. 2021 , 33, e13998	0
669	Surface-enhanced Raman scattering for the diagnosis of ulcerative colitis: will it change the rules of the game?. 2021 , 413, 827-838	5
668	Adrenomedullin for steroid-resistant ulcerative colitis: a randomized, double-blind, placebo-controlled phase-2a clinical trial. 2021 , 56, 147-157	6
667	Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study. 2021 , 214, 128-133	6

666	Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study. 2021 , 9, 102-109	2
665	Long-term outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort study. 2021 , 9, 507-516	0
664	Milan ultrasound criteria are accurate in assessing disease activity in ulcerative colitis: external validation. 2021 , 9, 438-442	4
663	Medical therapy versus surgery in moderate-to-severe ulcerative colitis. 2021 , 53, 403-408	3
662	Central Reading of Ulcerative Colitis Clinical Trial Videos Using Neural Networks. 2021 , 160, 710-719.e2	22
661	Dissecting Common and Unique Effects of Anti-IL17 and Anti-Tumor Necrosis Factor Treatment in Ulcerative Colitis. 2021 , 15, 441-452	7
660	Increased expression of extracellular matrix metalloproteinase inducer (EMMPRIN) and MMP10, MMP23 in inflammatory bowel disease: Cross-sectional study. 2021 , 93, e12962	5
659	Long-term outcomes of antibiotic combination therapy for ulcerative colitis. 2021 , 12, 20406223211028790	2
658	Effectiveness of administering zinc acetate hydrate to patients with inflammatory bowel disease and zinc deficiency: a retrospective observational two-center study. 2021 ,	1
657	Intestinal Ultrasound to Assess Disease Activity in Ulcerative Colitis: Development of a novel UC-Ultrasound Index. 2021 , 15, 1264-1271	4
656	Histologic Activity and Steroid Use History are Risk Factors of Clinical Relapse in Ulcerative Colitis with Endoscopic Remission.	
655	Advanced Colonoscopy Techniques in Inflammatory Bowel Diseases. 2021 , 1-23	
654	Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study. 2021 , 14, 17562848211023386	3
653	Diagnosis and Monitoring in Inflammatory Bowel Disease: Who, When, Where, and How. 2021 , 25-59	1
652	Training and deploying a deep learning model for endoscopic severity grading in ulcerative colitis using multicenter clinical trial data. 2021 , 14, 2631774521990623	8
651	Efficacy of Multi Matrix System Mesalazine for the Induction of Remission in Patients with Ulcerative Colitis who Insufficiently Respond to other Mesalazine Formulations: A Japanese Single-center Study. 2021 , 74, 357-363	
650	Efficacy of Budesonide Foam in Patients with Mild-to-Moderate Ulcerative Colitis Treated with a Maximum Dose of Oral Mesalazine. 2021 , 74, 153-161	
649	Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study. 2021 , 15, 1120-1129 ¹⁶	

648	Serum PR3-ANCA Is a Predictor of Primary Nonresponse to Anti-TNF- α Agents in Patients with Ulcerative Colitis. 2021 , 6, 117-122	3
647	Ulcerative Colitis in Children and Adolescents. 2021 , 474-492.e8	0
646	Update on the therapeutic management of patients with either psoriatic arthritis or ulcerative colitis: focus on the JAK inhibitor tofacitinib. 2021 , 13, 1759720X20977777	4
645	Effective immune-inflammation index for ulcerative colitis and activity assessments. 2021 , 9, 334-343	4
644	Myosin Light Chain 9/12 Regulates the Pathogenesis of Inflammatory Bowel Disease. 2020 , 11, 594297	1
643	Fecal calprotectin as a noninvasive test to predict deep remission in patients with ulcerative colitis. 2021 , 100, e24058	2
642	Rapid prediction of 1-year efficacy of tofacitinib for treating refractory ulcerative colitis. 2021 , 19, 115-118	4
641	Role of EUS in idiopathic ulcerative colitis. 2021 , 10, 313-314	0
640	Efficacy of Oral, Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Network Meta-analysis. 2021 , 15, 1184-1196	7
639	Ulcerative Colitis Diagnosis and Management: Past, Present, and Future Directions. 2021 , 61-88	0
638	Factors associated with the persistence of oral 5-aminosalicylic acid monotherapy in ulcerative colitis: a nationwide Norwegian cohort study. 2021 , 14, 17562848211021760	
637	 2021 , 161-184	1
636	Liver X Receptor Exerts Anti-Inflammatory Effects in Colonic Epithelial Cells via ABCA1 and Its Expression Is Decreased in Human and Experimental Inflammatory Bowel Disease. 2021 , 27, 1661-1673	2
635	Abdominal pain in patients with inflammatory bowel disease: association with single-nucleotide polymorphisms prevalent in irritable bowel syndrome and clinical management. 2021 , 21, 53	2
634	Effect of Kangfuxin Liquid enema combined with mesalazine on gestational outcomes and quality of life in child-bearing female with active ulcerative colitis: A protocol for randomized, double-blind, controlled trial. 2021 , 100, e23915	2
633	A Simple Emergency Department-Based Score Predicts Complex Hospitalization in Patients with Inflammatory Bowel Disease. 2021 , 1	1
632	Single Donor FMT Reverses Microbial/Immune Dysbiosis and Induces Clinical Remission in a Rat Model of Acute Colitis. 2021 , 10,	1
631	Mucosal Integrity Testing Can Detect Differences in the Rectums of Patients with Inflammatory Bowel Disease Compared to Controls: A Pilot Study. 2021 , 1	1

630	Evaluation of Serum Leucine-Rich Alpha-2 Glycoprotein as a New Inflammatory Biomarker of Inflammatory Bowel Disease. 2021 , 2021, 8825374	3
629	Cyclosporine modulates neutrophil functions via the SIRT6-HIF-1 β glycolysis axis to alleviate severe ulcerative colitis. 2021 , 11, e334	10
628	Scoring Endoscopy in Pediatric Inflammatory Bowel Disease: A Way to Improve Quality. 2021 , 73, 48-53	
627	Role of Telemedicine in Inflammatory Bowel Disease: a Systematic Review and Meta-analysis of Randomized Clinical Trials (Preprint).	
626	Role of endoscopy in inflammatory bowel disease including scoring systems. 2021 , 213-219	
625	The efficacy of linked color imaging for the endoscopic diagnosis of mucosal healing in quiescent ulcerative colitis. 2021 , 36, 2448-2454	2
624	Advances in the optimization of therapeutic drug monitoring using serum, tissue and faecal anti-tumour necrosis factor concentration in patients with inflammatory bowel disease treated with TNF-antagonists. 2021 , 21, 539-548	3
623	Corrected ESR/Albumin Ratio as a Simple, Practical Marker Predicts the Severity in Egyptian Ulcerative Colitis Patients. 2021 , 11, 8-16	
622	Long-term real-life efficacy and safety of infliximab and adalimumab in the treatment of inflammatory bowel diseases outpatients. 2021 , 33, 670-679	4
621	Issues of inflammatory bowel disease management in primary care.. 2021 , 2021, 109-115	
620	Real-life pilot study on the impact of the telemedicine platform EasyMICI-MaMICI on quality of life and quality of care in patients with inflammatory bowel disease. 2021 , 56, 530-536	1
619	Chronic inflammation in ulcerative colitis causes long term changes in gobletcell function.	0
618	Serum 1,3-beta-D-glucan as a noninvasive test to predict histologic activity in patients with inflammatory bowel disease. 2021 , 27, 866-885	
617	Fecal Dipeptidyl Peptidase-4: An Emergent Biomarker in Inflammatory Bowel Disease. 2021 , 12, e00320	3
616	The impact of clinical symptoms and endoscopic and histologic disease activity on health-related quality of life in patients with ulcerative colitis following treatment with multimatrix mesalazine. 2021 , 30, 1925-1938	1
615	Expression of tricellular tight junction proteins and the paracellular macromolecule barrier are recovered in remission of ulcerative colitis. 2021 , 21, 141	7
614	(Poly)phenols in Inflammatory Bowel Disease and Irritable Bowel Syndrome: A Review. 2021 , 26,	8
613	Recurrent myocarditis in a patient with active ulcerative colitis: a case report and review of the literature. 2021 , 8,	2

612	Possible Earlier Diagnosis of Ulcerative Colitis-Associated Neoplasia: A Retrospective Analysis of Interval Cases during Surveillance. 2021 , 10,	3
611	Influence of the COVID-19 Outbreak on Disease Activity and Quality of Life in Inflammatory Bowel Disease Patients. 2021 , 12, 664088	2
610	Stratification of Risk of Progression to Colectomy in Ulcerative Colitis using Measured and Predicted Gene Expression.	0
609	An International Multicenter Real-Life Prospective Study of Electronic Chromoendoscopy Score PICaSSO in Ulcerative Colitis. 2021 , 160, 1558-1569.e8	9
608	Colitis and Crohn's Foundation (India): a first nationwide inflammatory bowel disease registry. 2021 , 19, 206-216	5
607	Carotid Plaque Assessment Reclassifies Patients with Inflammatory Bowel Disease into Very-High Cardiovascular Risk. 2021 , 10,	2
606	An Overview of Tools to Score Severity in Pediatric Inflammatory Bowel Disease. 2021 , 9, 615216	0
605	Residual Short-Segment Distal Inflammation Has No Significant Impact on the Major Relapse of Extensive Ulcerative Colitis. 2021 ,	2
604	Evaluation of nutritional status and its association with the grade of activity of ulcerative colitis in Mexican patients. 2021 , 86, 107-109	
603	Single-Cell Transcriptional Survey of Ileal-Anal Pouch Immune Cells From Ulcerative Colitis Patients. 2021 , 160, 1679-1693	8
602	Increased Gene Copy Number of DEFA1A3 Is Associated With the Severity of Ulcerative Colitis. 2021 , 12, e00331	0
601	Evaluation of nutritional status and its association with the grade of activity of ulcerative colitis in Mexican patients. 2021 , 86, 107-109	
600	Clinical Efficacy of Tofacitinib in Moderate to Severe Ulcerative Colitis. 2021 , 15, 1774	1
599	Clinical and Host Biological Factors Predict Colectomy Risk in Children Newly Diagnosed With Ulcerative Colitis. 2021 ,	0
598	Combined endocytoscopy with pit pattern diagnosis in ulcerative colitis-associated neoplasia: Pilot study. 2021 ,	4
597	Coronary Microvascular Dysfunction Restored After Surgery in Inflammatory Bowel Disease: A Prospective Observational Study. 2021 , 10, e019125	2
596	Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. 2021 , 56, 489-526	40
595	Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study. 2021 , 56, 560-569	4

594	Ultra-high Magnification Endocytoscopy and Molecular Markers for Defining Endoscopic and Histologic Remission in Ulcerative Colitis-An Exploratory Study to Define Deep Remission. 2021 , 27, 1719-1730 ¹	
593	Assessment of mesalamine in the alterations of metabolic parameters in comorbid ulcerative colitis and metabolic syndrome patients: A retrospective study.	
592	Faecal Calprotectin in Assessment of Mucosal Healing in Adults with Inflammatory Bowel Disease: A Meta-Analysis. 2021 , 10,	7
591	Effect of golimumab on health-related quality of life, other patient-reported outcomes and healthcare resource utilization in patients with moderate-to-severe ulcerative colitis: a real-world multicenter, noninterventional, observational study in Greece. 2021 ,	1
590	Mayo Endoscopic Score and Ulcerative Colitis Endoscopic Index Are Equally Effective for Endoscopic Activity Evaluation in Ulcerative Colitis Patients in a Real Life Setting. 2021 , 12, 217-224	1
589	Effects of Anti-Inflammatory Treatment and Surgical Intervention on Endothelial Glycocalyx, Peripheral and Coronary Microcirculatory Function and Myocardial Deformation in Inflammatory Bowel Disease Patients: A Two-Arms Two-Stage Clinical Trial. 2021 , 11,	2
588	Evaluation of the efficacy of MMX mesalazine therapy for moderate ulcerative colitis. 2021 , 113-123	1
587	Reduction of Calciprotein Particles in Adults Receiving Infliximab for Chronic Inflammatory Disease. 2021 , 5, e10497	1
586	Leucine-rich alpha-2 glycoprotein as a marker of mucosal healing in inflammatory bowel disease. 2021 , 11, 11086	6
585	Network-based response module comprised of gene expression biomarkers predicts response to infliximab at treatment initiation in ulcerative colitis. 2021 ,	
584	Control of intestinal inflammation by glycosylation-dependent lectin-driven immunoregulatory circuits. 2021 , 7,	1
583	Raman spectroscopy accurately differentiates mucosal healing from non-healing and biochemical changes following biological therapy in inflammatory bowel disease. 2021 , 16, e0252210	0
582	Use of the ulcerative colitis endoscopic index of severity and Mayo endoscopic score for predicting the therapeutic effect of mesalazine in patients with ulcerative colitis. 2021 , 4, 33-39	0
581	Metformin-Inducible Small Heterodimer Partner Interacting Leucine Zipper Protein Ameliorates Intestinal Inflammation. 2021 , 12, 652709	1
580	Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study. 2021 , 19, 2324-2332.e6	4
579	Simple bicarbonate buffer system for dissolution testing: Floating lid method and its application to colonic drug delivery system. 2021 , 63, 102447	3
578	Disease Activity Indices for Pouchitis: A Systematic Review. 2021 ,	0
577	Effect of disease duration on the association between serum albumin and mucosal healing in patients with ulcerative colitis. 2021 , 8,	3

576	Integrative analysis of colonic biopsies from inflammatory bowel disease patients identifies an interaction between microbial bile-acid inducible gene abundance and human Angiopoietin-like 4 gene expression. 2021,	3
575	[The IBD-Control questionnaire: German translation and validation of the standardized questionnaire for Patient Reported Outcome Measurement in inflammatory bowel disease]. 2021,	
574	Anti-TNF and immunosuppressive combination therapy is preferential to inducing clinical remission in patients with active inflammatory bowel disease: A systemic review and meta-analysis. 2021, 22, 408-418	1
573	C-reactive protein is superior to fecal biomarkers for evaluating colon-wide active inflammation in ulcerative colitis. 2021, 11, 12431	1
572	A Real-world retrospective multi-centre cohort study comparing infliximab and adalimumab for the maintenance of remission in ulcerative colitis. 2021, 3, 229-235	0
571	Early serum albumin changes in patients with ulcerative colitis treated with tacrolimus will predict clinical outcome. 2021, 27, 3109-3120	1
570	Endoscopic and Histologic Predictors of Outcomes in Pediatric Ulcerative Colitis-. 2021, 9, 678132	
569	Endoscopic evaluation of surgically altered bowel in inflammatory bowel disease: a consensus guideline from the Global Interventional Inflammatory Bowel Disease Group. 2021, 6, 482-497	9
568	Identification of an Anti-Integrin $\alpha 4 \beta 7$ Autoantibody in Patients With Ulcerative Colitis. 2021, 160, 2383-2394.e2111	
567	The Toronto Ibd Global Endoscopic Reporting (Tiger) Score: A Single, Easy To Use Endoscopic Score For Both Crohn's Disease And Ulcerative Colitis Patients. 2021,	1
566	Incidence and risk factors for venous thrombosis among patients with inflammatory bowel disease in China: a multicenter retrospective study. 2021, 19, 313-322	4
565	Comparing the clinical application values of the Degree of Ulcerative Colitis Burden of Luminal Inflammation (DUBLIN) score and Ulcerative Colitis Endoscopic Index of Severity (UCEIS) in patients with ulcerative colitis.. 2021, 9, 533-542	1
564	The deubiquitinating enzyme OTUD5 sustains inflammatory cytokine response in inflammatory bowel disease. 2021,	2
563	Letter: tofacitinib in biologic-experienced ulcerative colitis-a single-centre real-world experience in Australia. 2021, 54, 532-533	1
562	[Position paper on endoscopic reporting in IBD]. 2021, 59, 1091-1109	1
561	Patient-Reported Outcome and Clinical Scores Are Equally Accurate in Predicting Mucosal Healing in Ulcerative Colitis: A Prospective Study. 2021, 1	1
560	Effectiveness of treatment moderate ulcerative colitis with prolonged-release ethylcellulose-coated mesalazine in real clinical practice in Moscow. 2021, 2, 65-74	
559	Systematic review and Meta-analysis: Clinical, Endoscopic, Histologic and Safety Placebo Rates in Induction and Maintenance trials of Ulcerative Colitis. 2021,	0

558	Predictors of surgical intervention in patients with inflammatory bowel disease (two-center study). 2021 , 33,	1
557	Endotrophin and C6Ma3, serological biomarkers of type VI collagen remodelling, reflect endoscopic and clinical disease activity in IBD. 2021 , 62-68	0
556	Endotrophin and C6Ma3, serological biomarkers of type VI collagen remodelling, reflect endoscopic and clinical disease activity in IBD. 2021 , 11, 14713	0
555	Randomised clinical trial: Efficacy and safety of Qing-Chang-Hua-Shi granules in a multicenter, randomized, and double-blind clinical trial of patients with moderately active ulcerative colitis. 2021 , 139, 111580	2
554	Leucine-Rich Alpha-2 Glycoprotein May Be Predictive of the Adalimumab Trough Level and Antidrug Antibody Development for Patients with Inflammatory Bowel Disease: A Sub-Analysis of the PLANET Study. 2021 , 102, 929-937	0
553	Trends of inflammatory bowel disease at a tertiary care center in northern India. 2021 , 19, 282-290	1
552	Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study. 2021 ,	2
551	Integrative analysis of gut microbiome and host transcriptomes reveals associations between treatment outcomes and immunotherapy-induced colitis. 2021 ,	5
550	The reliability and accuracy of endoscopic items and scores used in the assessment of the ileoanal pouch and cuff. 2021 ,	0
549	Insulin Resistance Is Not Increased in Inflammatory Bowel Disease Patients but Is Related to Non-Alcoholic Fatty Liver Disease. 2021 , 10,	1
548	The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surgical Management of Ulcerative Colitis. 2021 , 64, 783-804	2
547	Efficacy and tolerability of very low-volume bowel preparation in patients with inflammatory bowel diseases. 2021 , 33, 977-982	0
546	Discrete terminal ileal ulcers in patients diagnosed with ulcerative colitis: clinical significance and natural course. 2021 , 21, 285	0
545	Relationship between clinical features and intestinal microbiota in Chinese patients with ulcerative colitis. 2021 , 27, 4722-4737	4
544	Evaluation of nutritional status using bioelectrical impedance analysis in patients with inflammatory bowel disease. 2021 ,	0
543	MIN score predicts primary response to infliximab/adalimumab and vedolizumab therapy in patients with inflammatory bowel diseases. 2021 , 113, 1988-1998	1
542	Long-term outcomes of infliximab in a real-world multicenter cohort of patients with acute severe ulcerative colitis. 2021 , 19, 323-331	4
541	Predictive factors of relapse after dose reduction of oral 5-aminosalicylic acid in patients with ulcerative colitis in the remission phase. 2021 , 16, e0255620	1

540	Clinical effectiveness of golimumab in ulcerative colitis: a prospective multicentre study based on the Swedish IBD Quality Register, SWIBREG. 2021 , 56, 1304-1311	1
539	Real-World Efficacy and Safety Monitoring for Predicting Continuation of Tofacitinib Therapy in Patients with Ulcerative Colitis. 2021 , 1	1
538	Clinical efficacy and increased donor strain engraftment after antibiotic pretreatment in a randomized trial of ulcerative colitis patients receiving fecal microbiota transplant.	0
537	Machine learning using clinical data at baseline predicts the efficacy of vedolizumab at week 22 in patients with ulcerative colitis. 2021 , 11, 16440	1
536	Anti-proteinase 3 antineutrophil cytoplasmic antibody reflects disease activity and predicts the response to steroid therapy in ulcerative colitis. 2021 , 21, 325	1
535	Chronic Inflammation in Ulcerative Colitis Causes Long-Term Changes in Goblet Cell Function. 2021 , 13, 219-232	1
534	The method for diagnosing the activity of inflammatory bowel diseases based on a combination of electrical and viscoelastic parameters of erythrocytes and the level of fecal calprotectin. 2021 , 1, 40-49	1
533	Prospective Evaluation of Endoscopic and Histologic Indices in Pediatric Ulcerative Colitis Using Centralized Review. 2021 , 116, 2052-2059	0
532	Comparison between Prostaglandin E-major urinary metabolite and C-reactive protein levels to reflect endoscopic scores in patients with ulcerative colitis. 2021 , 11, 16205	0
531	Video capsule endoscopy in inflammatory bowel disease.. 2022 , 2, e26	0
530	Further research on the clinical relevance of the ulcerative colitis colonoscopic index of severity for predicting 5-year relapse. 2021 , 36, 2661-2670	2
529	ABCC7/CFTR Expression Is Associated with the Clinical Course of Ulcerative Colitis Patients. 2021 , 2021, 5536563	1
528	A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis. 2021 , 8,	2
527	Endoscopy within 7 days after detecting high calprotectin levels can be useful for therapeutic decision-making in ulcerative colitis. 2021 , 100, e27065	
526	Patient Preference and Adherence to Aminosalicylates for the Treatment of Ulcerative Colitis. 2021 , 14, 343-351	1
525	Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2021 , 385, 1280-1291	59.2 35
524	Deoxycholic acid delays the wound healing of colonic epithelial cells via transmembrane G-protein-coupled receptor 5. 2021 ,	1
523	The characteristics of pediatric ulcerative colitis with primary sclerosing cholangitis: A single-center study in Taiwan. 2021 , 62, 483-490	0

522	Application of Artificial Intelligence to Clinical Practice in Inflammatory Bowel Disease - What the Clinician Needs to Know. 2021 ,	1
521	Oral Fluconazole Therapy in Patients With Active Ulcerative Colitis Who Have Detectable Candida in the Stool: A Double-Blind Randomized Placebo-controlled Trial. 2021 ,	0
520	QRISK3 Performance in the Assessment of Cardiovascular Risk in Patients with Inflammatory Bowel Disease. 2021 , 10,	1
519	Prevalence of extraintestinal manifestations in ulcerative colitis and associated risk factors. 2021 , 1	0
518	Management of Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer. 2021 , 11, 720759	1
517	Serum Levels of PCSK9 Are Increased in Patients With Active Ulcerative Colitis Representing a Potential Biomarker of Disease Activity: A Cross-sectional Study. 2021 ,	0
516	Keratin 1 maintains the intestinal barrier in ulcerative colitis. 2021 , 43, 1389-1402	0
515	Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy. 2021 ,	
514	Stratification of risk of progression to colectomy in ulcerative colitis via measured and predicted gene expression. 2021 , 108, 1765-1779	0
513	Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-What, Why, and How. 2021 , 15, 1410-1430	11
512	The role of alcohol dehydrogenase 1C in regulating inflammatory responses in ulcerative colitis. 2021 , 192, 114691	1
511	Diagnosis of Inflammatory Bowel Disease by Abdominal Ultrasound and Color Doppler Techniques. 2021 , 17, 1085-1093	
510	Comparison of the Mayo Endoscopy Score and the Ulcerative Colitis Endoscopy Index of Severity and the Ulcerative Colitis Colonoscopy Index of Severity. 2021 , 9, E130-E136	3
509	Association between Ulcerative Colitis and Helicobacter pylori Infection: A Case-Control Study.	
508	Time spent per day in strenuous activity and total physical activity are inversely associated with mucosal healing but not with clinical remission in patients with ulcerative colitis. 2021 , 34, 796-801	0
507	The safety of drugs for inflammatory bowel disease during pregnancy and breastfeeding: the DUMBO registry study protocol of GETECCU. 2021 , 14, 17562848211018097	2
506	Is histological healing a feasible endpoint in ulcerative colitis?. 2021 , 15, 665-674	0
505	An image classification model based on transfer learning for ulcerative proctitis. 2021 , 27, 627-636	1

504	Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study. 2021 , 14, 17562848211023384	4
503	Full, Partial, and Modified Permutations of the Mayo Score: Characterizing Clinical and Patient-Reported Outcomes in Ulcerative Colitis Patients. 2021 , 3,	0
502	Transanal proctocolectomy and ileal pouch-anal anastomosis (TaIPAA) for ulcerative colitis: medium term functional outcomes in a single centre. 2021 , 21, 17	3
501	The role of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio in ulcerative colitis. 2021 , 19, 62-70	10
500	Impaired Luminal Control of Intestinal Macrophage Maturation in Patients With Ulcerative Colitis During Remission. 2021 , 12, 1415-1432	3
499	Transdermal nicotine decreases mucosal IL-8 expression but has no effect on mucin gene expression in ulcerative colitis. 5, 174-181	9
498	5-Aminosalicylate Therapy. 317-328	1
497	Contrast and Comparison of Mesalamine Derivatives in the Treatment of Ulcerative Colitis. 2014 , 69-99	1
496	Gastrointestinal Tract Adverse Events. 2020 , 1244, 247-253	2
495	Clinical pharmacology of mesalazine (5-aminosalicylic acid) in chronic inflammatory bowel disease. 1989 , 17-30	1
494	Ulcerative Colitis. 2010 , 1975-2013.e9	2
493	Inflammatory Bowel Disease. 2012 , 243-264	1
492	A fully defined 3D matrix for ex vivo expansion of human colonic organoids from biopsy tissue. 2020 , 262, 120248	10
491	GETECCU 2020 guidelines for the treatment of ulcerative colitis. Developed using the GRADE approach. 2020 , 43 Suppl 1, 1-57	3
490	SULFASALAZINE AND 5-ASA COMPOUNDS. 1992 , 21, 643-658	24
489	MEDICAL MANAGEMENT OF SPECIFIC CLINICAL PRESENTATIONS. 1995 , 24, 541-558	6
488	New Oral Salicylates in the Therapy of Chronic Idiopathic Inflammatory Bowel Disease. 1989 , 18, 43-50	10
487	Aktualisierte S3-Leitlinie Colitis ulcerosa [Living Guideline. 2020 , 58, e241-e326	6

486	The IBD-disk Is a Reliable Tool to Assess the Daily-life Burden of Patients with Inflammatory Bowel Disease. 2021 , 15, 766-773	1
485	5-Aminosalicylic acid, 1,000-mg caplets versus 500-mg tablets, in maintenance of remission in ulcerative colitis. 1997 , 24, 287-8	7
484	Comparison of 5-amino salicylic acid plus glucocorticosteroid with metronidazole and ciprofloxacin in patients with active ulcerative colitis. 2001 , 33, 85-6	8
483	Pulse steroids for ulcerative colitis: good news, bad news, and no news. 2002 , 35, 291-2	4
482	A Systematic Review With Meta-Analysis of the Efficacy of Cannabis and Cannabinoids for Inflammatory Bowel Disease: What Can We Learn From Randomized and Nonrandomized Studies?. 2021 , 55, 798-809	4
481	Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis. 2018 , 47, 454-465	87
480	Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy. 2020 , 52, 1658-1675	15
479	Drug management of ulcerative colitis. 1992 , 305, 35-8	5
478	IFN- α drives inflammatory bowel disease pathogenesis through VE-cadherin-directed vascular barrier disruption. 2019 , 129, 4691-4707	54
477	The Degree of Ulcerative Colitis Burden of Luminal Inflammation score is superior to predicting medium- to long-term prognosis in patients with active ulcerative colitis. 2020 , 13, 1756284820981210	3
476	Efficacy of long-term 4.0 g/day mesalazine (Pentasa) for maintenance therapy in ulcerative colitis. 2014 , 20, 1314-8	8
475	Evaluation of Early Atherosclerosis Markers in Patients with Inflammatory Bowel Disease. 2016 , 22, 3943-3950	6
474	Inflammatory bowel disease register: Steps towards Crohn's & colitis foundation of Saudi Arabia (CCFSA). 2012 , 6, 232-6	3
473	Immune checkpoint inhibitor-induced colitis: A comprehensive review. 2019 , 7, 405-418	96
472	Remission endpoints in ulcerative colitis: A systematic review. 2017 , 5, 85	3
471	Ulcerative colitis induces changes on the expression of the endocannabinoid system in the human colonic tissue. 2009 , 4, e6893	78
470	Adhesion Molecules Associated with Female Genital Tract Infection. 2016 , 11, e0156605	4
469	The miR-200 family is increased in dysplastic lesions in ulcerative colitis patients. 2017 , 12, e0173664	10

468	Combination Therapy With Adalimumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis in Patients With Refractory Ulcerative Colitis. 2015 , 7, 884-9	6
467	A practical marker to determining acute severe ulcerative colitis: CRP/albumin ratio. 2020 , 7, 49-55	5
466	Platelet-to-lymphocyte Ratio and Neutrophil-to-lymphocyte Ratio Predict Mucosal Disease Severity in Ulcerative Colitis. 2018 , 37, 155-162	28
465	[The efficiency of influenza vaccines in patients with inflammatory bowel disease on immunosuppressive therapy]. 2012 , 153, 1870-4	1
464	FACTORS ASSOCIATED WITH PATIENT'S PREFERENCE IN CHOOSING THEIR THERAPY FOR INFLAMMATORY BOWEL DISEASE IN BRAZIL. 2020 , 57, 491-497	2
463	Initial experience with golimumab in clinical practice for ulcerative colitis. 2016 , 108, 129-32	13
462	What is the real-life maintenance mesalazine dose in ulcerative colitis?. 2017 , 109, 114-121	6
461	The Inflammatory Bowel Disease Questionnaire in Randomized Controlled Trials of Treatment for Ulcerative Colitis: Systematic Review and Meta-Analysis. 2020 , 7, 189-205	6
460	Linking estrogen receptor expression with inflammatory bowel disease activity. 2015 , 6, 40443-51	44
459	Infliximab biosimilar CT-P13 is effective and safe in treating inflammatory bowel diseases: a real-life multicenter, observational study in Italian primary inflammatory bowel disease centers. 2019 , 32, 392-399	7
458	Curcumin use in ulcerative colitis: is it ready for prime time? A systematic review and meta-analysis of clinical trials. 2020 , 33, 53-58	14
457	Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model. 2016 , 20, 1-326	32
456	PROJECT: CLINICAL GUIDELINES FOR THE DIAGNOSTICS AND TREATMENT OF ULCERATIVE COLITIS. 2019 , 18, 7-36	30
455	CYTOMEGALOVIRUS INFECTION IN PATIENTS WITH MODERATE AND SEVERE ULCERATIVE COLITIS. 2020 , 19, 26-36	2
454	Expression of 5-LOX and NF- κ B P65 in mucosal tissues of patients with ulcerative colitis and their relationship. 2011 , 31, 339-341	1
453	Partial overlap of anti-mycobacterial, and anti-Saccharomyces cerevisiae mannan antibodies in Crohn's disease. 2008 , 14, 3650-61	7
452	Decrease of reactive-oxygen-producing granulocytes and release of IL-10 into the peripheral blood following leukocytapheresis in patients with active ulcerative colitis. 2005 , 11, 3085-90	24
451	Plasma interleukin-18 reflects severity of ulcerative colitis. 2005 , 11, 605-8	27

- 450 Predictors of disease severity in ulcerative colitis patients from Southwestern Ontario. **2010**, 16, 232-6 25
- 449 Prediction of flare-ups of ulcerative colitis using quantitative immunochemical fecal occult blood test. **2010**, 16, 1110-4 16
- 448 Autofluorescence imaging endoscopy for identification and assessment of inflammatory ulcerative colitis. **2011**, 17, 5110-6 28
- 447 Correlations between endoscopic and clinical disease activity indices in intestinal Behcet's disease. **2012**, 18, 5771-8 21
- 446 Utility of faecal calprotectin analysis in adult inflammatory bowel disease. **2012**, 18, 6782-9 45
- 445 Epithelial markers of colorectal carcinogenesis in ulcerative colitis and primary sclerosing cholangitis. **2013**, 19, 2234-41 5
- 444 Clinical outcomes and predictive factors in oral corticosteroid-refractory active ulcerative colitis. **2013**, 19, 265-73 14
- 443 Clinical significance of serum procalcitonin in patients with ulcerative colitis. **2013**, 19, 8335-41 19
- 442 Synergistic effect of interleukin-10-receptor variants in a case of early-onset ulcerative colitis. **2013**, 19, 8659-70 23
- 441 Frequency and prognostic role of mucosal healing in patients with Crohn's disease and ulcerative colitis after one-year of biological therapy. **2014**, 20, 2995-3001 26
- 440 Treating inflammatory bowel disease by adsorptive leucocytapheresis: a desire to treat without drugs. **2014**, 20, 9699-715 55
- 439 Prevalence, significance and predictive value of antiphospholipid antibodies in Crohn's disease. **2015**, 21, 6952-64 14
- 438 Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2. **2015**, 21, 8776-86 11
- 437 Are faecal markers good indicators of mucosal healing in inflammatory bowel disease?. **2015**, 21, 11469-80 38
- 436 Effects of oral tacrolimus as a rapid induction therapy in ulcerative colitis. **2015**, 21, 1880-6 23
- 435 Endocytoscopic narrow-band imaging efficiency for evaluation of inflammatory activity in ulcerative colitis. **2015**, 21, 2108-15 21
- 434 Assessment of disease activity by fecal immunochemical test in ulcerative colitis. **2016**, 22, 10617-10624 11
- 433 Levels and activities of von Willebrand factor and metalloproteinase with thrombospondin type-1 motif, number 13 in inflammatory bowel diseases. **2017**, 23, 4796-4805 3

432	Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China. 2017 , 23, 8235-8247	24
431	Practical fecal calprotectin cut-off value for Japanese patients with ulcerative colitis. 2018 , 24, 4384-4392	16
430	Novel oral-targeted therapies for mucosal healing in ulcerative colitis. 2018 , 24, 5322-5330	19
429	First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. 2020 , 26, 6710-6769	4
428	Plasma matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 as biomarkers of ulcerative colitis activity. 2003 , 9, 2843-5	34
427	Diagnosis of Ulcerative Colitis. 2011 , 64, 807-816	4
426	Fecal microbiota transplantation ameliorates active ulcerative colitis. 2020 , 19, 2650-2660	18
425	Comparing the clinical outcomes of young-onset and adult-onset ulcerative colitis: a multi-center Korean Association for the Study for Intestinal Diseases study. 2017 , 32, 69-78	4
424	Recent trends in diagnostic techniques for inflammatory bowel disease. 2015 , 30, 271-8	5
423	The usefulness of fecal calprotectin in assessing inflammatory bowel disease activity. 2019 , 34, 72-80	14
422	Rapid fecal calprotectin testing to assess for endoscopic disease activity in inflammatory bowel disease: A diagnostic cohort study. 2015 , 21, 360-6	9
421	Alterations of pulmonary function in patients with inflammatory bowel diseases. 2016 , 11, 249-253	11
420	Noninvasive biomarkers as surrogate predictors of clinical and endoscopic remission after infliximab induction in patients with refractory ulcerative colitis. 2017 , 23, 238-245	10
419	Diagnostic Value of Fecal Calprotectin and Serum MMP-9 in Diagnosing Disease Activity of Ulcerative Colitis. 2018 , 08, 234-244	1
418	Assessment of disease activity in inflammatory bowel diseases: Non-invasive biomarkers and endoscopic scores. 2020 , 12, 504-520	6
417	Endoscopy in inflammatory bowel disease when and why. 2012 , 4, 201-11	18
416	Endoscopic evaluation in diagnosis and management of inflammatory bowel disease. 2016 , 8, 723-732	13
415	"Mucosal healing" in ulcerative colitis: Between clinical evidence and market suggestion. 2014 , 5, 54-62	7

414	Mucosal healing in inflammatory bowel disease: Maintain or de-escalate therapy. 2016 , 7, 1-16	15
413	Inflammatory bowel disease in Korea: epidemiological, genomic, clinical, and therapeutic characteristics. 2010 , 4, 1-14	67
412	Sacroiliitis is common in Crohn's disease patients with perianal or upper gastrointestinal involvement. 2010 , 4, 338-44	18
411	Disability due to Inflammatory Bowel Disease Is Correlated with Drug Compliance, Disease Activity, and Quality of Life. 2017 , 11, 370-376	18
410	Fecal Immunochemical Test and Fecal Calprotectin Results Show Different Profiles in Disease Monitoring for Ulcerative Colitis. 2018 , 12, 142-148	17
409	An Elevated Platelet Count Increases the Risk of Relapse in Ulcerative Colitis Patients with Mucosal Healing. 2018 , 12, 420-425	10
408	Unmet Psychosocial Needs of Patients with Newly Diagnosed Ulcerative Colitis: Results from the Nationwide Prospective Cohort Study in Korea. 2020 , 14, 459-467	6
407	Screening for latent tuberculosis infection in patients with inflammatory bowel disease: Can interferon-gamma release assays replace the tuberculin skin test?. 2018 , 29, 292-298	4
406	The influence of disease type and activity to sexual life and health quality in inflammatory bowel disease. 2019 , 30, 33-39	2
405	Change of Circulating Leptin, Adiponectin, Resistin, and Visfatin Level after Treatment of Patients with Active Inflammatory Bowel Disease. 2010 , 8, 151	1
404	Guidelines for the Management of Ulcerative Colitis. 2012 , 10, 1	9
403	Efficacy of Infliximab Rescue Therapy in Hospitalized Patients with Steroid-Refractory Ulcerative Colitis: Single Center Experience. 2012 , 10, 152	0
402	Narrow-band imaging with magnifying endoscopy for Peyer's patches is useful in predicting the recurrence of remissive patients with ulcerative colitis. 2016 , 14, 314-321	1
401	Usefulness of fecal immunochemical test and fecal calprotectin for detection of active ulcerative colitis. 2018 , 16, 563-570	8
400	Patient self-reported symptoms using visual analog scales are useful to estimate endoscopic activity in ulcerative colitis. 2018 , 16, 579-587	5
399	The novel latex agglutination turbidimetric immunoassay system for simultaneous measurements of calprotectin and hemoglobin in feces. 2019 , 17, 202-209	6
398	Efficacy and safety of abrilumab, an $\alpha 4$ integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II study. 2019 , 17, 375-386	10
397	Distribution of cytomegalovirus genotypes among ulcerative colitis patients in Okinawa, Japan. 2018 , 16, 90-98	4

396	The role of colonoscopy in inflammatory bowel disease. 2013 , 46, 317-20	8
395	Chronological Review of Endoscopic Indices in Inflammatory Bowel Disease. 2019 , 52, 129-136	9
394	Clinical outcomes and risk factors of secondary extraintestinal manifestation in ulcerative colitis: results of a multicenter and long-term follow-up retrospective study. 2019 , 7, e7194	5
393	Role of Telemedicine in Inflammatory Bowel Disease: Systematic Review and Meta-analysis of Randomized Controlled Trials.. 2022 , 24, e28978	0
392	Can we predict mucosal remission in ulcerative colitis more precisely with a redefined cutoff level of C-reactive protein?. 2021 ,	
391	Evaluation in real-time use of artificial intelligence during colonoscopy to predict relapse of ulcerative colitis: a prospective study. 2021 ,	1
390	Limited endoscopic mucosal inflammation on equivalent to Mayo endoscopic subscore of 0 unaffected clinical relapse of ulcerative colitis. 2021 , 1-4	
389	Evaluation of Serum Calprotectin Levels in Patients with Inflammatory Bowel Disease. 2021 ,	1
388	Association of Fecal Calprotectin With Endoscopic and Histologic Activity in Pediatric Inflammatory Bowel Disease. 2021 , 2, e129	0
387	Analysis of Endoscopic Evaluation Reliability for Ulcerative Colitis in Histological Remission. 2021 , 9,	0
386	Effectiveness of treatment of moderate ulcerative colitis with prolonged mesalazine in real clinical practice. 2021 , 144-151	
385	Perioperative parenteral fish oil supplementation improves postoperative coagulation function and outcomes in patients undergoing colectomy for ulcerative colitis. 2021 ,	
384	A longitudinal model for the Mayo Clinical Score and its sub-components in patients with ulcerative colitis. 2021 , 1	
383	Efficacy and safety of tofacitinib in moderate and severe ulcerative colitis in real clinical practice: three years of observation. 2021 , 20-29	
382	Lymphocyte-to-Monocyte Ratio as a Marker for Endoscopic Activity in Ulcerative Colitis. 2021 , 1, 360-368	
381	Grenzbereiche der Dosierung von Mesalazin. 2001 , 51-68	
380	Clinical pharmacology in inflammatory bowel disease: optimizing current medical therapy. 2003 , 495-521	1
379	Medical management of ulcerative colitis. 2003 , 605-629	

- 378 Colon, Rectum, and Anus. **2008**, 1011-1110 1
- 377 INFLAMMATORY BOWEL DISEASES. **2009**, 487-503 1
- 376 Repeat Endoscopy Affects Patient Management in Pediatric Inflammatory Bowel Disease. **2009**, 104, 722-727 3
- 375 Oral budesonide for induction of remission in ulcerative colitis.
- 374 La cicatrisation muqueuse endoscopique est-elle un nouvel objectif thérapeutique dans les MICI?. **2010**, 173-180
- 373 Activity Indices-Based Assessment of Disease Activity in Inflammatory Bowel Disease. **2012**, 307-320
- 372 The Role of Ileoscopy in Inflammatory Bowel Disease. **2012**, 35-40
- 371 Improvement of Peripheral Arthritis by Infliximab in a Patient with Refractory Ulcerative Colitis: a Case Report. **2012**, 65, 277-282
- 370 Mucosal Healing in IBD: Does it Matter?. 201-206
- 369 Clinical Trials (Clinician Perspective). **2013**, 467-472
- 368 A Primer on IBD: Phenotypes, Diagnosis, Treatment, and Clinical Challenges. **2013**, 3-21
- 367 Value of transabdominal bowel ultrasonography and splanchnic vascular parameters in the evaluation of inflammatory bowel disease. **2013**, 03, 99-106
- 366 Evaluation of mucosal healing of ulcerative colitis by a quantitative fecal immunochemical test. **2013**, 125, 221-223
- 365 Two Cases of Ulcerative Colitis Followed up Endoscopically after Administration of Infliximab. **2013**, 66, 234-240
- 364 Correlation between endoscopic healing and histological healing of ulcerative colitis determined using the Mayo score. **2014**, 85, 43-46
- 363 Step-Up Versus Top-Down Therapy in Ulcerative Colitis. **2014**, 457-467
- 362 Idiopathic Inflammatory Bowel Diseases. **2014**, 345-392
- 361 The Natural History of Ulcerative Colitis. **2014**, 23-30

360 Oral Mesalamine. **2014**, 55-68

359 Chemoprevention in Ulcerative Colitis. **2014**, 291-296

358 Principles of Medical Management of Ulcerative Colitis. **2014**, 31-44

357 Assessment of Disease Activity in Ulcerative Colitis. **2014**, 345-357

356 Neue Entwicklungen und Tendenzen in der Pharmakotherapie chronisch entzündlicher Darmerkrankungen. **1988**, 178-184

355 Chronisch-entzündliche Darmerkrankungen. **1990**, 104-121

354 5-ASA Preparations in the Treatment of Inflammatory Bowel Disease. **1990**, 179-211

353 5-ASA in Ulcerative Colitis. **1990**, 167-177

352 Problematik von Therapiestudien. **1991**, 491-509

351 Macrogol. **1993**, 787-1056

350 Overview of 5-ASA in the therapy of IBD. **1994**, 361-366

349 A gastroenterologist's perspective of the medical management of patients with Crohn's disease and ulcerative colitis. **1994**, 385-423

348 The Evaluation, Diagnosis, and Treatment of Inflammatory Bowel Diseases over the Past 100 Years: A Brief Review. **2015**, 3-28

347 Do I Really Have to Have Another Colonoscopy or Another CT Scan? Appropriate Disease Monitoring of Newly Diagnosed and Established Inflammatory Bowel Disease. **2015**, 151-160

346 Appendicular Histology and Its Clinical Significance in Patients with Ulcerative Colitis: A Prospective Study from North India. **2016**, 50, 141-147

345 Assessment of Disease Severity and Role of Cytomegalo Virus Infection in Patients with Ulcerative Colitis. **2017**, 11, EC07-EC11

1

344 Clinical Indices for Pediatric Inflammatory Bowel Disease Research. **2017**, 571-590

343 Anti-TNF Biologic Therapies Other than Infliximab. **2017**, 401-416

- 342 Is infection a real threat in patients with ulcerative colitis? A prospective, multicenter study in Korea. **2018**, 16, 267-272 2
- 341 Idiopathic Inflammatory Bowel Diseases. **2018**, 379-430
- 340 Endoscopic Score in CD and UC. **2018**, 47-54
- 339 Clostridium difficile in ulcerative colitis; a retrospective study. **2018**, 46, 474-481
- 338 Accuracy of the Full Spectrum Endoscopy (FUSE) system for assessment of disease activity in Inflammatory Bowel Diseases (IBD) compared to high-definition endoscopy. **2019**, 5, 034-038
- 337 Endoscopy. **2019**, 33-42
- 336 Medical Treatment of Ulcerative Colitis: Does Traditional Therapy Still Have a Role?. **2019**, 93-104
- 335 A blood-based prognostic biomarker in inflammatory bowel disease.
- 334 Diagnosis of Ulcerative Colitis: the Role of Endoscopy. **2019**, 45-60
- 333 The use of fecal calprotectin in monitoring activity of inflammatory bowel diseases. **2019**, 91, 53-61 5
- 332 The effectiveness of mesalazine therapy of ulcerative colitis of moderate severity in real clinical practice. **2019**, 80-86
- 331 Immunosuppression for inflammatory bowel disease does not influence Epstein-Barr viral load in the short-term. **2019**, 42, 542-547 0
- 330 Risk Factors for Central Line Associated Bloodstream Infection in Patients with Inflammatory Bowel Disease. **2019**, 34, 296-301
- 329 Budesonide Foam for Ulcerative Colitis Patients Experiencing Inadequate Response to Biological Therapy. **2019**, 25, 9855-9863 1
- 328 The value of adenosine deaminase level in assessing activation of inflammatory bowel disease. **2020**, 4, 654-659 1
- 327 Endoscopic remission can be predicted by golimumab concentrations in patients with ulcerative colitis treated with the changed label. **2021**, 33, 54-61 2
- 326 New insights in Ulcerative Colitis Associated Gut Microbiota in South American Population: Akkermansia and Collinsella, two distinctive genera found in Argentine subjects.
- 325 Optimization of prediction of UC relapse and adjustment of adequate therapy in patient with ulcerative colitis. **2020**, 1, 65-71

- 324 Expression of Oncogenic Molecules in Pediatric Ulcerative Colitis. **2021**, 1-9 0
- 323 Endoscopic tissue sampling - Part 2: Lower gastrointestinal tract. European Society of Gastrointestinal Endoscopy (ESGE) Guideline. **2021**, 53, 1261-1273 2
- 322 Estudio descriptivo de la enfermedad inflamatoria intestinal en un centro de atención terciario egipcio. **2021**,
- 321 6-thioguanine nucleotide monitoring in azathioprine and mercaptopurine monotherapy for the treatment of inflammatory bowel disease. **2021**, 2021, 0
- 320 Using Dose-Effect Relationship for Optimising Systemic Corticosteroid Dosage in Treatment of Inflammatory Bowel Diseases. **2020**, 30, 18-25 1
- 319 Colonoscopic evaluation of diarrhea/colitis occurring as an immune-related adverse event. **2021**, 51, 363-370 1
- 318 A clinical case of ulcerative colitis in a patient with viral hepatitis. **2020**, 1, 95-102
- 317 Modeling Endoscopic Improvement after Induction Treatment With Mesalamine in Patients With Mild-to-Moderate Ulcerative Colitis. **2020**, 1
- 316 Combination Therapy With Tofacitinib Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis as Induction Therapy for Refractory Ulcerative Colitis. **2020**, 12, 36-40 1
- 315 Characteristics of Hemorheology in Patients with Acute Severe Ulcerative Colitis and the Clinical Study of Rivaroxaban Anticoagulant Therapy. **2020**, 19,
- 314 Klassifikationen, Indizes, Aktivitätsbeurteilung. **2020**, 117-136
- 313 A Case of Cytomegalovirus Enteritis following Ulcerative Colitis with Spontaneous Pneumoperitoneum. **2020**, 81, 513-518
- 312 Advanced Colonoscopy Techniques in Inflammatory Bowel Diseases. **2022**, 485-507
- 311 Psychometric validation of the Chinese version of the Short Inflammatory Bowel Disease Questionnaire and evaluation of its measurement invariance across sex. **2021**, 19, 253
- 310 Transcriptional Atlas of Ileal-Anal Pouch Immune Cells from Ulcerative Colitis Patients.
- 309 Optimizing the use of current drugs for inflammatory bowel disease. 180-185
- 308 Clinical Trials (Clinical Perspective). **2008**, 531-539
- 307 Importance of mucosal healing in Crohn's disease and ulcerative colitis. 122-127

306	A Novel Method for Quantifying Intestinal Inflammatory Burden in Inflammatory Bowel Disease Using Register Data. 2020 , 12, 1059-1072	0
305	Ulcerative colitis that developed during radiotherapy for prostate cancer, deteriorated rapidly and required emergency surgery. 2020 , 6, 250	0
304	Impaired IFN- γ -dependent STAT3 Activation Is Associated With Dysregulation of Regulatory and Inflammatory Signaling in Monocytes of Ulcerative Colitis Patients. 2021 , 27, 887-901	1
303	Towards a universal definition of disease activity score thresholds: The AS135 score (Preprint).	
302	Towards a universal definition of disease activity score thresholds: The AS135 score (Preprint).	
301	Immunotherapy induced enterocolitis and gastritis - What to do and when?. 2020 , 48-49, 101703	3
300	Inflammatory bowel disease. 1989 , 141, 113-23; discussion 123-4	2
299	Ulcerative colitis: an overview. 1990 , 36, 343-51	
298	The role of mesalamine in the treatment of ulcerative colitis. 2007 , 3, 893-903	36
297	Limitations in assessment of mucosal healing in inflammatory bowel disease. 2010 , 16, 15-20	10
296	Infliximab: the evidence for its place in therapy in ulcerative colitis. 2008 , 2, 151-61	1
295	Promising effect of infliximab on the extent of involvement in ulcerative colitis. 2011 , 16, 6-15	1
294	A new look at a mainstay ulcerative colitis therapy. 2008 , 4, 1-12	
293	Mucosal healing in inflammatory bowel disease-a true paradigm of success?. 2012 , 8, 29-38	44
292	The relation between the level of interleukin-23 with duration and severity of ulcerative colitis. 2012 , 5, 49-53	11
291	Effectiveness of adalimumab for ambulatory ulcerative colitis patients after failure of infliximab treatment: a first "real-life" experience in primary gastroenterology centers in Italy. 2014 , 27, 369-373	15
290	Serum IL-17 and IL-6 increased accompany with TGF- β and IL-13 respectively in ulcerative colitis patients. 2014 , 7, 5498-504	11
289	Emerging Treatment Options in Mild to Moderate Ulcerative Colitis. 2015 , 11, 1-16	3

288	Neutrophil-lymphocyte ratio: a controversial marker in predicting Crohn's disease severity. 2015 , 8, 14779-85	29
287	Short-Term and Long-Term Outcomes of Infliximab and Tacrolimus Treatment for Moderate to Severe Ulcerative Colitis: Retrospective Observational Study. 2018 , 64, E140-E148	5
286	Apoptosis markers of circulating leukocytes are associated with the clinical course of inflammatory bowel disease. 2018 , 11, S53-S58	3
285	Inducible nitric oxide synthase as a potential blood-based biomarker in inflammatory bowel diseases. 2018 , 11, S124-S128	9
284	Biosimilars for the Treatment of Inflammatory Bowel Disease. 2019 , 43, 84-91	6
283	IgG4+ plasma cell infiltration is correlated with the development of inflammatory bowel disease and can be regulated by TLR-4. 2018 , 11, 4537-4544	2
282	Potential role of plasma miR-21 and miR-92a in distinguishing between irritable bowel syndrome, ulcerative colitis, and colorectal cancer. 2020 , 13, 147-154	4
281	Validation and reliability of the Turkish version of the inflammatory bowel disease questionnaire for ulcerative colitis and Crohn's disease. 2020 , 31, 566-572	
280	A Practical Clinical Approach to the Management of High-Risk Ulcerative Colitis. 2021 , 17, 59-66	
279	Automatic estimation of ulcerative colitis severity from endoscopy videos using ordinal multi-instance learning. 1-9	3
278	Fecal Microbiome Changes and Specific Anti-Bacterial Response in Patients with IBD during Anti-TNF Therapy. 2021 , 10,	1
277	Characterization of Mycophenolate Mofetil Gastrointestinal Toxicity and Risk Factors for Severe Disease and Poor Prognosis. 2021 ,	0
276	Deep neural network for video colonoscopy of ulcerative colitis: a cross-sectional study. 2021 ,	0
275	The influence of disease activity on fatigue in patients with ulcerative colitis - a longitudinal study. 2021 , 1-8	
274	Updates in Clinical, Endoscopic, and Histologic Composite and Co-primary Endpoints for Clinical Trials in Inflammatory Bowel Disease. 2021 , 19, 608	
273	IBD Diagnosis and Evaluation. 2022 , 751-764	
272	Long-Term Outcomes and Predictive Factors of Hospitalized Patients with Severe Ulcerative Colitis Treated with Intravenous Corticosteroids. 2021 , 10,	0
271	Serum oncostatin M is a potential biomarker of disease activity and infliximab response in inflammatory bowel disease measured by chemiluminescence immunoassay. 2021 , 100, 35-35	1

- 270 Beyond complete endoscopic healing: goblet appearance using an endocytoscope to predict future sustained clinical remission in ulcerative colitis. **2021**, 0
- 269 Subcutaneous vedolizumab in moderately to severely active ulcerative colitis or Crohn's disease: a profile of its use. **2021**, 37, 563-572
- 268 Association Between Peripheral Blood Monocyte Count and Mucosal Healing in Japanese Patients With Ulcerative Colitis. **2021**, 12, e00429 1
- 267 Differential serum-intestinal dynamics of infliximab and adalimumab in inflammatory bowel disease patients. **2021**,
- 266 Combination Therapy With Ustekinumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis in Patients With Refractory Ulcerative Colitis.. **2021**, 13, 510-514 0
- 265 Medical Management of Ulcerative Colitis. **2022**, 765-779
- 264 Combined Use of Fecal Biomarkers in Inflammatory Bowel Diseases: Oncostatin M and Calprotectin. **2021**, 14, 6409-6419 0
- 263 Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial. **2021**, 13
- 262 AJM300 (Carotegrast Methyl), an Oral Antagonist of α 4-Integrin, as Induction Therapy for Patients with Moderately Active Ulcerative Colitis: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase 3 Study. 0
- 261 Evolving short- and long-term goals of management of IBD: getting it right, making it last.. **2021**, 1
- 260 The effectiveness and safety of switching therapy with an original drug to biosimilars in treatment of inflammatory bowel diseases. **2022**, 35-41
- 259 Combined histo-endoscopic remission but not endoscopic healing alone in ulcerative colitis is associated with a mucosal transcriptional profile resembling healthy mucosa.. **2022**, 0
- 258 Outcomes of dietary management approaches in active ulcerative colitis: A systematic review.. **2021**, 41, 298-306 1
- 257 Clinical translation of advanced colonic drug delivery technologies. **2021**, 181, 114076 8
- 256 Validation and reliability of the Turkish version of the inflammatory bowel disease questionnaire for ulcerative colitis and Crohn's disease. **2020**, 31, 566-572
- 255 HEALTH-RELATED QUALITY OF LIFE IN ADOLESCENTS AND YOUNG ADULTS WITH INFLAMMATORY BOWEL DISEASE IS ASSOCIATED WITH REDUCTION IN SCHOOL AND WORK PRODUCTIVITY RATHER THAN PHYSICAL IMPAIRMENT: A MULTIDISCIPLINARY STUDY.. **2021**, 58, 541-547 0
- 254 Enriched CD45RACD62L central memory T and decreased CD3CD56 natural killer T lymphocyte subsets in the rectum of ulcerative colitis patients.. **2022**, 36, 20587384211051982 2
- 253 Treatment of severe and fulminant inflammatory bowel disease colitis. **2022**, 100864

252 5-Hydroxytryptamine and Its Receptor, 5-HT 7R, Facilitate Alleviation of Inflammation in Ulcerative Colitis via Functional Regulatory B Cells.

251 Monitoring of intestinal inflammation and prediction of recurrence in ulcerative colitis.. **2022**, 1-12 0

250 Prostaglandin E-Major Urinary Metabolite Diagnoses Mucosal Healing in Patients with Ulcerative Colitis in Remission Phase.. **2022**, 1

249 Advanced endoscopy for the management of inflammatory digestive diseases: a review of the JGES core session.. **2022**, 1

248 Double blind placebo-controlled trial for the prevention of ulcerative colitis relapses by Efructan prebiotics: efficacy and metabolomic analysis. 0

247 Effect of disease duration on the association between C-reactive protein-albumin ratio and endoscopic activity in ulcerative colitis.. **2022**, 22, 39 1

246 Disease Monitoring in IBD: evolving principles and possibilities.. **2022**, 2

245 Relationship Between Endoscopic and Clinical Disease Activity With Fatigue in Inflammatory Bowel Disease.. **2022**, 45,

244 Interim analysis of a multicenter registry study of COVID-19 patients with inflammatory bowel disease in Japan (J-COSMOS).. **2022**, 57, 174 0

243 Establishment of a validated central reading system for ileocolonoscopy in an academic setting.. **2022**,

242 A TIGER Among Endoscopic Indices in Inflammatory Bowel Disease.. **2022**, 1

241 Serum Immune-Inflammation Index Assessment in the Patients with Ulcerative Colitis.. **2022**, 2022, 9987214 0

240 A Case of Primary Sclerosing Cholangitis and Autoimmune Hepatitis Overlapping Syndrome Complicated by Ulcerative Colitis.. **2022**, 1

239 Health-related quality of life in patients with long-standing ulcerative colitis in remission.. **2022**, 15, 1756284821106240

238 Association between ulcerative colitis and infection: A case-control study.. **2022**, 8, e08930 0

237 Evolution and New Horizons of Endoscopy in Inflammatory Bowel Diseases.. **2022**, 11, 0

236 Indicators of suboptimal response to anti-tumor necrosis factor therapy in patients from China with inflammatory bowel disease: results from the EXPLORE study.. **2022**, 22, 44 0

235 The Colon Wall Thickness Measured Using Transabdominal Ultrasonography is Useful for Detecting Mucosal Inflammation in Ulcerative Colitis.. **2022**,

- 234 Lipidomic Trajectories Characterize Delayed Mucosal Wound Healing in Quiescent Ulcerative Colitis and Identify Potential Novel Therapeutic Targets.. **2022**, 18, 1813-1828 0
- 233 Automatic Estimation of Ulcerative Colitis Severity by Learning to Rank With Calibration. **2022**, 10, 25688-25695
- 232 PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicability in an artificial intelligence system.. **2022**, 4
- 231 Artificial intelligence enabled automated diagnosis and grading of ulcerative colitis endoscopy images.. **2022**, 12, 2748 6
- 230 Both fecal calprotectin and fecal immunochemical tests are useful in children with inflammatory bowel disease.. **2022**, 1 1
- 229 PICaSSO virtual electronic chromendoscopy accurately reflects combined endoscopic and histological assessment for prediction of clinical outcomes in ulcerative colitis.. **2022**, 3
- 228 Transfer of FROzen Encapsulated multi-donor Stool filtrate for active ulcerative Colitis (FRESCO): study protocol for a prospective, multicenter, double-blind, randomized, controlled trial.. **2022**, 23, 173 0
- 227 A review on the current status and definitions of activity indices in inflammatory bowel disease: how to use indices for precise evaluation.. **2022**, 57, 246 0
- 226 AJM300 (carotegrast methyl), an oral antagonist of α 4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.. **2022**, 2
- 225 Serum Albumin to Globulin Ratio is Associated with the Presence and Severity of Inflammatory Bowel Disease.. **2022**, 15, 1907-1920 1
- 224 Draft clinical guidelines for endoscopic diagnosis of ulcerative colitis in children. **2022**, 87-98
- 223 Predictive value of Milan ultrasound criteria in ulcerative colitis: A prospective observational cohort study.. **2022**, 1
- 222 Preoperative diagnosis of obstructive colitis in colorectal cancer patients who underwent self-expandable metallic stent insertion as a bridge to surgery.. **2022**,
- 221 Inflammatory Indexes for Assessing the Severity and Disease Progression of Ulcerative Colitis: A Single-Center Retrospective Study.. **2022**, 10, 851295 0
- 220 Poor engagement and adherence predict neoplasia in inflammatory bowel disease: a case-control study.. **2022**,
- 219 Network-based response module comprised of gene expression biomarkers predicts response to infliximab at treatment initiation in ulcerative colitis.. **2022**,
- 218 Efficacy of FODMAP Elimination and Subsequent Blinded Placebo-Controlled Provocations in a Randomised Controlled Study in Patients with Ulcerative Colitis in Remission and Symptoms of Irritable Bowel Syndrome: A Feasibility Study.. **2022**, 14, 0
- 217 The Mayo Endoscopic Score Is a Novel Predictive Indicator for Malignant Transformation in Ulcerative Colitis: A Long-Term Follow-Up Multicenter Study.. **2022**, 9, 832219 1

216	Pharmacokinetics, Safety, and Efficacy of Intravenous Vedolizumab in Paediatric Patients with Ulcerative Colitis or Crohn's Disease: Results from the Phase 2 HUBBLE Study.. 2022,	0
215	Predictor of primary response to antitumor necrosis factor- α therapy for inflammatory bowel disease: a single-center observational study.. 2022,	
214	Telemedicine Is an Effective Tool to Monitor Disease Activity in IBD Patients in the COVID-19 Era: A Single Centre Experience Based on Objective Data. 2022, 13, 117-126	1
213	Gender-Based Differences in Response to Tumor Necrosis Factor Inhibitor Therapies for Ulcerative Colitis: Individual Participant Data Meta-Analyses of Clinical Trials.. 2022,	0
212	Incorporating patient experience into drug development for ulcerative colitis: development of the Urgency Numeric Rating Scale, a patient-reported outcome measure to assess bowel urgency in adults.. 2022, 6, 31	0
211	Impact of ulcerative colitis on liver-related outcomes of children with primary sclerosing cholangitis.. 2022,	
210	Exposure-response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results from Phase 2 and Phase 3 Induction and Maintenance Studies.. 2022,	0
209	Pain characteristics in patients with inflammatory bowel disease: A monocentric cross-sectional study.. 2022,	1
208	Histologic Activity and Steroid Use History Are Risk Factors of Clinical Relapse in Ulcerative Colitis With Mayo Endoscopic Subscore of 0 or 1.. 2022,	
207	Strain-resolved analysis in a randomized trial of antibiotic pretreatment and maintenance dose delivery mode with fecal microbiota transplant for ulcerative colitis.. 2022, 12, 5517	0
206	Changes in Salivary Parameters of Oral Immunity after Biologic Therapy for Inflammatory Bowel Disease.. 2021, 11,	1
205	Nurse-Provided Medication Guidance for Improving Drug Adherence to Thiopurines in Outpatients With Inflammatory Bowel Disease: A Single-Center Prospective Study. 2022, 4,	
204	Dose-Intensified Infliximab Rescue Therapy for Severe Ulcerative Colitis Does not Reduce Short-term Colectomy Rates or Increase Postoperative Complications. 2021, Publish Ahead of Print,	0
203	Low adherence to treatment is a weak link in the problems of ulcerative colitis. 2021, 93, 1419-1427	0
202	Heterogeneity in outcome assessment for inflammatory bowel disease in routine clinical practice: a mixed-methods study in a sample of English hospitals. 2021, 11, e056413	1
201	A descriptive study of inflammatory bowel disease at an Egyptian tertiary care center. 2021,	
200	The Association between Temperament, Chronotype, Depressive Symptoms, and Disease Activity among Patients with Inflammatory Bowel Disease-A Cross-Sectional Pilot Study.. 2021, 11,	
199	Predictive value of fibrinogen in identifying inflammatory bowel disease in active stage.. 2021, 21, 472	1

- 198 A Clinical Predictive Model for One-year Colectomy in Adults Hospitalized for Severe Ulcerative Colitis. **2022**, 4,
- 197 Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy.. **2021**, 1-8
- 196 Novel diagnostic autoantibodies against Endothelial Protein C Receptor in patients with ulcerative colitis.. **2021**, 1
- 195 Histological remission of ulcerative colitis with combined anti-cytokine and cell therapy. **2021**, 93, 1435-1442
- 194 A Patient Self-Made Point-of-Care Fecal Test Improves Diagnostic Accuracy Compared with Fecal Calprotectin Alone in Inflammatory Bowel Disease Patients.. **2021**, 11,
- 193 Therapeutic Potential of the 4-SURE Diet in Adults with Mild to Moderately Active Ulcerative Colitis: An Open Label Feasibility Study.. **2022**, 0
- 192 Reproducibility of the electronic chromoendoscopy PICaSSO score (Paddington International Virtual ChromoendoScopy ScOre) in Ulcerative Colitis using multiple endoscopic platforms: A prospective multicenter international study.. **2022**, 1
- 191 Patient-reported continuous clinical response to golimumab in adults with moderately to severely active ulcerative colitis: results from GO OBSERVE, a real-world European observational study.. **2022**, 34,
- 190 Differentially deregulated microRNAs as novel biomarkers for neoplastic progression in ulcerative colitis.. **2022**, 0
- 189 Data_Sheet_1.pdf. **2019**,
- 188 Data_Sheet_1.pdf. **2019**,
- 187 Image_1.TIF. **2019**,
- 186 Image_2.TIF. **2019**,
- 185 Image_3.TIF. **2019**,
- 184 Image_4.TIF. **2019**,
- 183 Image_5.TIF. **2019**,
- 182 Image_6.TIF. **2019**,
- 181 Image_7.TIF. **2019**,

180 Image_8.TIF. **2019**,

179 Table_1.doc. **2020**,

178 Data_Sheet_1.docx. **2020**,

177 Image_1.TIF. **2020**,

176 Image_2.TIF. **2020**,

175 Image_3.TIF. **2020**,

174 Image_4.TIF. **2020**,

173 Image_5.TIF. **2020**,

172 Image_6.TIF. **2020**,

171 Table_1.docx. **2020**,

170 Image_1.tif. **2018**,

169 Table_1.xls. **2018**,

168 Table_2.xls. **2018**,

167 Table_3.xls. **2018**,

166 Table_4.xls. **2018**,

165 Table_5.xls. **2018**,

164 Table_6.xls. **2018**,

163 Table_7.xls. **2018**,

162 Table_8.xls. **2018,**

161 Table_9.docx. **2018,**

160 Immunotherapy-induced Colitis: A Comprehensive Review of Epidemiology, Clinical Presentation, Diagnostic Workup, and Management Plan.. **2022,**

0

159 Clinical response and changes in the fecal microbiota and metabolite levels after fecal microbiota transplantation in patients with inflammatory bowel disease and recurrent infection.. **2021, 7, 87-98**

0

158 Advanced technology for assessment of endoscopic and histological activity in ulcerative colitis: a systematic review and meta-analysis.. **2022, 15, 17562848221092594**

1

157 Is It a Gut Feeling? Bodily Sensations Associated With the Experience of Valence and Arousal in Patients With Inflammatory Bowel Disease.. **2022, 13, 833423**

156 One-year clinical efficacy and safety of indigo naturalis for active ulcerative colitis: a real-world prospective study.. **2022, 20, 260-268**

155 Artificial Intelligence Enables Quantitative Assessment of Ulcerative Colitis Histology.

0

154 MarvelD3 Is Upregulated in Ulcerative Colitis and Has Attenuating Effects during Colitis Indirectly Stabilizing the Intestinal Barrier.. **2022, 11,**

153 Anorectal function with high resolution anorectal manometry in active ulcerative colitis and after remission: a pilot study.. **2022,**

152 Comparison of Performances of Adalimumab Biosimilars SB5, APB501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study.. **2022,**

0

151 Low Fecal Calprotectin Predicts Histological Healing in Patients with Ulcerative Colitis with Endoscopic Remission and Leads to Prolonged Clinical Remission.. **2022,**

150 Apolipoprotein C3 is Downregulated in Patients with Inflammatory Bowel Disease.. **2022,**

1

149 Efficacy of oral consumption of curcumin/ for symptom improvement in inflammatory bowel disease: A systematic review of animal models and a meta-analysis of randomized clinical trials. **2022, 46, 2015-2047**

148 Interpersonal variability in gut microbial calprotectin metabolism. **2022,**

0

147 Predicting ulcerative colitis relapse in clinical remission with fecal immunochemical occult blood test or prostaglandin E-major urinary metabolite. **2022, Publish Ahead of Print,**

146 Multi-omics empowered deep phenotyping of ulcerative colitis.

145 Anti-TNF therapy for ulcerative colitis in Brazil: a comparative real-world national retrospective multicentric study from the Brazilian study group of IBD (GEDIIB). **2022, 22,**

1

- 144 El índice proteína C reactiva/albúmina como marcador para detectar colitis aguda ulcerosa grave en pacientes egipcios. **2022,**
- 143 Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis. 1
- 142 Minimally Invasive In Vivo Endoscopic Monitoring of Dextran Sulfate Sodium-induced Murine Colitis. **2022,** 101744
- 141 Mindfulness Intervention Decreases Frequency and Severity of Flares in Inactive Ulcerative Colitis Patients: Results of a Phase II, Randomized, Placebo-Controlled Trial.
- 140 Simplified Histologic Mucosal Healing Scheme (SHMHS) for inflammatory bowel disease: a nationwide multicenter study of performance and applicability.
- 139 Lymphocyte-to-monocyte ratio is a short-term predictive marker of ulcerative colitis after induction of advanced therapy. **2022,** 10,
- 138 Automated evaluation of colon capsule endoscopic severity of ulcerative colitis using ResNet50. **2022,** 17, e0269728 1
- 137 From Static to Dynamic: A Review on the Role of Mucus Heterogeneity in Particle and Microbial Transport. 0
- 136 Compositional changes in fecal microbiota associated with clinical phenotypes and prognosis in Korean patients with inflammatory bowel disease. 1
- 135 A Rare Case of New-Onset Ulcerative Colitis in a Nonagenarian. **2022,**
- 134 A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence with Inflammatory Bowel DiSease TherapyASSIST Study: A Randomized Controlled Trial (Preprint).
- 133 Efficacy, safety and tolerability of oral sulfate tablet for bowel preparation in patients with inflammatory bowel disease: Multicenter randomized controlled study. 0
- 132 Poor Patient-Reported Outcomes and Impaired Work Productivity in Patients With Inflammatory Bowel Disease in Remission. **2022,**
- 131 Hypo-osmotic stress induces the epithelial alarmin IL-33 in the colonic barrier of ulcerative colitis. **2022,** 12,
- 130 ileo-rectal anastomosis in ulcerative colitisLong-term outcome, failure and risk of cancer at a tertiary centre. 0
- 129 C-reactive protein/albumin ratio (CAR) as a marker for detecting acute severe ulcerative colitis in Egyptian patients. **2022,**
- 128 The Interplay Between Use of Biological Therapies, Psychological State, and the Microbiome in IBD. 9,
- 127 Adalimumab Biosimilar GP2017 versus Adalimumab Originator in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study. **2022,** 10, 1799

- 126 Impact of Endoscopic and Histologic Activity on Disease Relapse in Ulcerative Colitis. **2022**, Publish Ahead of Print,
- 125 Endoscopic activity in inflammatory bowel disease: clinical significance and application in practice. **2022**, 55, 480-488 ○
- 124 Association between clinical outcomes and restless legs syndrome in Japanese patients with ulcerative colitis. 1
- 123 Pancolonic Dye Spray Chromoendoscopy to Detect and Resect Ill-Defined Neoplastic Lesions in Colonic Inflammatory Bowel Disease.
- 122 Occurrence and Clinical Impact of Eosinophilic Esophagitis in a Large Cohort of Children With Inflammatory Bowel Disease.
- 121 (Re)Appraising Remission in Ulcerative Colitis.
- 120 Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review. ○
- 119 Lymphocyte to monocyte ratio and serum albumin changes predict tacrolimus therapy outcomes in patients with ulcerative colitis. **2022**, 12,
- 118 Proinflammatory role of basophils in oxazolone-induced chronic intestinal inflammation. ○
- 117 A novel deep learning-based computer-aided diagnosis system for predicting inflammatory activity in ulcerative colitis. **2022**, ○
- 116 Artificial Intelligence Analysis of Ulcerative Colitis Using an Autoimmune Discovery Transcriptomic Panel. **2022**, 10, 1476 ○
- 115 Probiotic supplementation induces remission and changes in the immunoglobulins and inflammatory response in active ulcerative colitis patients: A pilot, randomized, double-blind, placebo-controlled study. **2022**, ○
- 114 Comparative evaluation of the effectiveness of monotherapy of ulcerative colitis with mesalazine MMX and combination therapy with non-prolonged mesalazines with rectal forms. **2022**, 96-106
- 113 Regional brain activation during rectal distention and attenuation with alosetron in a nonhuman primate model of irritable bowel syndrome.
- 112 Immune checkpoint Inhibitor-induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysis. **2022**, 109, 102440 1
- 111 Endocytoscopy for assessing histologic inflammation in ulcerative colitis: development and prospective validation of the ELECT score (ErLangen Endocytoscopy in ColiTis). **2022**, ○
- 110 Tofacitinib Salvage Therapy for Children Hospitalized for Corticosteroid- and Biologic-Refractory Ulcerative Colitis. Publish Ahead of Print, ○
- 109 Risk Factors Affecting 90-day Readmission of Patients with Inflammatory Bowel Disease. **2022**, 14, 34-43 ○

108	A randomized controlled trial of a multicomponent online stress reduction intervention in inflammatory bowel disease. 2022 , 15, 175628482211272	0
107	Deep Bayesian Active-Learning-to-Rank for Endoscopic Image Data. 2022 , 609-622	0
106	Development and clinical usefulness of a unique red dichromatic imaging technology in gastrointestinal endoscopy: A narrative review. 2022 , 15, 175628482211183	0
105	The combination of sodium alginate and chlorogenic acid enhances the therapeutic effect on ulcerative colitis by the regulation of inflammation and the intestinal flora.	0
104	Class Distance Weighted Cross-Entropy Loss for Ulcerative Colitis Severity Estimation. 2022 , 157-171	0
103	Composition and diverse differences of intestinal microbiota in ulcerative colitis patients. 12,	0
102	Endoscopic imaging in inflammatory bowel disease.	0
101	Impact of a physician-led exercise programme on quality of life, muscle mass and clinical response in inflammatory bowel disease patients during induction with disease-modifying therapy: a study protocol. 2022 , 9, e000959	0
100	Agreement between patients and physicians on scores of inflammatory bowel disease activity and burden assessed on a telemonitoring platform. 1-8	0
99	Evaluation of Nutritional Characteristics Reveals Similar Prevalence of Malnutrition in Patients with Ulcerative Colitis and Crohn's Disease.	0
98	Crypt-top and crypt-bottom colonic epithelial cell microRNA profiling reveals cell type-specific response in active and quiescent ulcerative colitis.	0
97	Safety and efficacy of infliximab and corticosteroid therapy in checkpoint inhibitor-induced colitis.	2
96	Effect of disease duration on fecal biomarkers in ulcerative colitis: a prospective cohort study. 2022 , 22,	0
95	Prevalence and factors associated with vitamin C deficiency in inflammatory bowel disease. 2022 , 28, 4834-4845	1
94	External Validation of The Paddington International Virtual Electronic Chromoendoscopy Score As A Good Endoscopic Score to Define Mucosal Healing and Predict Long-term Clinical Outcomes in Ulcerative Colitis.	0
93	Endoscopic Predictors of Neoplastic Lesions in Inflammatory Bowel Diseases Patients Undergoing Chromoendoscopy. 2022 , 14, 4426	0
92	Concordance and Discordance Between Patient-reported Remission, Patient-reported Outcomes, and Physician Global Assessment.	0
91	Development of a Core Outcome Set for Real-World Data in Inflammatory Bowel Disease: A European Crohn's and Colitis Organisation (ECCO) Position Paper.	0

- 90 Endoscopy in the Surgically Altered Bowel. **2022**, 32, 777-799 ○
- 89 Inflammatory conditions play a role in recurrence of PSC after liver transplantation in international multicentre study. **2022**, 100599 1
- 88 Association between caregiver ability and quality of life for people with inflammatory bowel disease: The mediation effect of positive feelings of caregivers. 13, ○
- 87 Expression profile of serum LncRNA THRIL and MiR-125b in inflammatory bowel disease. **2022**, 17, e0275267 ○
- 86 Thiopurine naivety at tacrolimus induction is a predictor of long-term remission in patients with intractable ulcerative colitis who responded to tacrolimus. ○
- 85 A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence with Inflammatory Bowel DiSease TherapyASSIST Study: A Randomized Controlled Trial (Preprint). ○
- 84 Ulcerative Colitis and Acute Severe Ulcerative Colitis Patients Are Overlooked in Infliximab Population Pharmacokinetic Models: Results from a Comprehensive Review. **2022**, 14, 2095 ○
- 83 Serum Leucine-Rich α Glycoprotein: A Biomarker for Predicting the Presence of Ulcerative Colitis but Not Ulcerative Proctitis. **2022**, 11, 6366 ○
- 82 Early Clinical Remission Is a Predictor of Long-Term Remission with the Use of Vedolizumab for Ulcerative Colitis. **2022**, 10, 2526 ○
- 81 Generation of human colon organoids from healthy and inflammatory bowel disease mucosa. **2022**, 17, e0276195 ○
- 80 A Virtual Chromoendoscopy Artificial Intelligence system to detect endoscopic and histologic activity/remission and predict clinical outcomes in Ulcerative Colitis. ○
- 79 Most Placebo-Controlled Trials in Inflammatory Bowel Disease were Underpowered Because of Overestimated Drug Efficacy Rates: Results from a Systematic Review of Induction Studies. ○
- 78 Importance of eosinophilic infiltration of the colonic mucosa in ulcerative colitis patients who are refractory to maintenance therapy: A prospective, single-center study. **2022**, 101, e31017 ○
- 77 Application of Deep Learning Models to Improve Ulcerative Colitis Endoscopic Disease Activity Scoring Under Multiple Scoring Systems. ○
- 76 A prospective pilot study of a gluten-free diet for primary sclerosing cholangitis and associated colitis. ○
- 75 Reliability. **2022**, 83-150 ○
- 74 Diagnosis and Monitoring of Ulcerative Colitis. ○
- 73 Association between socioeconomic status and mucosal healing in Japanese patients with ulcerative colitis: a cross-sectional study. **2022**, 9, e001000 ○

72	Usefulness of the optimal cutoff value and delta value of leucine-rich alpha 2 glycoprotein in ulcerative colitis.	○
71	Article Topic: Positioning Ulcerative Colitis Therapies in 2022 and Beyond.	○
70	The impact of inflammation on the expression of drug transporters and metabolic enzymes in colonic tissue from ulcerative colitis patients. 2022 , 628, 122282	○
69	Comprehensive Phenotyping in Inflammatory Bowel Disease: Search for Biomarker Algorithms in the Transkingdom Interactions Context. 2022 , 10, 2190	○
68	Colorectal surgical management of colitis induced by vasculitis in the absence of inflammatory bowel disease: a case report and literature review.	○
67	Biological treatment interruption in Inflammatory Bowel Disease: motivation and predictive factors. 2022 ,	1
66	Computer-Aided Imaging Analysis of Probe-Based Confocal Laser Endomicroscopy With Molecular Labeling and Gene Expression Identifies Markers of Response to Biological Therapy in IBD Patients: The Endo-Omics Study.	○
65	Leucine-Rich Alpha-2 Glycoprotein Is a Reliable Serum Biomarker for Evaluating Clinical and Endoscopic Disease Activity in Inflammatory Bowel Disease.	○
64	Tofacitinib en el tratamiento de la colitis ulcerosa moderada a severa en Colombia: Experiencia en mundo real. 2022 ,	○
63	Burden of Fatigue Among Patients with Ulcerative Colitis and Crohn's Disease: Results from a Global Survey of Patients and Gastroenterologists.	○
62	Psychometric evaluation of the Urgency NRS as a new patient-reported outcome measure for patients with ulcerative colitis. 2022 , 6,	○
61	Effects of Schistosoma mansoni and Praziquantel Treatment on the Lower Gastrointestinal Mucosa: A Cohort Study in Tanzania. 2022 , 106752	○
60	Histologic healing and factors associated with complete remission following conventional treatment in ulcerative colitis. 2022 , 15, 175628482211406	○
59	The role and mechanism of flavonoid herbal natural products in ulcerative colitis. 2023 , 158, 114086	1
58	Long-Term Efficacy and Safety of Golimumab for Ulcerative Colitis in a Pediatric Inflammatory Bowel Disease Center in Japan. 2022 , 25, 461	○
57	Usefulness of Texture and Color Enhancement Imaging (TXI) in Assessing Mucosal Healing in Patients with Ulcerative Colitis. 2022 ,	○
56	Effectiveness And Safety Of Tofacitinib In The Management Of Ulcerative Colitis: A Brazilian Observational Multicentric Study.	○
55	RNA editing is a valuable biomarker for predicting carcinogenesis in ulcerative colitis.	○

- 54 Management of Ulcerative Colitis Flare-Ups in the Era of COVID-19. **2022**, ○
- 53 Successful long-term treatment of paediatric ulcerative colitis with vedolizumab: a case report. *ejhpharm-2022e003434* ○
- 52 Mucosal addressin cell adhesion molecule 1 expression reflects mucosal inflammation and subsequent relapse in patients with ulcerative colitis. ○
- 51 Clinical significance and long-term prognosis of ulcerative colitis patients with appendiceal orifice inflammation. **2022**, 22, ○
- 50 Abdominal Pain over 6 Months. **2022**, 97, 361-367 ○
- 49 Skin microbiota signature distinguishes IBD patients and reflects skin adverse events during anti-TNF therapy. 12, ○
- 48 Disease clearance in ulcerative colitis: Setting the therapeutic goals for future in the treatment of ulcerative colitis. 9, ○
- 47 Neutrophil-to-lymphocyte ratio may predict clinical relapse in ulcerative colitis patients with mucosal healing. **2023**, 18, e0280252 ○
- 46 Has the COVID-19 Pandemic Worsened Health-Related Quality of Life of Patients with Inflammatory Bowel Disease? A Longitudinal Disease Activity-Controlled Study. **2023**, 20, 1103 ○
- 45 Therapie des Morbus Crohn und der Colitis ulcerosa. **2023**, 131-151 ○
- 44 Concomitant pharmacologic medications influence the clinical outcomes of granulocyte and monocyte adsorptive apheresis in patients with ulcerative colitis: A multicenter retrospective cohort study. ○
- 43 Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study. **2023**, 1 ○
- 42 Endoskopie. **2023**, 87-96 ○
- 41 Influence of HLA-DQA1*05 Genotype in Adults With Inflammatory Bowel Disease and Anti-TNF Treatment With Proactive Therapeutic Drug Monitoring: A Retrospective Cohort Study. ○
- 40 Artificial intelligence and inflammatory bowel disease: Where are we going?. 29, 508-520 ○
- 39 International Consensus on Definition of Mild-to-Moderate Ulcerative Colitis Disease Activity in Adult Patients. **2023**, 59, 183 ○
- 38 Dietary Considerations for Inflammatory Bowel Disease Are Useful for Treatment of Checkpoint Inhibitor-Induced Colitis. **2023**, 15, 84 ○
- 37 Characteristics, clinical outcomes and patient-reported outcomes of patients with ulcerative colitis receiving tofacitinib: a real-world survey in the United States and five European countries. **2023**, 23, ○

- 36 Gender Biases and Diagnostic Delay in Inflammatory Bowel Disease: Multicenter Observational Study. ○
- 35 Patient-Reported Outcomes in Colorectal Surgery. ○
- 34 Evaluation of intestinal ultrasound for disease activity assessment in patients with inflammatory bowel disease: A cross-sectional study at a tertiary centre in Malaysia. **2023**, 0 ○
- 33 Hepcidin and Iron Status in Patients With Inflammatory Bowel Disease Undergoing Induction Therapy With Vedolizumab or Infliximab. ○
- 32 The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission. **2023**, 8, 458-492 ○
- 31 Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. **2023**, 8, 307-320 ○
- 30 How to Improve Your Success in Treating Mild and Moderate Inflammatory Bowel Disease. 2-9 ○
- 29 Postcolectomy Enteritis in a Pediatric Patient With Ulcerative Colitis. **2022**, 3, e255 ○
- 28 BSG 2024 IBD guidelines protocol (standard operating procedures). **2023**, 10, e001067 ○
- 27 Utility of a rapid assay for Prostaglandin E-major urinary metabolite as a biomarker in pediatric ulcerative colitis. ○
- 26 Collection of patient-generated health data with a mobile application and transfer to hospital information system via QR codes. **2023**, 3, 100099 ○
- 25 Risk prediction model based on blood biomarkers for predicting moderate to severe endoscopic activity in patients with ulcerative colitis. 10, ○
- 24 Potential of Mesalazine Therapeutic Drug Monitoring by Measuring Fecal Excretion in Patients With Ulcerative Colitis. **2023**, Publish Ahead of Print, ○
- 23 Multiomic spatial analysis reveals a distinct mucosa-associated virome. **2023**, 15, ○
- 22 Comparison of The Toronto IBD Global Endoscopic Reporting (TIGER) score, Mayo endoscopic score (MES), and ulcerative colitis endoscopic index of severity (UCEIS) in predicting the need for ileal pouch-anal anastomosis in patients with ulcerative colitis. **2023**, 38, ○
- 21 Mercaptopurine for the treatment of ulcerative colitis - a randomised placebo-controlled trial. ○
- 20 Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study. **2023**, 23, 293-304 ○
- 19 Clinical Indices for Pediatric Inflammatory Bowel Disease Research. **2023**, 653-670 ○

- 18 Novel biomarkers for neoplastic progression from ulcerative colitis to colorectal cancer: a systems biology approach. **2023**, 13,
- 17 Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. **2023**, 401, 1159-1171
- 16 Comparative study between histochemical mucus volume, histopathological findings, and endoscopic scores in patients with ulcerative colitis. **2023**, 102, e33033
- 15 Artificial Intelligence Enabled Histological Prediction of Remission or Activity and Clinical Outcomes in Ulcerative Colitis. **2023**,
- 14 COVID-19 Vaccine Booster Shot Preserves T Cells Immune Response Based on Interferon-Gamma Release Assay in Inflammatory Bowel Disease (IBD) Patients on Anti-TNF Treatment. **2023**, 11, 591
- 13 Ulcerative colitis (K51), adults. **2023**, 22, 10-44
- 12 Serum Levels of Lipoprotein Lipase Are Increased in Patients with Inflammatory Bowel Disease. **2023**, 24, 5194
- 11 Focal Cancer in Colitis.
- 10 Advances in Endoscopy for Pediatric Inflammatory Bowel Disease. **2023**, 33, 447-461
- 9 Biopsies from ulcer edge yield higher histological activity scores than biopsies from non-ulcerated mucosa in active ulcerative colitis. Publish Ahead of Print,
- 8 Mise au point de l'utilisation de l'intelligence artificielle dans la prise en charge des maladies inflammatoires chroniques de l'intestin. **2023**,
- 7 A Review of Colonoscopy in Intestinal Diseases. **2023**, 13, 1262
- 6 A Systematic Review of the Economic and Health-Related Quality of Life Impact of Advanced Therapies Used to Treat Moderate-to-Severe Ulcerative Colitis.
- 5 Changes in health-related quality of life and associations with improvements in clinical efficacy: a Phase 2 study of mirikizumab in patients with ulcerative colitis. **2023**, 10, e001115
- 4 Efficacy of vedolizumab as maintenance therapy in a patient with ulcerative colitis receiving haemodialysis in end-stage kidney failure: A case report. **2023**, 11, 2050313X2311656
- 3 CB-HRNet: A Class-Balanced High-Resolution Network for the evaluation of endoscopic activity in patients with ulcerative colitis.
- 2 Real-world experience with CurcuminQingDai combination for patients with active ulcerative colitis: A retrospective multicentre cohort study.
- 1 Ustekinumab Decreases Circulating Th17 Cells in Ulcerative Colitis. **2023**,

